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ABSTRACT 
 
This thesis focuses on the design of novel strategies for the prevention and treatment of 
bacterial infections using polyanhydride nanoparticles as a vaccine delivery platform. The 
overall goal of this research is to design efficacious vaccines against the respiratory bacterial 
pathogens Streptococcus pneumoniae and Yersinia pestis using polyanhydride nanoparticles to 
elicit a protective immune response to the pneumococcal surface protein, PspA, and the Yersinia 
fusion protein, F1-V, respectively.  
Polymers and copolymers based on the various anhydride chemistries (i.e., CPTEG, CPH, 
and SA) were investigated as nanovaccine formulations for antigen delivery. The mechanism of 
action of polyanhydride nanoparticles as vaccine adjuvants was investigated to better understand 
how these nanovaccines interact with immune cells at early time points (48 hours) and through 
the evaluation of the immune response at extended time points (~several months). Fluorescently-
labeled antigen was delivered in 50:50 CPTEG:CPH nanoparticles and compared to soluble 
protein and protein adjuvanted with MPLA initially.  Polyanhydride nanoparticle-encapsulated 
protein demonstrated enhanced persistence, cellular uptake and immune cell interactions at early 
time points compared to soluble protein, or MPLA-adjuvated protein. To investigate how 
prolonged antigen presence affected vaccine efficacy, several polyanhydride chemistries were 
tested and compared to MPLA at 14, 36, and 63 days after administration. The 50:50 
CPTEG:CPH nanovaccine formulation elicited a robust humoral immune response, which 
significantly increased in titer and avidity at each of the time points investigated, suggesting the 
presence of long-lived plasma cells as a result of immunization with this polyanhydride 
nanovaccine. 
xii 
 
 
 
Once a better understanding of the mechanism of action of polyanhydride nanoparticles was 
obtained, these findings were used to design efficacious nanovaccines against two respiratory 
pathogens, S. pneumoniae and Y. pestis. The encapsulation and release of PspA from 
polyanhydride nanoparticles was examined and it was demonstrated that PspA retaining its 
stability, antigenicity, and biological functionality upon release from both 50:50 CPTEG:CPH 
and 20:80 CPH:SA nanoparticles. Based on these results, the in vivo immune response to 
vaccination with PspA nanovaccine formulations was evaluated and a protective vaccine against 
lethal challenge with S. pneumoniae based on polyanhydride nanoparticles was designed. 
Additionally, the in vivo immune response to vaccination with F1-V nanovaccine formulations 
was examined to design a protective vaccine against lethal challenge with Y. pestis including 
novel small molecule adjuvants in nanovaccine formulations with the goal of inducing protective 
immunity against Y. pestis challenge at both early time points (~several weeks) as well as after 
extended periods of time (~several months). Overall, the work described in this thesis lays a 
platform for the use of polyanhydride nanoparticles for a combination vaccine against both 
influenza and pneumonia as well as for the delivery of antimicrobial drugs. 
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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
Since the development of Edward Jenner’s smallpox vaccine in the early 19th century, 
science, technology, and medicine have progressed exponentially.  Paradoxically, vaccine-
preventable infectious diseases remain a significant cause of morbidity and mortality in both the 
developed and developing world. Acute lower respiratory infections such as pneumonia are the 
leading cause of death among infectious diseases and the third-highest global killer overall, 
behind heart disease and stroke
1
. Additionally the global burden of pneumonia is high, resulting 
in the greatest number of disability-adjusted life years lost of all medical conditions considered
2
. 
The world-wide incidence of pneumonia infections is increased by the synergistic effects of viral 
and bacterial infections. A major cause of morbidity and mortality during each of the major 
influenza events of the past century has been attributed to secondary pneumonia infections, of 
which the most common is pneumococcus
3–5
. Despite this, research on bacterial pneumonia is 
exceedingly sparse in comparison to the disease burden, as reported recently
6
. Therefore, a 
strong need exists for increased research on the pathogens that cause respiratory disease with the 
goal of increased worldwide vaccination against these preventable diseases.  
Many microbes are responsible for deadly lower respiratory tract infections. In addition to 
bacterial infections caused by pathogens such as Staphylococcus aureus, Yersinia pestis, and 
Streptococcus pneumoniae, viral infections such as influenza and respiratory syncytial virus as 
well as some fungi contribute to the disease burden
7
. Community-acquired pneumonia remains 
the leading cause of lower respiratory infections, with S. pneumoniae being the most common 
causative agent
8
. S. pneumoniae is a gram-positive bacterium with greater than 90 known 
serotypes, which differ in their polysaccharide capsule. This pathogen can result in asymptomatic 
2 
 
 
 
nasopharyngeal carriage, pneumonia, or systemic infection, which may be lethal
9
. During 
colonization, S. pneumoniae resides in the upper respiratory tract, specifically the naso-
oropharynx region. If the bacteria are able to gain access to the sterile lower respiratory tract, the 
resultant inflammatory response results in the onset of disease, commonly referred to as 
pneumonia. The systemic spread of the organism, known as bacteremic pneumonia or 
bacteremia, is a complication that is associated with increased mortality
9
. It is well documented 
that pneumococcal carriage is a precursor to systemic bacteremia with many factors that 
contribute to virulence, including capsular type and the presence of surface proteins such as 
choline binding protein A, phosphorylcholine, and pneumococcal surface protein A (PspA)
10
.  
Another bacterial pathogen of interest is Yersinia pestis, a vector-born zoonotic pathogen 
transmitted from a rodent reservoir to humans by fleas, which is the etiologic agent of plague, 
and which over the course of recorded history has killed an estimated 200 million people 
11
. 
Historically, the most common form of plague infection in humans has been bubonic plague, 
transmitted through flea bites or direct contact with an infected individual.  Septicemic plague 
may follow resulting in a mortality rate between 50 and 60% for infections of bubonic plague 
11
.  
Worldwide plague pandemics have been made increasingly improbable through the introduction 
of modern sanitation.  However, Y. pestis remains enzootic in many animal populations 
worldwide and there is growing concern regarding the use of Y. pestis as a bioterrorism agent
12
.  
Current treatment for Y. pestis infections includes the use of the antibiotics streptomycin and 
gentamicin, with doxycycline as an emerging alternative therapy. Fluoroquinolones such as 
ciprofloxacin have demonstrated success in research settings, but have not been widely tested in 
humans
13
. Additionally, treatment must be administered rapidly after the onset of symptoms for 
optimal efficacy
13
.  
3 
 
 
 
Respiratory infections are particularly common, in part due to the unique role the lungs play 
in interacting with the environment. The lungs must constantly intake air from the surrounding 
environment, which is more often than not, contaminated with microbial pathogens and other 
inert nano and micro-scale materials. The host defenses of the lung must therefore determine 
when a threat is present and respond accordingly. There are many defense mechanisms within 
the lung that can remove inert particulate matter and recognize pathogens such as bacteria. The 
first innate immune defense systems of the lung are non-specific factors such as the mucocilliary 
escalator and the cough reflex. The cellular component of the pulmonary innate immune 
response is mediated by resident and recruited cells including epithelial cells of the respiratory 
tract and leukocytes such as macrophages, dendritic cells, and neutrophils. The innate humoral 
component of the pulmonary immune system includes antimicrobial factors, including lysozyme, 
lactoferrin, collectins, and defensins, that are secreted into lung surfactant
14
. It is often this innate 
immune response that leads to pneumococcal disease through the increased inflammation caused 
by the recruitment of immune cells. This unique immunological environment presents a number 
of challenges when designing vaccines against respiratory diseases such as S. pneumoniae and Y. 
pestis. 
There are currently two widely used vaccine formulations against S. pneumoniae: the 23-
valent polysaccharide vaccine and the 7-valent pneumococcal conjugate vaccine
15,16
. Both of 
these vaccines have limitations that affect their efficacy. The polysaccharide-based vaccine does 
not effectively provide protection in young children and the elderly
16
. The 7-valent conjugate 
vaccine avoids this problem, but is not ideal because it does not provide cross protection across 
strains with capsular phenotypes that have not been included in the vaccine. This inadequacy has 
been observed to lead to serotype substitution within a few years of vaccine introduction
17
. 
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Furthermore, the polysaccharide-protein conjugate vaccine is difficult to produce leading to high 
cost and limited supply, precluding its use in developing countries
18
. Next-generation vaccine 
research has focused on using S. pneumoniae surface proteins as protective antigens. One such 
protein is pneumococcal surface protein A (PspA), a choline-binding protein found on the 
surface of all pneumococcal strains, which has been shown to be critical to the virulence of 
infections with S. pneumoniae
15,16
. Vaccination with PspA has been shown to be protective 
against a lethal challenge with S. pneumoniae making it a promising candidate for use in an 
improved vaccine
19,20
. In addition, PspA can be economically synthesized as a recombinant 
protein and the protein-based vaccine avoids the loss of antigenicity observed with the 
polysaccharide-based vaccine
18
.  
Despite the threat of antibiotic resistance, both naturally-occurring and engineered, and 
the potential for use as a biological warfare agent, there is no commercially licensed plague 
vaccine available in the United States and Europe.  There is currently a live, attenuated strain of 
Y. pestis, EV76, which has been in use as a vaccine in the countries of the former Soviet Union 
and Asia, but it is not commercially available in the United States and Europe
21
.  Due to the 
safety concerns of live, attenuated Y. pestis vaccines, much of the emerging research has focused 
on the identification and testing of protective protein subunits of the Y. pestis bacterium
22
. A F1-
V subunit based on polyanhydride nanoparticles has recently been demonstrated to provide 
protective immunity against lethal challenge with pneumonic plague. The polyanhydride 
nanovaccine formulation provided 100% protection against challenge with CO92 Y. pestis, with 
both soluble protein alone and protein adjuvanted with MPLA failing to elicit a protective 
immune response
24
. These results suggest the potential for an effective, easily synthesized 
vaccine against Y. pestis. 
5 
 
 
 
Unlike live attenuated vaccines, most non-replicating vaccines, including subunit vaccines 
based on recombinant proteins, such as PspA and F1-V, are poorly immunogenic when 
administered alone. Therefore, in order to generate protective immunity, an adjuvant must be 
used to safely and effectively boost the immune response against the protein. Currently, there are 
only two widely used licensed vaccine adjuvants: alum, a mixture of aluminum salts, and MF59, 
a squalene-based oil-in-water emulsion adjuvant approved for human use in Europe
25
. Neither is 
approved for mucosal administration, an effective option against respiratory pathogens because 
of the induction of mucosal immunity, and other benefits such as improved patient compliance 
through needle-free administration
25,26
. Recently, nano-carriers have been studied for their 
potential use in pulmonary drug delivery
27
. The small particle size leads to increased surface area 
and the ability to evenly distribute the inhaled dose to the alveoli.  
Polyanhydrides are a class of synthetic biodegradable polymers that can be formulated into 
nanoparticles for mucosal administration. These materials have many additional properties that 
make them ideal candidates for vaccine delivery, including the ability to stabilize and protect 
fragile protein antigens, provide sustained release of antigen, and modulate and enhance the 
immune response 
28–30
. These polymers have excellent biocompatibility and have been shown to 
have non-toxic, non-mutagenic degradation products
31
. The Gliadel
®
 wafer, a post-surgical 
implant composed of a copolymer of sebacic acid and 1,3(bis-p-carboxyphenoxy)propane, is 
FDA-approved for the treatment of brain cancer
32
. Polyanhydrides are characterized by a 
backbone of monomeric dicarboxylic acids (diacids) connected by anhydride linkages which are 
hydrolytically labile and cleaved in the presence of water to form carboxylic acid moieties
33
.  
Polymers and copolymers based on sebacic acid (SA) (Figure 1.1), 1,6(bis-p-
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carboxyphenoxy)hexane (CPH) (Figure 1.2) and 1,8(bis-p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) (Figure 1.3) have been shown to be effective vaccine adjuvants
24,34–36
.  
Proteins, such as PspA and F1-V, are fragile molecules, comprised of intricate hierarchical 
structures that are prone to physical and chemical degradation
37
. When using protein antigens, it 
is imperative to have a delivery device that can prevent antigen degradation and as a result 
preserve functionality and antigenicity upon release. Polyanhydride particles have been shown to 
successfully preserve antigenicity during fabrication, storage, and release
38,39
. Synthesis of 
polyanhydride particles using a non-aqueous process can prevent protein degradation due to 
prolonged exposure to water, and also maintain high encapsulation efficiency, in contrast to 
aqueous processes
37
. The penetration of water into the bulk of a polymeric device determines the 
erosion method, which can be classified as either bulk or surface erosion. Biodegradable 
polymers, including polyesters such as PGLA and polyethers such as poly(ethylene oxide), 
undergo bulk erosion, indicating that water is easily able to penetrate into the bulk of the 
device
40
. This influx of water into the core of the delivery device has been shown to lead to 
protein degradation and a loss of antigenicity in some cases
41,42
. The hydrophobic chemistry of 
polyanhydrides prevents this bulk penetration of water, both protecting the payload and leading 
to controlled surface erosion and zero-order payload release kinetics
43,44
. 
Polymeric vaccine adjuvants, such as polyanhydrides, also provide sustained release of 
antigens as the polymer erodes. The time scale and mechanism of polymer erosion depends on a 
number of factors including polymer chemistry, hydrophobicity, and molecular weight
45
. The 
persistence of particles, and, by extension, antigen, may have an advantageous effect on vaccine 
efficacy. In non-replicating vaccines, such as protein subunit vaccines, persistence may serve to 
mimic the effect of a replication-competent vaccine, such as a live attenuated vaccine. Similarly, 
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polyanhydride nanoparticles can activate the immune response and act as a vaccine 
adjuvant
28,46,47
. It has been shown that polyanhydride nanoparticles possess pathogen-mimicking 
properties and thus can activate the innate immune response by stimulating pattern recognition 
receptors (PRRs) on the surface of antigen presenting cells, specifically dendritic cells
46
. In 
addition to the stimulation of the innate immune response, it has also been shown that 
vaccination using polyanhydride nanoparticles as an adjuvant can enhance the adaptive immune 
response as measured by antibody titer and avidity
24
. Polyanhydride particles can also be used to 
modulate the immune response
48
. There are a number of ways that polyanhydride particles can 
be modified in order to target specific immune cells including particle size, chemistry, and 
surface modification. It has been suggested that increased oxygen in the polymer backbone by 
using CPTEG-rich chemistries (Figure 1.3) leads to increased recognition by PRRs
46
.  
The overall goal of this research is to design efficacious vaccines against the respiratory 
pathogens S. pneumoniae and Y. pestis based on polyanhydride nanoparticles. Polymers and 
copolymers based on CPTEG, CPH, and SA were investigated as nanovaccine formulations for 
antigen delivery. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Abstract 
Traditional vaccine design, as exemplified by the work of Edward Jenner, is centered on the 
principle of introducing or mimicking a mild pathogenic infection to train the immune system to 
protect against a subsequent severe pathogenic infection.  As such, the optimal training regimen 
for the immune system against pathogens of different tissue tropisms is to mimic a pathogenic 
infection in that same tissue site.  Respiratory pathogens remain a significant cause of morbidity 
and mortality because of their ease of transmission, population dynamics of infection, and the 
social and economic impact. There is an unmet need for highly effective vaccines against 
respiratory pathogens. However, the mucosal surface of the lungs presents a unique and tightly 
regulated immunological environment that is highly to adverse to inflammation. Therefore, when 
designing a pulmonary vaccine to elicit a mucosal immune response in respiratory tissues, 
minimizing reactogenicity is paramount.  Adjuvants can provide enhanced immune responses 
against the pathogens of interest but must straddle the line between engaging the immune system 
and avoiding detrimental immunopathology. Insights into immunological mechanisms of innate 
and adaptive immunity have led to myriad applications in pulmonary adjuvant design.  Herein 
we attempt to outline, albeit non-exhaustively, and review advances in pulmonary adjuvant 
technologies by combining information about lung biology at the cellular and molecular levels 
with advances in nanotechnology and polymer chemistry. 
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2.2 Introduction to Pulmonary Immunology 
The human body constantly encounters infectious pathogens and non-infectious particulate 
matter. It is incumbent upon the body’s natural defenses to determine when a true threat is 
present and respond appropriately. The epithelium, shown in Figure 1, is typically the first 
surface to have contact with an infectious pathogen
1
. This may be the external epithelium, or 
skin, in the case of pathogens transmitted through physical contact, such as some fungi or insect 
bites. The internal epithelium, which consists of mucosal surfaces such as the respiratory, 
reproductive, and gastrointestinal tracts, acts as the first line of defense against pathogens 
transmitted through aerosolized droplets, sexually, or through tainted water or food, 
respectively
2
. Both the external and internal epithelia have unique properties that make these 
surfaces effective barriers against invading pathogens. Made up of tightly bound epithelial cells, 
both the surface and internal epithelia secrete numerous antimicrobial factors
3
. Internal mucosal 
surfaces are covered in a layer of mucosa that may help prevent the deposition of microbes onto 
the epithelium itself. The respiratory tract, for example, contains what is known as the 
mucociliary escalator, which expels microbes through the beating of epithelia associated cilia
4
.  
 Few microbes are able to pass through these epithelial barriers and replicate in the host. 
Those that do are encountered first by phagocytic innate immune cells and a chemically 
mediated system of proteins known as complement
5
. These initial encounters release a chemical 
signaling cascade in which cytokines and chemokines recruit additional innate immune cells in a 
process known as recruited innate immunity. This process is able to eliminate many pathogens 
that are able to evade the initial defenses of the body’s epithelial tissues. However, some 
microorganisms are able to overwhelm or evade the initial and recruited innate immune 
responses and persist as a replicating infection. This is where the adaptive immune system has 
14 
 
 
 
evolved to mount a highly specific cellular response based on the clonal selection of 
lymphocytes. This is a delayed process which may take 4-7 days to develop, during which time 
the resident and recruited immune cells play a crucial role in directing the adaptive immune 
response and controlling the infection
2
.  
 Because of the unique interaction of the lungs with the outside environment, infections 
within the mucosal surfaces of the respiratory tract pose a unique set of challenges for the 
immune system, which must distinguish between countless particulates aspirated through normal 
breathing and potentially dangerous invading microorganisms
6
. The lungs provide mechanisms 
of defense against pathogens beginning with resident innate immune defenses. Then, if 
necessary, they recruit additional innate immune defenses, which serve to direct the development 
of microbe-specific adaptive immunity. The lungs contain a delicate environment that is highly 
susceptible to inflammation-induced damage, which can often be a product of dysregulated 
innate immune responses to infections. Because of this, the development of mucosal immunity to 
pathogens is often an important factor in preventing infection-associated pathology. In this 
section, the development of the immune response to an infection within the unique pulmonary 
environment from initial or resident innate immune responses to recruited innate immune 
responses, the development of adaptive immunity, and the generation of a memory response are 
discussed.  
 
2.2.1 Resident innate immune response 
Innate immunity represents the earliest stages of the host response against an infection. Germ 
line-encoded and constantly present in all healthy individuals, innate immunity does not increase 
or develop with repeated exposure to a pathogen, but rather discriminates based on common 
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features of a group of pathogens, using microbe associated molecular patters (MAMPs)
7
. Innate 
immune responses are particularly important in the context of the lung because of the constant 
interface between the lungs and the environment. The lungs inhale as many as 15 breaths per 
minute containing up to 500 mL of air each, which is ubiquitously contaminated with inert 
particulates and potentially dangerous microbes, at over 1000 colony forming units (CFUs) of 
bacteria per cubic meter in a university auditorium
8
. The upper respiratory tract can become 
asymptomatically colonized with a number of commensal bacteria, typically resulting in the 
formation of a biofilm
9
. These inert infections may become serious if the pathogen is able to 
reach the sterile lower airspaces of the lungs through the aspiration of air from the upper airways, 
which is common during sleep, or due to pathogen-associated virulence factors
10,11
.  
When a microbe is able to reach the lower airspaces, the lungs present a number of resident 
defense mechanisms, including mechanical, antimicrobial, and cellular responses to infectious 
organisms. The first line of defense against invading organisms is the epithelial layer itself, 
which separates the lung lumen from the basolateral surface
5
. The epithelial layer is made up of 
many different cell types (up to eight), which have been classified into three categories: basal, 
ciliated and secretory, with ciliated columnar epithelial cells being the most common (up to 
50%). Basal cells are thought to be a common progenitor, giving rise to secretory cells such as 
mucus cells, goblet cells, serous cells and Clara cells, and to terminally-differentiated ciliated 
cells. Immune cells such as inflammatory mast cells and phagocytic cells such as dendritic cells 
(DCs) and macrophages can also reside within the epithelium
12
. Mechanical defenses within the 
lung include the cough reflex and the mucociliary escalator, which uses ciliated columnar 
epithelial cells to expel inhaled particulates. This network of cells extends from the larynx to the 
terminal bronchioles. Ciliated airway epithelial cells are punctuated by secretory cells such as 
16 
 
 
 
goblet cells, serous cells, and Clara cells at a ratio of about five to one, which cover the epithelial 
layer with a film of mucus
13
. The cilia beat together at a rate of 700-1000 beats per minute to 
expel particulate matter to the upper respiratory area, where it is swallowed. Mucociliary 
clearance is further augmented by the cough reflex
13
. 
As mentioned above, the respiratory tract is coated by a layer of mucus that has been shown to 
have inherent antimicrobial activity due to its slightly acidic composition (pH 6.4-7.3) and the 
presence of a number of antimicrobial peptides and proteins
14
. Pulmonary secretions are 
generated by airway and alveolar epithelial cells, sub-mucosal glands and phagocytic cells such 
as neutrophils and macrophages
15
. Antimicrobial proteins found in the pulmonary surfactant 
include lysozyme, lactoferrin, secretary leukoprotease inhibitor, and human defensins and 
cathelicidins
15
. Of these molecules, lactoferrin and lysozyme are the most abundant
15
. 
Lactoferrin is secreted by both serous cells and neutrophils, and binds iron, reducing the ability 
of bacteria to replicate
14
. Lysozyme is secreted by serous cells and neutrophils as well as 
macrophages and leads to the hydrolysis of peptidoglycan, a component of gram-positive 
bacteria
14
. It is also important here to note the role played by the complement system, which 
opsonizes pathogens and leads to increased phagocytosis by immune cells
14
. 
In addition to the mechanical and antimicrobial defenses within the lung, cell-mediated innate 
immunity plays an important role in the clearance of pathogens as well as in generating an 
inflammatory response to recruit additional immune cells. Macrophages are present in both the 
interstitial tissue and in the alveolar spaces and play an important role in the pulmonary immune 
response through the phagocytosis of pathogens or particulates, and when necessary through the 
secretion of inflammatory cytokines and antimicrobial compounds such as reactive oxygen and 
nitrogen species (ROS and RNS, respectively)
14
. Mast cells are located at epithelial surfaces 
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throughout the body and express Toll-like receptors which can detect pathogens. These cells also 
release inflammatory molecules to recruit additional cells and can serve to direct the adaptive 
immune response
14
. Other important resident cell types within the lung include DCs, which are 
professional antigen presenting cells (APCs) that internalize and present pathogens to 
lymphocytes along with providing activation signals to stimulate the adaptive immune response. 
Neutrophils phagocytize and kill invading pathogens and eosinophils are associated with allergic 
inflammation
14
.  
 
2.2.2 Recruited innate immunity 
 When the resident pulmonary defenses are not able to clear a replicating infection, 
additional immune cells are recruited. The epithelial cells lining the respiratory tract have been 
shown to be responsive to the presence of microorganisms, leading to the induction of a recruited 
innate immune response
16,17
. Though not typically thought of as immune cells, airway epithelial 
and endothelial cells have been shown to interact with MAMPs through a number of pattern 
recognition receptors (PRRs) including CD14, Toll-like receptors, and intracellular adhesion 
molecules (ICAMs)
18–20
. Airway epithelial cells can also be stimulated by cytokines through 
tumor necrosis factors (TNFs) and interleukin 1 (IL-1) receptors. Activated epithelial cells are 
able mount an inducible response to an infection in two ways: by increasing production of 
antimicrobial polypeptides, such as lysozyme and lactoferrin, and through the secretion of 
cytokines and chemokines to recruit additional immune cells to the site of infection, resulting in 
an inflammatory response. These cells have been shown to increase levels of CCL2 (MCP-1) in 
response to infection with Burkholderia pseudomallei, leading to the recruitment of monocytes, 
lymphocytes, and DCs to the site of infection
2,21
. 
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 In addition to the airway epithelial cells that make up the mechanical structure of the 
respiratory tract, other resident cells play an important role in the recruited innate immune 
response to pulmonary infection, including macrophages, mast cells, and DCs. Activated 
macrophages play an important role in recruiting additional phagocytic cells to the lungs. 
Macrophages within the lung may be classically or alternatively activated by the presence of 
IFN-γ and TNF or IL-4, respectively22. Classically activated pro-inflammatory macrophages play 
an important role in the innate immune response to infection and are stimulated by IFN-γ 
produced by natural killer (NK) cells and TNF
23
. These cells secrete cytokines, including IL-1, 
IL-6, and IL-12, IL-23, and TNF
22,23
, and have been demonstrated to recruit monocytes, 
lymphocytes, and eosinophils to the site of infection through CCL15 and NK and T cells through 
CXCL9, 10 and 11
24
. Alternatively activated macrophages are activated by IL-4 released by 
basophils or granulocytes and play an important role in wound healing, though they have been 
shown to be associated with the development of a TH2 adaptive immune response, in comparison 
to classically activated macrophages, which have been shown to direct to a TH1 type adaptive 
response
23
.  
 Recruited innate immunity is an especially important consideration in infections such as 
pneumonia, where disease occurs as a result of an increased inflammatory response within the 
lung. Additionally, the cytokines released and cell types recruited during this phase of the 
immune response play a large role in informing and directing the adaptive immune response to 
the infection. As stated above, the polarization of activated macrophage phenotype can play a 
large role in the type of adaptive immune response with classically activated macrophages 
inducing a more TH1-type response through the increased secretion of IL-12 and alternatively 
activated macrophages recruiting TH2 cell types, which has been attributed to CCL22 
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expression
23,25
. In addition, the antimicrobial and phagocytic activity of resident and recruited 
innate immune cells plays an important role in controlling infection during the development of 
an adaptive immune response, which is highly specific and relies on a process of clonal selection 
which may take days or a week to become functional.  
 
2.2.3 Adaptive response 
 Few pathogens are able to evade or overwhelm the innate immune responses.  Those that 
do persist lead to the induction of an adaptive immune response. This process is mediated by 
chemical signals from the resident and recruited innate immune responses to an infection. 
Adaptive immunity is a time-dependent process that can take days to a week to reach its full 
potential
14
. There are two interrelated branches of adaptive immunity that both play important 
roles in the response to a pulmonary infection: cell-mediated and humoral (or antibody-
mediated) immunity.   
Cell-mediated immunity within the lung focuses on the interactions of T cells, NK cells, and 
DCs. Although NK cells do not exhibit RAG-dependent receptors, meaning adaptive immune 
receptors, like B and T lymphocytes, this cell type plays an important role in the development of 
the pulmonary adaptive immune response, specifically to viral pathogens
26
. The pulmonary 
adaptive immune response begins with immature myeloid DCs (mDCs), which transport antigen 
from the lung to the lung-associated lymph nodes. Immature DCs reside in the healthy lung and 
are able to phagocytize microorganisms, but do not typically display antigen on the cell surface. 
Two phenotypes of these resident DCs are especially important in the pulmonary immune 
response: mDCs and plasmacytoid DCs (pDCs), which are derived from bone-marrow monocyte 
precursors and lymphoid precursors, respectively
27
. The distinction between these two cell types 
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is important due in large part to the different TLR expression of each, with TLRs 1, 2, 3, and 4 
expressed on mDCs, responding to viral RNA and LPS, and TLRs 7 and 9 expressed in pDCs, 
responding to bacterial DNA
28
. In order to develop into a professional APC, DCs must be 
stimulated through TLR ligation or by the secretion of cytokines, at which point the cells will 
migrate to the lymph node and mature
28
. DCs play the important role of instructing the immune 
response through interactions with T cells, with possible outcomes of a TH1, TH2 or regulatory T 
cell-type response, as classified by the CD4 cell subset elicited. 
 After entering the lymph nodes through the afferent lymphatics, DCs encounter naïve T 
cells, which have been recruited by the secretion of cytokines from activated DCs. These T cells 
recognize antigen displayed on the surface of DCs in the context of either major 
histocompatibility complex (MHC) class I or II, based on their co-receptor phenotype with CD8
+
 
T cells recognizing the former and CD4
+
 T cells the latter
20
. In this way, the innate immune 
response of the APC serves to direct the adaptive immune response based on the properties of the 
pathogen, with intracellular pathogens being degraded in the cytosol and presented on MHC 
class I and extracellular pathogens being degraded in endocytic vesicles and presented on class 
II
2
. CD8
+
 or cytotoxic T cells act to seek out and kill APCs or other cells of the body which 
display antigen presented in MHC class I. This type of cellular adaptive immune response is 
considered to be of increased importance in viral and intracellular infections. CD4
+
 T cells 
function to activate other effector cells such as B cells and macrophages. These cells are 
classified into two types, TH1 and TH2 cells, which serve to activate macrophages and initiate an 
inflammatory response and activate B cells to produce antibodies, respectively
2
.  
 In addition to directing the T cell immune response to infection, DCs play an important 
role in the activation of the humoral immune response through interactions with B lymphocytes. 
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In an adaptive immune response, there are two types of antigen-specific cellular receptors, T cell 
receptors and immunoglobulins, which act as B cell receptors. As discussed above, DCs activate 
and direct the TH2 helper cell response, which then induces B cell expansion and the production 
of antibodies. Antibodies serve a number of functions in the adaptive immune response, 
including opsonization and the activation of complement, activation of effector cells, and 
neutralization to block an essential function of a pathogen. There are five classes of 
immunoglobulins that differ in their C regions, IgA, IgD, IgE, IgG, and IgM. Of these, the most 
important molecules from the perspective of the pulmonary immune response are IgG, typically 
associated with antibody-mediated immunity, and IgA, which is found in mucosal areas such as 
the respiratory tract and may prevent colonization through the ability to cross the epithelial 
layer
29
.   
 The adaptive immune response takes place in the lymph nodes, a specialized tissue which 
provides an environment for APCs to interact with T cells and B cells. These organs are 
organized with sub-sections for T cells and B cells around a germinal center. B cell follicles are 
located near the outer capsule with T cell zones located on the interior in the paracortical areas. 
Lymphocytes home to the lymph nodes from the blood, entering through high endothelial 
venules (HEVs) into the T cell zones. B cells also enter through this T cell zone and migrate to B 
cell follicles, where they encounter antigen and become activated
2
. In addition to the draining 
lymph nodes (i.e., the mediastinal lymph nodes in the case of pulmonary environment), epithelial 
tissue such as the respiratory tract often has associated lymphoid tissues. This highly organized 
area is known as the mucosal associated lymphoid tissue or MALT
29
. MALT is organized 
similarly to a lymph node, with germinal centers of T cell areas and a B cell follicle. This 
22 
 
 
 
specialized pulmonary tissue plays an important role for the endogenous presentation of antigen 
to lymphocytes driving the adaptive immune response. 
 
2.3 Review of Licensed Pulmonary Vaccines and Adjuvants 
The vaccinia virus, the causative agent of smallpox, was a ubiquitous pathogen believed to 
originate around 10,000 BC, and has been discovered to have been present in a number of early 
cultures including India, Egypt and China and frequently affected Europe during the middle 
ages. During this time it was common knowledge that survival of the disease conferred immunity 
against future infections. This understanding led to the practice of inoculation (or variolation), 
where material from an infected individual was injected subcutaneously into a naïve patient. 
Believed to have originated in Turkey and championed in Europe by Lady Mary Wortley 
Montague, this practice had a number of risks, including transfer of other blood borne diseases 
and the possibility of dissemination of the subcutaneous injection of virus. The next major 
development in the fight against smallpox came at the end of the 18
th
 century, when Edward 
Jenner hypothesized that deliberate infection with cowpox could confer immunity against 
subsequent infections with smallpox. Jenner’s discovery is widely credited to be the first instance 
of vaccination, and two hundred years later in 1980, the World Health Assembly announced the 
successful eradication of smallpox
30
. 
 Since its introduction, vaccination has proved to be one of the greatest human health 
triumphs of modern times. After the introduction of the smallpox vaccine in the late 1700’s, the 
19
th
 century saw the introduction of vaccines against rabies, typhoid, cholera and plague, with 
the introduction of vaccines against many more diseases in the 20
th
 century, including 
tuberculosis, pertussis, diphtheria toxoid, influenza, polio, measles, mumps and rubella, to name 
23 
 
 
 
a few
31
. Despite the many technological advances during the 19
th
 and 20
th
 centuries, the field of 
vaccine design has not changed much since the introduction of the smallpox vaccine. Most 
vaccines rely on a timely process of trial-and-error to either remove the virulence factors or 
improve the immune response to a killed pathogen. This section will attempt to summarize 
current vaccine technologies and discuss recent advances in the field of vaccine design, 
specifically the use of biodegradable polymer particles for vaccine delivery, which may lead to 
improved efficacy, reduced production time, and lower cost. 
 
2.3.1 Vaccine classifications 
Most similar to the original use of the cowpox virus to vaccinate against smallpox, live 
attenuated vaccines rely on using living organisms from which the virulence factors have been 
selected against. These vaccines are able to replicate in the host, and therefore, often able to 
successfully confer protective immunity without the need for an adjuvant or a multiple-dose 
regimen. Currently used commercially available live attenuated vaccines include the measles, 
mumps and rubella vaccine (MMR combined vaccine) consisting of live attenuated strains of the 
three pathogens, the varicella (chicken pox) vaccine, the Sabin oral polio vaccine, the 
Mycobacterium bovis (BCG) vaccine against Mycobacterium tuberculosis, and the live influenza 
vaccine (Flu-mist nasal spray). The success of the Sabin oral polio vaccine is a prototypical 
example of the benefits of a live vaccine. The attenuated organism is delivered orally, and like a 
live infection, it is replicated in the gut for a period of several weeks. Additionally, the fecal-oral 
transmission route led to the passive immunization of persons in close contact with the 
vaccinated patient
32
. While these live attenuated vaccines have been effective, this strategy is 
costly and inefficient, relying predominantly on a trial-and-error approach to vaccine design. In 
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addition, live attenuated organisms may not produce an effective immune response against 
chronic pathogens, which have evolved to avoid detection by the host immune system
33
. 
Conversely, in immune-compromised patients, an attenuated strain, cleared quickly in healthy 
patients, may lead to a persistent infection or cause disease. Additionally, even with the ability to 
replicate in a host, live attenuated vaccines have been reported to require multiple doses to 
induce long-lived immunity. A single dose of the MMR combination vaccine has been reported 
to lead to outbreaks of measles and mumps among highly vaccinated populations with most 
countries implementing a compulsory second dose
34
. 
Killed vaccines consist of a whole non-attenuated pathogen that has been killed or otherwise 
inactivated through the use of heat, radiation or chemicals. Due to the retention of the surface 
PAMPs of the organism, killed vaccines are often able to induce a strong humoral immune 
response without the associated risks of administering a live pathogen to patients. Additionally, 
killed vaccines do not require the multiple in vitro passes to eliminate virulence as live 
attenuated vaccines do and have been shown to be less sensitive to storage and temperature 
fluctuations than their live counterparts. Killed/inactivated vaccines in current use include the 
Salk polio vaccine, the trivalent seasonal influenza vaccine, the typhoid, cholera and pertussis 
vaccines and the current vaccine against plague. While these vaccines maintain the antigen in its 
native state, i.e., not attenuated, the organisms are not able to replicate in the host like their live 
counterparts, often leading to reduced immunogenicity and the need for multiple doses or the use 
of an adjuvant. Despite being potent initiators of humoral immunity, killed vaccines are often 
poor at inducing a cellular response, making them ineffective against many intracellular 
pathogens. Finally, like live vaccines, the microbial components of killed vaccines such as LPS 
25 
 
 
 
and other inflammation-associated MAMPs remain intact, which has been shown to lead to 
discomfort and adverse reactions associated with vaccination
35
.   
Subunit vaccines involve identifying a specific antigen from an infectious microorganism that is 
able to elicit protection. Subunits may be a polysaccharide, protein, or DNA. Current subunit 
vaccines that are available to the public include the 7 and 13-valent pneumococcal conjugate 
vaccines, the meningococcal and the Haemophilus influenza type B vaccines that utilize the 
bacterial polysaccharide capsule conjugated to a protein, the hepatitis B vaccine, and vaccines 
against human papilloma virus, which are composed of self-assembling recombinant proteins 
which make up the viral capsid. Subunit vaccines have the advantage of being able to be 
delivered through a number of different routes which may mimic the route of infection. 
Additionally, by using only a component of a pathogen, subunit vaccines, avoid exposure to 
microbially associated compounds such as LPS, which may cause adverse reactions through 
innate immune triggering of inflammatory responses. Like killed vaccines, subunits from 
microorganisms such as proteins or DNA are typically poorly immunogenic and require the use 
of an adjuvant to be effective
36,37
. In addition, these vaccines, often based on recombinant 
proteins, can be expensive to produce
38
. 
 
2.3.2 Vaccine adjuvants 
Vaccines that cannot replicate in the host such as killed vaccines and subunit vaccines are often 
poorly immunogenic, and therefore require the use of an adjuvant to boost the immune response 
to the antigen. Adjuvants have been added to vaccines to improve efficacy since the early 20
th
 
century
39
. It has been proposed that adjuvants can act to improve the immune response by five 
mechanisms
7
. The first, immunomodulation, upregulates the immune response through the 
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cytokine network and may skew the immune response to a TH1 or TH2 immune phenotype. The 
second, preservation or presentation, refers to adjuvants that can protect the payload and that are 
able to display intact antigen to cells in its native state. Thirdly, adjuvants can act to induce cell-
mediated or cytotoxic T lymphocyte (CTL) responses. Fourthly, vaccine adjuvants can be 
designed to target effector immune cells. For example, carbohydrate adjuvants target C-type 
lectin receptors on macrophages and DCs
40
. Finally, vaccine adjuvants may improve the immune 
response through the generation of a depot for antigen, leading to the potential for a single-dose 
vaccine regimen
39
. 
 
2.3.2.1 Aluminum salts 
The first, and most commonly used, licensed vaccine adjuvant is based on aluminum salts, or 
Alum, and has been used in vaccines for over 70 years
39
. First reported to successfully boost the 
immune response to diphtheria toxoid in 1926, this adjuvant is characterized as aluminum 
oxyhydroxide (AlOOH) and aluminum hydroxyphosphate (Al(OH)x(PO4)y)
41
. It has been 
suggested that aluminum salt adjuvants the immune system by two mechanisms: the generation 
of an antigen depot and immune stimulation
41
. The mechanism of the depot effect is explained 
via the trapping of soluble antigen in the aluminum matrix through adsorption, which is thought 
of to extend the ability of antigen to drive the immune response
42
. Additionally vaccines 
adjuvanted with aluminum salts have been shown to stimulate the complement system and 
activate macrophages and eosinophils
43
. These adjuvants tend to induce only a modest TH2 
phenotype immune response, making for ineffective vaccines against viruses and intercellular 
bacteria. While generally considered safe and widely used in human vaccines, the production of 
IgE antibodies, associated with allergic responses, have been reported with the use of vaccines 
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formulated with mineral salts
43
. Toxic buildup of aluminum has also been reported in patients 
who are unable to metabolize the mineral effectively, resulting in neurological symptoms. 
Additionally, mineral salts are only effective in intramuscular delivery applications
42
, making it 
ineffective against mucosal-associated pathogens which may require vaccine delivery to the site 
of infection for optimal efficacy. Calcium, iron and zirconium have also been investigated for the 
adsorption of antigens, with far less use than aluminum, despite the advantages of reduced 
neurological and allergic effects
42
. However due to the increased recruitment of monocyte and 
granulocyte cell populations, aluminum salts may not prove an appropriate adjuvant for the 
delicate immune environment of the lung
44
. 
 
2.3.2.2 Adjuvant emulsions 
The next vaccine adjuvant to be approved for human use since the introduction of alum is the oil-
in-water emulsion adjuvant, MF59. MF59 consists of squalene, a steroidal precursor to 
cholesterol in humans, in citrate buffer stabilized by polyoxyethylene sorbitan monooleate and 
sorbitan trioleate, commonly known as Tween 80 and Span 85, respectively
45,46
. MF59 has been 
extensively studied as an adjuvant for vaccines against the influenza virus
47
. MF59 has been used 
clinically in patients over the age of 65 and has been shown to produce statistically higher anti-
hemagglutinin titers than the traditional seasonal influenza vaccine
48
. MF59 has also been shown 
to be an effective adjuvant for use against pandemic strains of influenza in naïve populations. It 
was used in the 2009 H1N1 pandemic influenza vaccine
49
.  It has also been shown to outperform 
alum in trials with the H5N1 avian influenza virus
50
.  
MF59 creates a localized inflammatory response at the injection site, but unlike other adjuvants, 
it does not provide a depot effect for antigen
51,52
.  The mechanism of action of MF59 has been 
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shown to be resultant from increased uptake by dendritic cells
44
.  Seubert et al.
44
 further 
elucidated this mechanism by proving that MF59 stimulates differentiation of lymphoid 
precursors into dendritic cells and also enables the release of chemokines to attract other immune 
cells to the injection site.  The ability to recruit innate immune cells is attributed to the up-
regulation of ICAM-1, as it has been shown that MF59 loses this ability in ICAM-1-deficient 
mice
53
.  Caproni et al. recently reported that MF59 induces an IFN-independent immune 
response to both influenza and tetanus toxoid
47
.  While MF59 has been studied extensively for 
safety, data from numerous clinical trials indicate an increased risk for both local and systemic 
reactions
44
. These data present a reason for concern when considering MF59 for use in a 
pulmonary vaccine, because increased inflammation in the lung could pose serious health risks.   
In addition to squalene-based oil-in-water emulsion adjuvants, other oils, such as grapeseed, 
soybean, and sesame, have been investigated for their adjuvant properties.  Though the 
triglycerides tested had similar particles sizes and stability to squalene, they produced 
significantly lower IgG titers when administered with Fluzone
54
. Additionally, AS03, a 
proprietary squalene-based oil-in-water emulsion containing α-tocopherol has been investigated 
for use in pandemic influenza vaccines
55
. 
Microemulsions and water-in-oil-in-water emulsions have also been investigated as potential 
vaccine adjuvant systems.  Leclercq et al. recently reported improved serum protection against 
rabies challenge with both microemulsion and water-in-oil-in-water emulsions as compared to 
alum and complete Freund’s adjuvant56. 
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2.3.2.3 Biologically-derived vaccine adjuvants 
 There are a number of microbially derived compounds currently being studied for use as 
vaccine adjivants. Most of this research relies on isolating specific MAMPs that interact with 
immune cells through pattern recognition receptors (PRRs) on the cells
40
. The adjuvant effect of 
these compounds comes from the stimulation of the innate immune response, which can be used 
to direct the phenotype of the resultant adaptive immune response
57
. TLR-agonists based on 
lipopolysaccharide (LPS), a component of cell walls of gram-negative bacteria have been 
extensively studied as immune-boosting vaccine additives
58
. LPS and LPS-derived compounds 
are known to interact with immune cells through the TLR4 endotoxin receptor
58
. However, LPS 
has toxic effects and is not an appropriate adjuvant for human use. Monophosphoryl lipid A, a 
compound derived from LPS, has been shown to provide immune-stimulating properties without 
the toxicity of LPS
35
. The TLR9-agonist, CpG DNA has also demonstrated promise as a vaccine 
adjuvant through stimulation of the innate immune response
57
. Poly(I:C) or polyinosine-
polycytidylic acid has also been studied as a potential vaccine adjuvant
59
. This compound 
interacts with TLR3, which is found in human mDCs and T cells, making it a good candidate for 
vaccines that require a cellular immune response.  
 
2.3.2.4 Cytokines as vaccine adjuvants 
 The ability to modulate the immune response to a desired phenotype may be beneficial 
when designing vaccines. This has been studied through the inclusion of various cytokines in 
vaccine formulations
58,60
. As reviewed in Section 2.2, the cytokine profile of the innate immune 
response to a pathogen, or an adjuvant, plays a large role in directing the adaptive immune 
response. By including cytokines in vaccine formulations, or by using cytokines as adjuvants in 
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vaccines, it is possible to design vaccines with the desired immune phenotype(s)
61
.  A large body 
of work is available using cytokines to adjuvant experimental, or even commercial, vaccines
60
. 
Cytokines that have been tested include IL-1, IL-2, IL-3, IL-6, IL-12, TNF and GMCSF
60
. The 
addition of these proteins has been studied as vaccine additives or through fusion to a protective 
antigen such as pneumococcal surface adhesion A (PsaA) and IL-2 or IL-4 constructs in vaccines 
against S. pneumoniae
62
. For example, in order to adjuvant other vaccines against S. pneumoniae, 
the cytokines IL-12 or IL-17 have been added to vaccine formulations to improve performance
63
. 
 
2.4. Current Vaccine Technology Against Pulmonary Infections 
 In this section, we summarize the current state of vaccine technologies against several 
important pulmonary infections, including pneumonia, influenza, and pneumonic plague. 
 
2.4.1 Streptococcus pneumoniae 
Since its first isolation in the 1880s, Streptococcus pneumoniae (shown in Figure 2), often 
referred to as the pneumococcus, has been found to be endemic globally in all areas which have 
been tested
64
. This bacteria is so prevalent that it is considered to be part of the commensal 
bacteria flora of the human nasopharynx, with rates of colonization peaking in those of 1-2 years 
of age and declining thereafter
65
. The bacteria may colonize the upper respiratory tract, 
specifically the nasopharynx, asymptomatically for anywhere from several to upwards of 30 
weeks depending on the immunogenicity of the serotype
65,66
. When the pneumococcus spreads 
from the colonized nasopharynx to the sterile lower respiratory tract or systemically to the 
bloodstream, the result is what is known as pneumococcal disease
10
. Clinical diseases resulting 
from S. pneumoniae range from upper respiratory symptoms including otitis media and sinusitis 
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to lower respiratory tract infections such as pneumonia to systemic bacteremia and 
meningitis
10,65
. Despite having a higher disease burden in children
67
, pneumococcal pneumonia 
can affect individuals in any age range, and if left completely untreated has been reported to have 
a case fatality rate upwards of 30%
68
.    
There are over one million pneumococcal infections each year resulting in significant global 
morbidity and mortality
65
. S. pneumoniae however is largely vaccine-preventable, with the 
introduction of the heptavalent pneumococcal conjugate vaccine in 2000 leading to a significant 
reduction in cases of invasive pneumococcal disease in both the United States and Europe
69,70
. 
The introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States 
in 2010 included the 13 most prevalent serotypes, responsible for over 90% of childhood cases of 
invasive pneumonia
69
. Analysis of the results of the introduction of the PCV13 is still ongoing, 
and it remains to be seen whether serotype substitution occurs within a few years of introduction, 
as observed after introduction of the PCV7 vaccine.   
A considerable amount is known about the colonization and pathogenesis of S. pneumoniae. 
Much of this information has been thoughtfully used to discover protective antigens, design 
novel vaccines, and reduce pneumococcal colonization and disease. Herein, we outline the 
classification strategies for S. pneumoniae, review current literature on the pathogenesis of the 
organism from colonization to clinical disease, and discuss current and emerging vaccine 
technologies.  
 
2.4.1.1 Classification 
 S. pneumoniae bacteria are gram-positive, alpha-hemolytic diplococci
69
. There are over 
90 known serotypes of pneumonia which differ in their polysaccharide capsule, specifically the 
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sugars making up the capsule and the linkages between those sugars, and are classified based on 
its interaction with anti-sera
10,71
. The capsular type has been demonstrated to have a large impact 
of the ability of S. pneumoniae to cause invasive disease, with serotypes lacking a capsule 
exhibiting greatly attenuated properties
72
. Medically-relevant S. pneumoniae serotpyes include 
19 A, the most common serotype causing invasive pneumococcal disease (IPD) in children 
(before inclusion in the PCV13 vaccine), with these serotypes accounting for a significant 
portion of the disease burden. Before the introduction of the 23-valent polysaccharide vaccine or 
the PCV7 or 13, serotypes 6, 14 and 18 accounted for over half of cases of systemic bacteremia 
and meningitis, with the majority of otitis media infections caused by serotypes 3, 19, and 23
73
. 
Capsular serotype has also been shown to have an effect on the development of antibiotic 
resistance. Resistance to penicillin was first noted in S. pneumoniae in 1965. Since that time 
highly resistant strains, as well as β-lactam resistance, and multi-drug resistance, defined as 
resistance to antibiotics of at least three different classes, have been reported with increasing 
frequency
74
.       
 
2.4.1.2 Pathogenesis 
Unlike many circulating diseases, humans provide the main reservoir for S. pneumoniae, making 
person to person transmission a crucial step in the survival and spread of the pathogen
65
. While 
transmission from symptomatic patients is possible, the pneumococcus is most commonly spread 
through aerosolized droplets from healthy individuals with asymptomatic S. pneumoniae 
colonization of the upper respiratory tract
65
. It is estimated that at any given time up to 40% of 
adults and children are colonized with S. pneumoniae, with the most commonly found serotypes 
being 6, 14, 18, 19, and 23, which account for upwards of 60% of pneumococcal infections. This 
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bacterial carriage in the upper respiratory tract or nasopharynx typically lasts from 4-6 weeks, 
but has been shown to persist for upwards of 30 weeks depending on the immunogenicity of the 
serotype
65,66
. Adherence to epithelial cells and the ability to colonize the nasopharynx is 
mediated by pili, filamentous structures decorating the outer surface of the pneumococcus
75
. 
How this bacteria disseminates from the nasopharynx to the lower respiratory tract has been the 
subject of numerous investigations, with a number of virulence factors identified which play 
roles in infection with S. pneumoniae
76
.  
S. pneumoniae is a transient member of the commensal bacteria of the upper respiratory tract, 
often remaining asymptomatic for the duration of the infection. It is when bacteria reach the 
sterile lower airways that disease can occur, often due to inflammation associated with the innate 
immune response to infection, leading to pneumonia. Capsular polysaccharide (CPS) has been 
shown to be one of the main virulence factors in IPD. Other virulence factors include cell wall 
components, choline-binding proteins, and secreted factors such as hemolysin, pneumolysin, 
autolysin, and hydrogen peroxide
77
. Cytolysins such as pneumolysin are released by 
pneumococcus during infection, and contribute to lung inflammation and lung injury during 
pneumonia
78
. Systemic infection can occur when S. pneumoniae disseminates from the lung into 
the bloodstream. These types of infections may be lethal. Virulence factors that have been 
demonstrated to have an effect of the ability of S. pneumoniae to disseminate to the bloodstream 
include pneumococcal surface adhesin A (PsaA) and the first capsular gene, cpsa
79
. Additionally 
the cell surface protein pneumococcal adherence and virulence factor A (PavA), important in 
bacterial binding to fibronectin, has been shown to play an important role in the establishment of 
a septicemia in a murine model
80
.  
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2.4.1.3 Current vaccine strategies 
 S. pneumoniae is the leading cause of community-acquired pneumonia; it is also the 
causative agent of most cases of bacterial meningitis. Untreated bacteremia has a fatality rate of 
upwards of 70%. The use of antibiotics has greatly improved morbidity and mortality associated 
with S. pneumoniae, but with the increase in prevalence of antibiotic-resistant strains of S. 
pneumoniae, vaccination against this pathogen remains one of the most important strategies in 
combating pneumococcal disease
81
. S. pneumonia had long been a public health concern 
globally, and vaccination attempts against the pathogen have been reported since the 1940s, 
culminating in commercial availability of a 6-valent vaccine formulation of purified 
polysaccharide capsule, including types 1, 2, 3, 5, 7, 12
82
. The drive for an effective vaccine 
against S. pneumoniae was abruptly ended after the introduction of effective antibiotics against 
the pathogen, the first, sulfapyridine, was introduced in 1939
83
. After the introduction of the 
widespread use of antibiotics to treat these bacterial infections, both doctors and lawmakers 
abandoned support for new vaccination programs
83
. It would not be until the 1990s that the 
increasing prevalence of antibiotic resistant S. pneumoniae strains and the lack of widespread 
pneumococcal vaccinations would lead to renewed public health awareness about the disease.   
Given the number of serotypes of polysaccharide capsule of S. pneumoniae, a universal vaccine 
based on the capsule polysaccharides has not yet been developed. Polysaccharide-based vaccines 
have been utilized including Pneumovax 23 (Merck) and Pnu-Immune 23 (Lederle Laboratories). 
These 23-valent polysaccharide vaccines against S. pneumoniae has been shown to protect 
against the serotypes included in the vaccine, 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
81
. These vaccines tend to induce antibody-
based immunity against the serotypes included in the vaccines. Serotype-specific antibodies 
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induced by vaccination with the 23-valent polysaccharide vaccines have been shown to increase 
opsonization and induce complement-mediated phagocytosis by immune cells. Epidemiological 
studies have shown that these vaccines have been very effective at preventing infections and may 
also provide protection against serotypes closely related to those included in the vaccine, 6A, for 
example
84
. In most patients a single vaccination has been shown to maintain antibody level for 
five years, although in elderly and immune-compromised patients, diminished results have been 
documented, though still conferring over 70% protection in these groups
81,85–87
.  
One drawback of the polysaccharide vaccine formulations is the T cell-independent nature of the 
immune response generated. These vaccines are not optimal for use in infants, and in fact, have 
demonstrated limited to no efficacy in this population in which rates of pneumococcal 
colonization are the highest
81
. Polysaccharide-conjugate vaccines use a carrier protein for the 
delivery of the purified polysaccharide capsule, eliciting a T cell-dependent immune response
86
. 
The introduction of the 7-valent polysaccharide conjugate vaccine (PCV7) in 2000 in the US and 
2001 in Europe, which includes serotypes 14, 4, 9V, 19F, 18C, 6B, and 23F, led to a significant 
decrease in circulation of the serotypes included in the vaccines
88
. From 1995 (before the 
introduction of PCV7) to 2009 in one US city, there was a 10% reduction of the number of 
children colonized with pneumonia, with a decrease in colonization of the serotypes included in 
the vaccine from 83% to none in patients tested
89
. In contrast, this led to an increase in 
prevalence of strain 19A, not included in the vaccine, from 5% to 49% of invasive pneumococcal 
disease (IPD) cases
89
. In many countries the PCV7 vaccine has been replaced by the PCV 13 
vaccine, introduced in 2010 in Europe, which includes 6 additional serotypes 1, 5, 7F, 19A, 6A, 
and 3
88
. Though no comprehensive studies on the epidemiological effects of this vaccine have 
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been published yet, preliminary findings suggest a reduction of the incidences of the PCV13 only 
serotypes by at least 50%
90
.  
 Antibody-mediated immunity against the pneumococcal polysaccharide capsule plays an 
important role in protection against infection. The successes of the 23-valent polysaccharide 
vaccine and the PCV7 and PCV13 vaccines have led to the assumption that anti-capsular 
antibodies are in large part responsible for clearance of infections, however this theory is 
challenged by the epidemiological similarities of infections across serotypes. Pneumococcal 
disease peaks and declines in infants according to near-identical patterns across serotypes, 
indicating another possible mechanism for protection other than capsule-specific antibodies, 
which would be dependent on exposure to specific serotypes
91
. It has been proposed that other 
antigenic components of S. pneumoniae are responsible for the generation of the natural 
immunity observed in infants
91
; these protective antigens consist of surface proteins or cell wall 
components that are universally or near-universally present across serotypes, and include 
pneumococcal surface protein A (PspA), pneumococcal adhesin A (PsaA), pneumolysin, cell 
wall components and lipteichoic acid (LTA).  
 While it has long been assumed that antibody-mediated immunity to S. pneumoniae 
polysaccharide capsule plays a role in protection, the induction of cell-mediated response may 
also be important in the generation of immunity. Age-specific acquired immunity to S. 
pneumoniae appears to occur in a serotype-independent mechanism, indicating the possibility of 
a T cell-mediated response
91
. Several reports have indicated that CD4
+
 T cells are important in 
generating protective immunity against pneumococcal carriage
92
. It has recently been reported 
that monocytes play an important role in the generation of TH1 and TH17-mediated immunity to 
S. pneumoniae infection
93
. 
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2.4.1.4 Novel vaccine strategies 
Many of the specific virulence factors reviewed above have been investigated for use as 
protective antigens in vaccine formulations, including PspA, PsaA, pilus components, and 
pneumolysin. These antigens are summarized in Table 2.2. The most well-known and researched 
S. pneumoniae subunit for potential vaccines is PspA. This choline-binding surface protein is an 
important virulence factor in S. pnuemoniae infections and is therefore present on all medically-
relevant strains of the bacteria
94
. PspA plays two different roles in invasive infection and 
nasopharyngeal carriage. In invasive, systemic infections with S. pneumoniae, PspA prevents the 
deposition of complement, an immune that assists antibodies and phagocytic cells
2,95
. PspA also 
plays a role in carriage by binding the bactericidal glycoprotein, apolactoferrin
96
. Vaccination 
with PspA has been shown to be protective against a lethal challenge with S. pneumoniae making 
it a promising candidate for use in an improved vaccine
97–99
. In addition, PspA can be 
economically synthesized as a recombinant protein and the protein-based vaccine avoids the loss 
of antigenicity observed with the polysaccharide-based vaccine
100
. Even though this protein 
exhibits a high degree of serological variance, it has been demonstrated to provide cross-
protection across multiple capsular serotypes
94,101
. 
Another choline binding protein, pneumococcal surface protein C (PspC), also known as choline 
binding protein A (CbpA), has been studied for use in vaccines against S. pneumoniae as 
well
102,103
. These proteins function to bind to human factor H and inhibit the activation of the 
alternative complement pathway and the binding of secretory IgA
102
. PspC is present on 
approximately 75% of all serotypes. Antibodies against these proteins have been found in 
patients with pneumococcal carriage and invasive pneumococcal disease. These proteins have 
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been shown to be protective against carriage, meningitis, and sepsis when fused to pneumolysin 
toxin
103
. Pneumolysin is a contributor to inflammation and lung injury during pneumococcal 
infection, it is also an important contributor to host recognition of pneumococci through 
interactions with TLR-4 and activating the classical complement pathway
78
. Detoxified 
pneumolysin components have been shown to enhance protection in vaccines containing 
PspA
100
.  
PsaA has also been investigated as a potential protective antigen against S. pneumoniae and has 
demonstrated the ability to protect against lethal challenge
104
. Thought to play a role in the 
dissemination of the bacteria to the bloodstream, PsaA is a metal-binding surface protein which 
has also been shown to be important for bacterial binding
79,105
. Like PspA, this protein has also 
been shown to provide protection against heterologous challenge with S. pneumoniae with up to 
five different capsular serotype
105
. Additionally, peptides of PsaA have been demonstrated to 
reduce carriage, an important consideration in the design of a S. pneumoniae vaccine
106
.  
The surface of some serotypes S. pneumoniae bacteria is decorated with pili. Surface pili are 
associated with bacterial adhesion in colonization and have been indicated in biofilm 
formation
107,108
. These structures have been investigated as possible protective antigens against 
infection. Recombinant pilus proteins, RrgA, RrgB, and RrgC were demonstrated to be 
protective against challenge with piliated S. pneumoniae
109
.   
Gene analysis, DNA sequencing, and advances in microbiology have led to the identification of a 
host of S. pneumoniae surface proteins and virulence factors which may be potential candidates 
for a cross-protective vaccine formulation. Recombinantly-expressed surface proteins such as 
PspA, PspA (CbpA), PsaA and pili proteins are typically poorly immunogenic when 
administered alone, requiring the use of an adjuvant to elicit a protective immune response. S. 
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pneumoniae toxins such as pneumolysin have been investigated not only as a protective antigen 
but also as a way to adjuvant other surface proteins such as PspA with resulting in protective 
immunity
100
.  
Additionally, novel vaccine adjuvants including the use of cytokines and polymeric nano and 
microparticles have been investigated. Alginate microspheres containing PsaA have been shown 
to generate mucosal immunity when administered orally and provide protection against lethal 
challenge
105
. Polyanhydride nanoparticles encapsulating PspA have shown controlled release of 
antigen and the induction of measurable antibody titer against the protein
110
. 
 
2.4.1.5 Review and future directions 
With the increasing prevalence of multi-drug resistant S. pneumoniae, vaccination remains an 
important tool in reducing morbidity and mortality associated with pneumococcal disease. While 
two classes of vaccine are currently used, the 23-valent polysaccharide vaccine and the 7- and 
13-valent pneumococcal conjugate vaccine, S. pneumoniae-associated disease remains the 
greatest global contributor to deadly acute lower respiratory infections. Capsular-dependent 
vaccine strategies have the significant limitation of not being able to induce universal protection, 
leaving vaccinated persons vulnerable to bacterial serotypes not included in the vaccine. 
“Species-specific” antigens, based on surface proteins, cell wall components, and other virulence 
factors, rather than “serotype-specific” capsule have been suggested to be responsible for the 
acquired natural resistance to S. pneumoniae observed in infants and have the potential to 
generate a universal vaccine against the pathogen (ref needed). Many potential protective 
antigens have been identified, including PspA, PsaA, and pneumolysin to name a few, yet a 
universal vaccine based on one or more of these “species-specific” components remains elusive. 
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These protective antigens tend to be poorly immunogenic, requiring the use of an adjuvant. 
Future work on the development of a universal vaccine against S. pneumoniae must include a 
safe, effective vaccine adjuvant capable of providing protection against pneumococcal carriage 
and disease. 
 
2.4.2 Yersinia pestis 
 Over the course of recorded history plague related disease has killed an estimated 200 
million people.  There are three major plague pandemics, beginning in the 6
th
 century and 
spanning the course of over a millennium. The causative agent, Yersinia pestis, was not isolated 
until the late 19
th
 century
111
. Y. pestis is a vector-born zoonotic pathogen, transmitted from a 
rodent reservoir to humans by fleas
112
. Historically, the most common form of plague infection 
in humans has been bubonic plague, transmitted through flea bites or direct contact with an 
infected individual.  Septicemic plague may follow resulting in a mortality rate between 50 and 
60% for infections of bubonic plague 
112
. 
 Worldwide plague pandemics have been made increasingly improbable through the 
introduction of modern sanitation.  However, Y. pestis remains enzootic in many animal 
populations worldwide, including rabbits, squirrels, chipmunks, and prairie dogs in the American 
west, and marmots in China and Mongolia, with isolated cases documented globally
113
.  Current 
treatment for Y. pestis infections includes the use of antibiotics. In murine models, intravenous 
and subcutaneous models of bubonic and septicemic plague responded well to quinolones and 
fluoroquinolones such as streptomycin, ceftriaxone, doxycycline, ciprofloxacin, and ofloxacin
113
. 
Intranasal models of pneumonic plague were treatable by fluoroquinolones including 
ciprofloxacin
113
. In humans, streptomycin and gentamicin are widely used, with doxycycline as 
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emerging alternative therapy. Fluoroquinolones such as ciprofloxacin have demonstrated success 
in research settings, but have not been widely tested in humans
114
. Additionally, treatment must 
be administered rapidly after the onset of symptoms for optimal efficacy
114
.  
 Though the likelihood for a modern plague pandemic remains low due to the introduction 
of enhanced sanitation and antibiotics for the treatment of infection, there is growing concern 
regarding the use of Y. pestis as a bioterrorism agent. Beginning with the use of plague infected 
fleas by the Japanese in World War II to cause plague outbreaks in China
115
, the ability of Y. 
pestis to be used in biological warfare has been well-researched.  Following World War II, 
research by the United States and the Soviet Union intensified with the US reportedly reaching 
production capabilities of up to 650 tons of at least seven classified agents
116
. This research was 
purportedly abandoned after the ratification of the Biological and Toxin Weapons Convention 
(BWC) in 1969, with the Soviet Union reportedly continuing research until as late as 1992
116
.   
Modern bioterror threats have been focused on the ability to formulate Y. pestis into an aerosol 
form, eliminating the need for flea-born vector transmission, increasing the likelihood of 
widespread pulmonary infections, and as has been documented, greatly increasing the disease 
lethality
117
. Additionally, it is possible to introduce antibiotic resistance into the bacteria, with a 
wild-type multi-drug resistant strain isolated in 1995
118
.  Further, it was shown that this antibiotic 
resistance plasmid was readily transferable to other strains of Y. pestis and Escherichia coli, 
where it remained stable
118
. With the increased threat of natural and selected antibiotic 
resistance, current vaccine strategies, which have remained largely unchanged since the 1960’s 
may not provide the efficacy necessary to secure against emerging bioterror threats
111
. In this 
section, we review the classification for Y. pestis, assess current literature on the pathogenesis of 
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the organism from critical virulence factors to the manifestations of clinical disease, and analyze 
current and emerging vaccine strategies against Y. pestis. 
 
2.4.2.1 Classification and pathogenesis 
 There are three Yersinia species that are commonly found in humans, Y. pestis, Y. 
enterocolitica, and Y. pseudotuberculosis. The later pathogens are food and water-born, causing 
limited infections of the gastrointestinal tract and intestinal lymphatics
119
. In sharp contrast, the 
vector-born Y. pestis causes highly transmissible, systemic, often lethal infection
119
.  Y. pestis is 
considered to be an evolutionary product of Y. pseudotuberculosis and is classified as an 
intracellular, gram-negative bacteria
119,120
.  
Three types of human infections with Y. pestis exist: bubonic, septicemic, and pneumonic
121
.  
Bubonic plague is characterized by edema, or swelling of the lymph nodes, known as buboes.  
Accompanying symptoms include fever and headache.  Advanced bubonic plague and death 
occur when the bacteria disseminate from the lymph nodes and infect the liver and spleen 
causing necrotic lesions on the organs
119
. Septicemic plague occurs when the bacteria 
disseminate into the bloodstream, often leading to infection of the liver and spleen, resulting in 
necrosis
122
. Pneumonic plague occurs through the inhalation of the bacteria, where infection sets 
up in the lungs causing flu-like illness followed by pneumonia, and in nearly all untreated cases, 
death
119,123
.   
 As previously stated, Y. pestis is classified as an intracellular, gram-negative bacteria
120
. 
Upon infection the bacteria enters both neutrophils and macrophages through both phagocytosis 
and active entry. Typically killed in neutrophils, Y. pestis survives intracellularly in 
43 
 
 
 
macrophages, and develops antiphagocitic mechanisms, typically attributed to Yersinia outer 
proteins YopH and YopE, allowing it to survive extracellularly in vivo
120,124
 . 
 
2.4.2.2 Current vaccine strategies 
Despite the threat of antibiotic resistance, both naturally-occurring and engineered, and the 
potential for use as a biological warfare agent, there is no commercially licensed plague vaccine 
available in the United States and Europe.  There is currently a live, attenuated strain of Y. pestis, 
EV76, which has been in use as a vaccine in the countries of the former Soviet Union and Asia, 
but is not commercially available in the United States and European countries
125
. This 
spontaneous pgm deficient mutant conferred early (7 days) and long-lasting (up to 12 month) 
protection against bubonic, and to a lesser extent, pneumonic plague, however, there are 
concerns regarding safety as site reactions and incidence of disease in certain non-human 
primates have been reported
121
. Additionally, the pgm
-
 mutant used in the EV76 vaccine retains 
virulence when administered intranasally or intravenously.  
Previously, the United States has used killed whole cell vaccines to immunize military personnel 
travelling to areas where plague is endemic, with the majority of the data collected during the 
Vietnam War
126
.  Though protection through direct challenge in humans is not available due to 
ethical considerations, data collected of immunized US servicemen stationed in Vietnam shows a 
marked decrease in incidences of infection relative to expected exposure to plague
126,127
. This 
killed whole cell vaccine required multiple immunizations and immunized individuals often 
experienced local site reactions.  Additionally, the killed whole cell vaccine provided poor 
protection against pneumonic plague because parenteral administration resulted in poor mucosal 
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immunity, in contrast to the live, attenuated vaccine, which was shown to provide some 
protection against pneumonic plague
128
. 
 
2.4.2.3 Novel vaccine strategies 
 While the EV76 live, attenuated vaccine is not widely considered suitable for human use, 
with up to 1% lethality observed upon vaccination in mice, research into creating suitable 
attenuated Y. pestis mutants has continued
126
.  Attenuation of live strains of pathogens for use as 
avirulent vaccines has proven successful with Salmonella typhimurium, Salmonella typhi, 
Shigella flexneri
126
, leading to research into whether previously documented mutations may 
reduce virulence of Y. pestis. Research has shown that mutations in phoP and htrA reduced 
virulence of the Y. pestis strains from 30 to 75-fold
126
.  Additionally, it has been shown that 
administration of a sub-lethal dose of these mutant Y. pestis strains is able to confer protective 
immunity in certain animal models. With these promising results, research into live, attenuated 
vaccine candidates against plague continues
117
. 
Due to the safety concerns of live, attenuated Y. pestis vaccines, much of the emerging research 
has focused on the identification and testing of protective protein subunits of the Y. pestis 
bacterium
129
. There are many experimental vaccines in development including live attenuated 
vaccines and a number of vaccines based on Y. pestis subunits, summarized in Table 2, 
especially F1, LcrV, and F1-LcrV (F1-V) fusion proteins
130
. A F1-V subunit formulated with 
polyanhydride nanoparticles has recently been demonstrated to provide protective immunity 
against lethal challenge with pneumonic plague. The polyanhydride nanovaccine formulation 
provided 100% protection against challenge with CO92 Y. pestis, with both soluble protein alone 
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and protein adjuvanted with MPLA failing to elicit a protective immune response
131
. These 
results suggest the potential for an effective, easily synthesized vaccine against Y. pestis. 
  
2.4.2.4 Review and future directions 
The use of biological agents as bioterrorism weapons remains a considerable threat due to their 
relative ease of manufacture and the high mortality rates of many select pathogens
132
.  One 
pathogen that is considered to have the potential to be used as a biological weapon is Y. pestis, 
the causative agent of plague-related diseases, due to its ability to spread through aerosolized 
droplets and the ability to easily introduce antibiotic resistance
130
. Despite this, and the fact that 
plague is still endemic in many regions globally, no commercial vaccine against Y. pestis is 
available
130,133
. There are many experimental vaccines in development including live attenuated 
vaccines and a number of vaccines based on Y. pestis subunits, especially F1, LcrV, and F1-LcrV 
(F1-V) fusion proteins
130
. A F1-V subunit based on polyanhydride nanoparticles has recently 
been demonstrated to provide protective immunity against lethal challenge with pneumonic 
plague. The polyanhydride nanovaccine formulation provided 100% protection against challenge 
with CO92 Y. pestis, with both soluble protein alone and protein adjuvanted with MPLA failing 
to elicit a protective immune response
131
. These results suggest the potential for an effective, 
easily synthesized vaccine against Y. pestis. 
 
2.4.3 Influenza 
Although disease causing ultra-filterable agents were not identified until the beginning of the 20
th
 
century, a high mortality disease that affected birds was defined in 1878 and referred to as “fowl 
plague”134. It wasn’t until 1933 that the influenza virus was first isolated from swine. To this day, 
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the influenza virus continues to infect thousands of people each year while causing significant 
health and economic burdens
135,136
. The most dramatic of these effects have been the cause of 
influenza pandemics. There have been three pandemics in the 20
th
 century: in 1918, 1957, and 
1968. All three pandemics were caused by different subtypes of the influenza A virus and 
identified by their presumed sites of origin
137
.  
The “Spanish” influenza 1918 H1N1 pandemic has at times been referred to as the mother of all 
pandemics. An estimated one third of the world’s population was infected leading to 50 million 
deaths. Almost all cases of Influenza A globally are the cause of decedents from the 1918 virus. 
The “Asian” influenza 1957 H2N2 pandemic caused a million deaths worldwide from 1957 to 
1968
138,139
. This pandemic may have been the result of reassortment events in unknown 
mammalian hosts involving multiple avian viruses
140. The “Hong Kong” influenza 1968 H3N2 
pandemic, like the previous pandemic, was also the result of antigenic shift and contained genes 
from avian influenza viruses. This was the first known outbreak of the H3N2 strain and resulted 
in a million deaths
140
. The potential of a pandemic of several Influenza A viruses, including 
H5N1 and H9N2, is a public health priority for the 21
st
 century. 
 
2.4.3.1 Classification 
Influenza consists of three of the four genera of the Orthomyxoviridae family: influenza A, 
influenza B and influenza C
141
. Influenza is a negative sense RNA virus with single-stranded 
segmented genomes. The influenza B and C viruses primarily infect humans although Influenza 
C can occasionally infect pigs and dogs
142
. Influenza A viruses infect a wide range of hosts in 
different geographical regions. This virus type is further classified into subtypes on the basis of 
the antigenic properties of the haemagglutinin and neuraminidase. This includes 15 
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hemagglutinin and 9 neuraminidase subtypes all of which can be found in wild birds
143
. The 
influenza genome includes 8 segments that encode 11 viral genes. These viral genes include: 
hemagglutinin (HA), neuraminidase (NA), matrix 1 (M1), matrix 2 (M2), nucleoprotein (NP), 
non-structural protein-1 (NSP1), nuclear export protein (NEP) and polymerase proteins (PA, 
PB1, PB2, PB1-F2 (PB1-F2)). The influenza virus envelope is taken from the plasma membrane 
of the host cell during the budding process
144
. 
 
2.4.3.2 Pathogenesis 
Influenza is an acute respiratory disease that replicates in epithelial cells in the lower and upper 
respiratory tract. It is characterized by a multitude of clinical signs including the onset of a high 
fever, cough, headaches and inflammation of the respiratory tract. Although this disease affects 
all age groups, the severity is typically increased among the young, elderly and sick. 
Complications that can arise as a result of infection include hemorrhagic bronchitis, pneumonia 
and death. The influenza A virus reaches its apex of replication at approximately 2 days during 
the inoculation of the throat. After this time, replication starts to slow down with little virus shed 
after approximately day 6
145
. Influenza typically resolves within 1 – 2 weeks although a cough 
may persist for longer
146
.  
The hemagglutinin protein precursor, HA0, is composed of HA1 and HA2 subdomains which 
contain the receptor binding domain and the fusion peptide respectively. This protein interacts 
with sialic acid on the host cell for viral attachment and determines host tropism. The majority of 
linkages of the sialic acid residues on the host cell are α-2,6-linked and α-2,3-linked. Human and 
avian influenza viruses contain only one confirmation of sialic acid linkage while swine contain 
both. This makes swine an ideal vessel for viral RNA reassortment between human and avian 
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influenza viruses. After the influenza virus has attached to the host cell by binding to sialic acid 
resides, the virus enters via receptor-mediated endocytosis. The fusion peptide brings together 
viral and endosomal membranes allowing entry into the cytoplasm
144
. The fusion peptide of the 
HA protein is exposed after cleavage of the HA0 precursor by trypsin-like enzymes. This limits 
the site of infection to the respiratory and intestinal tract. The HA0 cleavage sites of highly 
pathogenic avian influenza (HPAI) are cleaved by more ubiquitously present proteases, most 
likely furin, allowing these viruses to replicate throughout the host’s organs and tissues. For this 
reason the mortality rate of HPAI influenza viruses is far greater
147
 
 Diagnostic methods of influenza include viral culture, the establishment of viral antigens 
or viral genetic material or through the monitoring of specific antibody titers. Infection can be 
treated with antiviral drugs or prevented with immunization which has been shown to be 70% to 
90% effective in preventing influenza A infection in healthy young adults
145
.  
 
2.4.3.3 Current vaccine strategies 
 Protection against influenza is mediated by both mucosal and systemic immunity with 
antibodies elicited in the upper respiratory tract as a major contributor to resistance. Antibodies 
are elicited against all influenza proteins during infection but antibodies targeted to surface 
proteins HA and NA are most associated with resistance. Although humoral immunity plays a 
significant role in immunity, a cytotoxic T cell response directed against M1, M2 and NP 
proteins has an important role in clearing the virus and recover from illness. Natural infection 
can lead to long lasting immunity but due to the high mutation rate of influenza individuals may 
only be protected against new strains for only a few years which is why seasonal vaccination is 
essential to protection
146
. 
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 Inactivated influenza vaccines have been available since the 1940s. This vaccine type is 
less common today due to the reactogenicitiy of delivered inactivated whole virus to children
148
. 
In 2010, the Advisory Committee on Immunization Practices (ACIP) started recommending two 
different vaccine types based on age groups for universal seasonal influenza vaccination. The 
trivalent inactivated vaccine (TIV) for individuals 6 months or older, or the live attenuated 
influenza vaccine (LAIV) for healthy non-pregnant individuals between 2 and 49 years of age
149
. 
The dominant component in TIV is HA polypeptide purified from inactivated virions and 
contains at least 15 μg of HA for each strain of influenza. These vaccines generally function by 
offering hemagglutination-inhibition (HI) antibodies in previously influenza primed recipients
148
. 
The goal of LAIV is to confer protection through the natural route of viral infection. These 
vaccines can be administered intranasally via a spray device
146
. A meta-analysis by Osterholm et 
al. reported that the LAIV and TIV immunizations had a pooled efficacy of 83% and 59% 
respectively when analyzing data from randomized controlled trials over multiple flu seasons
149
. 
 
2.4.3.4 Novel vaccine strategies 
 Recent focus on influenza vaccine research has focused on the use of subunit proteins as 
protective antigens
148,150,151
, summarized in Table 3. A difficult obstacle for influenza 
vaccination is the need to protect against multiple HA and NA subtypes. There is a desire to 
develop a novel vaccine strategy that can offer cross protection against all Influenza A subtypes. 
One method is to target more highly conserved viral protein such as the NP, M1 and M2 
proteins. An antibody response against the internal NP and M1 proteins does not offer protection 
because it does not neutralize the virus. However, there has been some effectiveness in eliciting 
antibody titers against the M2 surface protein in mice. Other research has focused on utilizing 
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DNA vaccination to establish a cell mediated immune response to the NP protein. The cell 
mediated immunity is a delayed response and may not offer protection against HPAI which can 
cause death as soon as 1 day after challenge
143
.   
 
2.4.3.5 Review and future directions 
 The high mutation rate and segmented genome of the influenza virus has made 
vaccination against this pathogen difficult. With the threat of a new pandemic from strains 
including H5N1 and H9N2, it’s increasingly important for government agencies to fund 
influenza based research. As we increase our knowledge of the pathogenicity of influenza we can 
continue to develop novel vaccine strategies against the virus. Newly developed vaccines will be 
tested against LAIV and TIV, which have a proven track record of safety and effectiveness.  
 
2.5. Rational Design of Next-Generation Pulmonary Vaccine Nanoadjuvants 
Traditionally used, off-the-shelf vaccine adjuvants differ greatly in their material properties and 
mechanisms of action.  The goal of a vaccine adjuvant is to successfully stimulate the innate 
immune response to generate a long-lasting adaptive immune response.  There is a unique 
opportunity to design efficacious vaccine adjuvants by exploiting knowledge of material 
properties from the many different approved vaccine adjuvants and combining them with 
polymer and particle synthesis methodologies.  One of the benefits of the use of polymeric 
particle-based adjuvants for pulmonary delivery is the ability to tailor their interactions with 
respiratory tract fluid, which consists of pulmonary surfactant and surfactant proteins. The first 
interaction of inhaled particles with respiratory tract fluid occurs at the air-fluid interface.  As 
inhaled particles come into contact with the pulmonary surfactant layer, they are introduced into 
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the fluid phase
152
. This interaction can be modified through the particle surface chemistry, 
particle shape, and particle size.  In addition, surfactants or other mucoactive compounds may be 
included to enhance particle distribution. 
 
2.5.1. Route 
The route of delivery is an important consideration in vaccine design. Routes of delivery that 
have been investigated for vaccines include oral, intramuscular, subcutaneous, and intranasal. 
The intramuscular route is the most common method of delivery for vaccines, being delivered 
via traditional syringe and needle
153
. Vaccines delivered intramuscularly include the seasonal 
influenza vaccine, the PCV 7 and 13 vaccines, meningococcal vaccines, and all vaccines on the 
childhood vaccination schedule (e.g., MMR, dTaP, etc.). The BCG vaccine is delivered 
transdermally. This approach is often optimal for inducing an effective systemic response to the 
injection. Intramuscular and subcutaneous administrations have the limitation of widespread 
patient aversion for needles as well as the need for a medical professional to administer the 
shot
32,154
.   
Oral immunization has been known about for millennia with some early Bedouin tribes having 
been reported to consume the cooked meat of rabid animals as a vaccination strategy
154
. The oral 
route provides some benefits for vaccine design, including a less invasive method of delivery and 
the ability to induce mucosal immune responses
155
. Oral vaccines include the Sabin live oral 
polio vaccine, rotavirus, typhoid, and cholera vaccines
156
. A prototypical example of oral 
immunization is the Sabin live oral polio vaccine, which has played an important role in the 
efforts to eradicate polio. This vaccine provided a number of advantages over Salk’s killed 
vaccine including ease of delivery, obviating the need for administration by medical workers, 
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reducing costs
32
. One drawback of the oral route of vaccination is diminished immune responses 
in infants, children, and adults living in poverty and in developing countries, as observed with 
oral polio, rotavirus, cholera and shigella vaccines
156
. The mechanism of this disparity is poorly 
understood, but is hypothesized to be associated with vitamin deficiency, nutrition, or Giardia 
infection
156
. Additionally, many vaccines may have problems with stability associated with the 
gastrointestinal tract, particularly subunit vaccines based on proteins, which can be susceptible to 
acid-induced degradation
153
.   
 The intranasal and pulmonary routes of administration have gained in interest in recent 
years due to the many advantages of this strategy, including needle-free administration and the 
high bioavailability and low metabolism of the respiratory tract. Vaccines delivered intranasally 
include the live attenuated influenza vaccine (LAIV, FluMist). Vaccines delivered intranasally 
and through aerosolization have the advantage of being able to elicit mucosal immunity in the 
nasal and respiratory tracts and be delivered via the route of natural infection for many 
respiratory pathogens
153
. However, this route of vaccination has safety concerns because the 
delicate immune environment of the lung is particularly susceptible to inflammation-associated 
pathology, which may be problematic when immunizing with whole cell vaccine formulations
153
. 
 
2.5.2 Adjuvant chemistry 
As stated above, the pulmonary route remains an attractive option for next-generation vaccine 
adjuvants due to high bioavailability, needle-free delivery, and the ability to induce mucosal 
immunity against respiratory pathogens such as influenza, pneumonia and plague
157
. Obstacles to 
pulmonary delivery include delivery to the alveoli, poor uptake, and expulsion through 
mucociliary clearance
158
.  Biodegradable polymers have the ability to overcome many of the 
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obstacles presented by the pulmonary delivery route, however polymer interactions with the 
immune mechanisms of the lung are not yet fully understood.  Herein we outline several classes 
of biodegradable polymers with the potential to improve pulmonary vaccine design, with each 
polymer class possessing unique chemical properties that may be used to rationally design 
protective vaccines against respiratory pathogens. Table 4 overviews the biodegradable polymer 
families that will be discussed in this review. 
 
2.5.2.1 Polysaccharides 
The polysaccharides that have been investigated to date include chitosan, dextran, and alginate. 
Particular attention has been given to the use of chitosan in vaccine formulations due to its ability 
to be delivered to mucosal surfaces and to generate IgA antibodies, due to its mucoadhesive 
properties
159
. Chitin and chitosan are polymers of D-glucosamine and N-acetylglucosamine with 
β-1,4 linkages, derived from glucose, found in the polysaccharide shells of crustaceans and 
insects
160
. Chitosan is formed from the deacetylation of chitin, using an excess of sodium 
hydroxide in water
161
. These polymers have mucoadhesive properties that have been shown to 
prolong residence time after intranasal administration
162
. In addition, one mechanism of action of 
these polymers is hypothesized to be through their ability to open the tight junctions between 
alveolar epithelial cells, facilitating transport of the vaccine
163
. Chitosan has demonstrated the 
ability to stimulate innate immune cells through interactions with TLR-2, macrophage mannose 
receptors, and C-type lectin receptors
164
. These interactions have been demonstrated to lead to 
the production of cytokines that recruit and activate innate and adaptive immune cells, resulting 
in the induction of a TH1, TH2, and TH17 adaptive immune phenotype
165
. Chitosan and chitin-
based vaccines against influenza and diphtheria have been reported
166,167
.   
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Dextrans have also been investigated for use as vaccine adjuvants
168,169
. These polysaccharides 
are α-glucans comprised of D-glucose with α-D (1,6) linkages produced by bacteria when grown 
in the presence of sucrose, purified by dissolving in water followed by precipitation in ethanol
170
. 
These polymers have been investigated for use in vaccines against tetanus toxoid, 
Mycobacterium tuberculosis, and cholera, with a mechanism of action proposed to be linked to 
its pro-inflammatory effects
160,169
. Acetylated dextran microparticles have demonstrated success 
as a vaccine carrier against Bacillus anthracis, however, the adjuvant, resiquimod, a TLR 
agonist, was also necessary to induce protection
171
. Additionally, diethylaminoethyl-dextran 
(DEAE-dextran) has been investigated and shown to enhance the immune response to a 
Venezuelan equine encephalomyelitis virus vaccine in non-human primates
160
. 
In addition to glucans such as dextran and chitins, other carbohydrate-based vaccine adjuvants 
that have been investigated include fructans, mannans, and bacterially-derived compounds such 
as lipopolysaccharide and its derivatives
160
. 
 
2.5.2.2 Polyesters 
 Polyesters are the most extensively studied biodegradable polymers for drug and vaccine 
delivery. Degradable polyesters that have potential for vaccine delivery applications include 
poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyric acid) 
(P3HB), poly(4-hydroxybutyric acid) (P4HB) and poly(ε-caprolactone) (PCL). Polyesters have 
been proposed to function as vaccine adjuvants by providing a depot for antigen and enable the 
controlled release of antigen over time. However, poly(glycolic acid) (PGA) by itself is limited 
as a vaccine delivery vector. Due to its hydrophilicity, it releases payload too rapidly and it is 
difficult to process using typical polymer solvents; instead it has mostly been used in degradable 
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sutures
172–176
.  In contrast, PCL has been shown to undergo extremely slow degradation with an 
in vitro and in vivo polymer weight loss of between 14 and 20% in one year
177–181
, release 
payload with high burst (40 – 70%) followed by very slow remaining extended release, and 
possess agent-dependent loading efficiency (14 – 70%) making it questionable for vaccine 
delivery applications
182–188
.  Among the most common polyesters investigated for use as 
adjuvants or for delivery are copolymers of lactic and glycolic acids. Poly(lactic-co-glycolic 
acid) (PLGA) degrades into biocompatible metabolites and is FDA-approved for human use
189
. 
These polymers are often used as nano and/or micro particles in vaccine delivery systems. With 
nano and microparticles based on PLGA shown to interact with APCs and induce the release of 
cytokines, stimulating the immune response and resulting in a TH1 immune phenotpye
190–192
. 
These polymers have been investigated for use in vaccines against a number of pathogens 
including hepatitis B, tetanus toxoid, and Bacillus anthracis
193–195
. 
Even with the extensive use of polyesters in drug delivery applications, there still exist 
significant shortcomings with their use, including limited flexibility in tuning payload release, 
the formation of low pH microenvironments, and the constant moisture exposure of payload due 
to its bulk erosion profile. The bulk erosion of polyesters allows for significant residence time 
with water for encapsulated materials. These factors combine to allow for sensitive amino acids 
and proteins like insulin and uterocalin to aggregate, hydrolyze and change conformation
196–198
. 
Another drawback of the use of polyesters for subunit vaccines is the report of protein instability 
during the manufacturing process and in the presence of acidic PLGA degradation products
199
. 
The polyesters PLA and PLGA demonstrate significant lack of control in payload release. While 
the lactic acid component of PLGA can be easily modulated between 50% and 100%, the release 
profiles of encapsulated material do not significantly change
200–202
. Coating the surface of PLGA 
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devices has been used to overcome this issue
202,203
, but changing surface chemistry could 
drastically modulate function and interaction with the host and host cells. When these polymers 
degrade, their monomers (lactic acid and glycolic acid) significantly decrease the pH of their 
environment to as low as 1.5
204,205
. Many drugs can be significantly affected by low pH, 
especially recombinant protein and subunit based vaccines (e.g., tetanus toxoid and diphtheria 
toxoid)
206–208
. To mediate protein instability in the presence of lactic and glycolic acid, the 
inclusion of an antacid in the vaccine formulation as well as the use of the protein stabilizer, 
trehalose, have been investigated
193
. While polyesters have been extensively used in drug and 
vaccine delivery, they possess significant limitations that must be accounted for in order to 
improve their function. 
 
2.5.2.3 Polyanhydrides 
 Polyanhydrides, used in the textile industry since the 1920s and investigated for possible 
use as drug delivery systems since the 1980s, are a class of materials characterized by a 
backbone of monomeric dicarboxylic acids (diacids) connected by anhydride linkages
209–211
. The 
anhydride linkages that join the monomer units are hydrolytically labile bonds that are cleaved in 
the presence of water to form non-toxic dicarboxylic acids
212
. Polyanhydrides have many 
properties that make them ideal candidates for vaccine delivery including the ability to stabilize 
and protect fragile antigens such as proteins, provide sustained release of antigen, and the ability 
to modulate the immune response
213–216
. These polymers have excellent biocompatibility and 
have been shown to result in non-toxic, non-mutagenic degradation products
209
. The FDA-
approved Gliadel
®
 wafer is a polyanhydride device composed of a copolymer of sebacic acid and 
1,3-bis(p-carboxyphenoxy)propane for the post-surgical treatment of brain cancer
217
.  
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 There are a number of classes of polyanhydrides, classified broadly as aliphatic, aromatic 
or unsaturated polyanhydrides, with sub-classes including copolymers of aliphatic, aromatic, 
polyester, and polyether polyanhydrides
212
. Polymers and copolymers based on sebacic acid 
(SA), 1,6-(bis-p-carboxyphenoxy)hexane (CPH), and 1,8-(bis-p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) have been studied for use in drug and vaccine delivery and other 
biomedical applications
217
. It has recently been shown that micro- and nanoparticles made from 
polyanhydrides can be effectively used as adjuvants in vaccine formulations
131
. Nanoparticles 
comprised of polyanhydrides possess pathogen-mimicking properties and thus can activate the 
innate immune response by stimulating PRRs on the surface of APCs, specifically DCs and 
macrophages
218
. In addition to the stimulation of the innate immune response, it has also been 
shown that vaccination using polyanhydride nanoparticles as an adjuvant can enhance the 
adaptive immune response
219
.  Antigen delivered in the context of poylanhydride nanoparticles 
has been shown to enhance the proliferation of cytotoxic T cells compared to antigen delivered 
alone or antigen delivered with alum
220
.   Additionally, shown that changing polyanhydride 
chemistry results in markedly different antibody responses after immunization
221
. This 
information may suggest the ability to tailor polymer chemistry to the desired immune profile. 
Polyanhydride particles can also be used to tailor the immune response to the pathogen of 
interest
221
. There are a number of methods by which polyanhydride particles can be modified in 
order to target specific immune cells, including modification of their size, chemistry, and surface 
charge
40,222
. It has been suggested that the presence of oxygen and hydroxyl moieties in the 
polymer backbone leads to increased recognition by PRRs
218
. In addition, carbohydrates have 
been attached to the surface of polyanhydride particles to target and stimulate selected immune 
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cells, leading to a change in surface charge, increased uptake, and a modification of serum 
adsorption profiles
40,222,223
.  
 
2.5.3 Safety 
 Of paramount importance to a vaccine candidate is an excellent safety profile.  
Particularly when administering to the delicate immune environment of the lung, 
biocompatibility, low to moderate inflammation, and a reduced recruitment of immune cells may 
provide the necessary adjuvant effects, while avoiding inducing immunopathology to the lung 
tissue.  Many traditional vaccine adjuvants such as alum and squalene-based adjuvants such as 
MF59 have not been approved for intranasal delivery due to concerns of excess inflammation 
and pulmonary injury.  Next-generation polymeric vaccine nanoadjuvants have the potential to 
meet these challenges by providing an optimal size and shape to reach and deliver antigen to the 
alveolar spaces
224
.  Additionally, these polymeric and particle-based vaccine delivery platforms 
have the potential to eliminate the need to deliver antigen in the form of a liquid suspension and 
transition to dry powder based formulations, potentially improving patient compliance and 
increasing ease of storage
225
.  Many polymers have been extensively tested for biocompatibility, 
including polyesters, polyanhydrides and polysaccharides, each demonstrating good safety 
profiles in early-stage testing
226–228
.  
 Polyanhydrides have previously been shown to have an excellent safety profile when 
delivered subcutaneously and intramuscularly at up to 10X doses
226
. Additionally polyanhydride 
nanoparticles have been delivered extensively intranasally without adverse effects. Compared to 
MPLA, polyanhydride nanovaccines induce less lung inflammation, as measured by ProSense
®
 
750 FAST, a fluorescent indicator activated by cathepsins produced by inflammatory cells such 
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as monocytes and macrophages
229
. The nanoparticle based vaccine induced a higher neutrophil 
infiltration at early time points, as determined by H&E staining and examination by a veterinary 
pathologist, but this inflammation had resolved by 48 hours post administration (unpublished 
data).  In contrast, the MPLA formulation induced less neutrophil infiltration at early time points, 
followed by a significantly higher presence of inflammatory cells, such as macrophages by 48 
hours after vaccine delivery
229
. Interactions between polyesters and lung cells have been studied 
in vitro, showing potential for safe delivery to lung cells, however surface modification with a 
hydrophilic polymer was necessary to cross the mucin barrier and increase intracellular 
accumulation
230
.   
 
2.5.4 Persistence 
One of the benefits of polymeric vaccine adjuvants is that they provide sustained release of 
antigen as the polymer erodes, creating a depot effect. The time scale and mechanism of polymer 
erosion depends on a number of factors including polymer chemistry, crystallinity, 
hydrophobicity, and molecular weight
231
. It has been proposed that the polymer erosion process 
occurs in three steps: the penetration of water into the polymer, degradation, and dispersion
232
. 
The entry of water into the polymer is determined by the erosion method, which can be classified 
as bulk or surface. Some biodegradable polymers, including polyesters such as PGLA and 
polyethers such as poly(ethylene oxide), undergo bulk erosion
233
. Bulk erosion is characterized 
by a diffusion-dependent release of payload since water will reach the encapsulated material 
much more quickly than the degradation and erosion of the polymeric device
234
. In addition, 
once water infiltration has occurred, all hydrolytically labile bonds can be attacked 
simultaneously throughout the material. These types of materials tend to fissure and break into 
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smaller subunits before completing degradation, as shown in Figure 3. This erosion mechanism 
is not ideal for the delivery of fragile proteins because it allows the influx of water into the core 
of the delivery device leading to potential degradation and a loss of antigenicity
235,236
. In 
addition, there is little control in payload release from bulk-eroding polyesters. The lactic acid 
component of PLGA can range from 50% and 100%, but the release profiles of encapsulated 
material do not significantly change
200–202
. 
In contrast, when water diffuses slowly compared to the rate of erosion, the material is said to be 
surface-eroding
234
. These devices require the degradation of the surface polymer and dissolution 
of the resulting monomer to allow for encapsulated payload release. The hydrophobic chemistry 
of polyanhydrides prevents this invasion of water into the bulk of the device, leading to surface 
erosion and release kinetics
231,232
.  This surface erosion profile leads to the ability to tailor 
payload release both in vitro and in vivo based on the chemistry of surface eroding polymer 
chosen
221,237
. Recent work by Haughney and Ross et al. has shown that the intranasal 
administration of three different polyanhydride nanoparticle chemistries with varying degrees of 
hydrophobicity modulated the availability of F1-V in vivo. However, the persistence of antigen 
alone was not sufficient for driving an immune response, as soluble F1-V was shown to persist in 
the lung, but failed to elicit and antibody response. Therefore, when designing an intranasal 
vaccine differences in polymer hydrophobicity leading to the induction of inflammatory signals, 
polymer degradation rates and antigen availability must all be taken into account
221
.  
 
2.6 Consequences for Vaccine Design 
 The pulmonary immune response to infection is a complex process mediated by both 
chemical and cellular components. An understanding of how the immune system responds to an 
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infection can provide key insights into the design of a vaccine against a pathogen. Based on the 
above summary of immunological concepts of the pulmonary environment, there are a number of 
conclusions that can be drawn regarding vaccine design for mucosal immunization. First, an 
effective pulmonary vaccine must effectively bypass the intrinsic defenses of the lung mucosa in 
order to reach the effector cells associated with the immune response. This means that after 
aspiration into the airways, the vaccine components must not be exhaled through the cough 
reflex or be expelled through mucociliary clearance. There are several ways that this may be 
avoided for successful vaccine design. First, a vaccine may be designed to break up the surface 
tension of the mucosal layer to deposit onto the epithelium through the use of a surfactant. 
Second, a vaccine may be designed or modified to target or bind to alveolar epithelial cells, 
reducing clearance.  
 Additionally, an ideal vaccine formulation will avoid a high level of inflammation.  
Within the delicate immune environment of the lung, inflammation can lead to many unwanted 
side effects including damage to the epithelial layer and pneumonia. As reviewed above, there 
are a number of mechanisms that may lead to a recruited innate immune or inflammatory 
response, including ligation of certain TLRs on immune cells, leading to the release of pro-
inflammatory cytokines. One way that vaccines may be designed to avoid activating these innate 
immune mechanisms is by coating them with polyethylene glycol, which has been shown to 
reduce the inflammatory response to adenoviral gene delivery vectors
238
.   
 A good pulmonary vaccine will lead to the development of a highly effective adaptive 
immune response, inducing both systemic and mucosal immunity and a long-lasting memory 
response. The pulmonary route of vaccination itself has been demonstrated to be important for 
protection against colonization at mucosal surfaces, with the induction of secretory IgA (sIgA) as 
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the primary goal. The pulmonary route of delivery is patient friendly because it avoids the 
discomfort caused by needles, leading to greater patient compliance and wider availability. It has 
also been observed that patients exhibit fewer adverse effects to therapeutics delivered via dry-
powder aerosols as compared to delivery via injection
239
. Pulmonary delivery also allows for the 
distribution of the antigen directly to the site of infection for respiratory pathogens, allowing for 
the targeting of the specific immune cells, such as alveolar macrophages, and a faster 
development of mucosal immunity. Because the lungs have a relatively low metabolic rate, 
pulmonary delivery avoids the first-pass metabolism that is often associated with therapeutics 
delivered orally
240
. The lung also offers a very high bioavailability, due to the large surface area 
(>100 m
2
) for drug deposition and action as well as for systemic absorption
240,241
. 
As discussed above, polymer chemistry can have a great effect on the immune response elicited 
from a vaccine formulation.  Affecting not only payload release and persistence, but also safety 
and biocompatibility, polymer chemistry must be a careful consideration when designing next-
generation vaccine adjuvants.  As described in detail above, the release profile and erosion 
mechanism must be carefully considered. In addition, within a class of polymer, polyanhydrides 
for example, the chemistry chosen may greatly affect the cellular uptake and recruitment
242
, with 
more hydrophobic chemistries eliciting danger signals
218
. Polymer chemistry can also greatly 
affect the in vivo release profile of antigen and can be used to modulate the immune response
221
, 
introducing the possibility to design a vaccine to create the optimal immune profile for a given 
pathogen rather than a trial-and-error method. 
The antigen delivery vector is also an important consideration in designing next-generation 
pulmonary vaccines. It is well known that the size of particles delivered to the lung will affect 
both the distribution within the lung and the submersion of the particle within the respiratory 
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tract fluid
243
.  Modification of the size of polymeric delivery systems can be used to tailor the 
distribution of particles within the lung and target specific regions or immune cell populations.  
The relationship between particle size and deposition within the respiratory tract is well 
known
244,245
.  When considering the deposition of particles within the lung the aerodynamic 
diameter is an important variable, which can be manipulated through the particle density as well 
as geometric diameter
246
.  For example, as previously discussed, PLGA particles have a low 
density due to their porous structure and therefore have smaller aerodynamic diameters, allowing 
for deeper lung penetration
246,247
. In addition, it has been shown that particle size may have an 
effect on the temporal recruitment of immune cells to the lungs
248
. It has also been proposed that 
the modification of particle shape could have an effect on the biodistribution of inhaled particles.  
Huang et al. have shown that mesoporous silica nanoparticles administered intravenously travel 
to different locations in vivo depending on their aspect ratio
249
. In addition, it has been shown 
that particle shape can have an effect on the adhesive properties of a particle.  Decuzzi et al. have 
shown through mathematical modeling that vascular adhesion is affected by the aspect ratio and 
that an oblong particle shape will maximize both adhesion and payload, including upon 
pulmonary administration
250,251
. 
 
2.7 Conclusions 
Respiratory pathogens are a significant contributor to the global disease burden.  Despite this, 
many of these transmissible respiratory infections are vaccine-preventable. There is an urgent 
need for improved vaccine technologies based on increased knowledge of the unique 
immunological environment of the lung. Recent advances in the fields of medicine and 
engineering have led to an increased understanding of the immune system and its interactions 
64 
 
 
 
with invading pathogens. These breakthroughs have the potential to greatly improve the fields of 
vaccine design. Next-generation vaccines based on antigenic subunits may provide greater 
protection, wider availability, and the ability to induce cross-protection against multiple strains 
or serotypes. Despite their promise, antigenic subunits are rarely able to induce an immune 
response without the addition of an adjuvant, and can be prone to degradation in the presence of 
physiological environments. In order to maximize the benefit of subunit vaccines novel vaccine 
adjuvants and vaccine delivery systems must be developed which can protect the payload and 
deliver intact, functional antigen to the appropriate immune cells. These cells must then be 
suitably stimulated to drive the induction of an adaptive immune response.  
 Biodegradable polyanhydrides have the ability to meet all of the challenges presented by 
the increased use of protein subunits in vaccine formulations. These polymers may be formed 
into nanoparticles to encapsulate antigen in the polymer matrix and prevent degradation 
associated with exposure to water or heat. Additionally, these nanoparticles provide an optimal 
size range for the pulmonary delivery of vaccine formulations to APCs located in the alveolar 
regions of the lung. It has also been demonstrated that particles based on polyanhydrides have 
the ability to stimulate the immune system, acting as a vaccine adjuvant. These data support the 
use of polyanhydrides in next-generation subunit vaccine formulations.  
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Figure 2.1. Schematic of the airway epithelium interacting with bacteria (S. pneumoniae) 
associated immune mechanisms. 
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Figure 2.2. Schematic of Streptococcus pneumoniae bacterium, relevant surface antigens, and 
virulence factors. 
 
 
Figure 2.3. Schematic of polymer degradation mechanisms.  Blue-colored particles represent 
surface-eroding polyanhydride particles releasing payload, i.e., protein, DNA, or other 
pathogenic subunits (red particulates). Green-colored particles represent bulk-eroding polymers 
such as polyesters, which lead to an infux of water into the core of the particle and burst release 
kinetics.  
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2.10 List of Tables 
 
Table 2.1. Summary of Streptococcus pneumoniae subunit protective antigens as vaccine 
candidates. 
Protective 
Antigen 
Biological 
Function 
Vaccine Status Cross-
Reactivity 
Adjuvant(s)  Selected 
References 
Polysaccharide 
Capsule  
Function in 
virulence, 
inhibits 
phagocytosis 
Licensed by 
Merck 
(Pneumovax), 
Lederle 
Laboratories 
(Pnu-Immune 23) 
Protective 
against 
vaccine 
serotypes 
None 
81,252
 
Polysaccharide 
Capsule-
Protein 
Conjugate 
Function in 
virulence, 
inhibits 
phagocytosis 
Licensed by 
Pfizer (Prevnar, 
Prevnar
13
), 
GlaxoSmithKline 
(Synflorix) 
Protective 
against 
vaccine 
serotypes 
Polysaccharide 
conjugated to 
immunologic 
CRM197 carrier 
protein 
253
 
PspA, PspC,  Choline-
binding 
proteins 
Experimental Cross-
reactivity 
across 
protein 
clades 
Polyanhydride 
nanovaccines, 
cholera toxin 
subunits, whole 
cell pertussis,  
97,98,102
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Table 2.1 (continued)  
PsaA, PiaA, 
PiuA 
Metal-binding 
proteins 
Experimental Serotype 
independent 
antibody  
responses 
observed 
IL-2, IL-4 fusion 
proteins 
62,254
 
Pneumolysin, 
Autolysin 
Bacterial 
virulence factors 
Experimental Broad 
reactivity 
across protein 
clades 
Highly 
immunogenic, 
investigated as 
fusion to 
immunogenic 
proteins (PspC) 
78,103
 
PavA, Eno Bacterial 
adherence and 
invasion, role in 
septicemia 
Potential for 
vaccine  
  
80
 
Pili Bacterial 
adherence 
Experimental Cross-reactive, 
not present on 
all S. 
pneumoniae 
serotypes 
Freund’s adjuvant  108,109 
NanA Neuraminidase, 
sialic acid residue  
Experimental  Freund’s adjuvant 252,255 
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Table 2.2. Summary of Yersinia pestis subunit protective antigens as vaccine candidates. 
Protective 
Antigen 
Biological 
Function 
Vaccine Status Recognized 
by Plague 
Survivor 
Serum 
(Murine)
256
 
Adjuvant(s)  Selected 
References 
Fraction 1 
antigen 
(F1) 
Role in 
prevention of 
phagocytosis 
by 
macrophages 
Experimental Yes PLGA 
microspheres, 
expression on 
live Salmonella 
typhimurium 
124,257,258
 
V antigen 
(LcrV) 
Role in 
virulence, 
alters host 
cytokine 
response, 
mediates 
function of 
Yops 
Experimental Yes Expression on 
live Salmonella 
typhimurium, 
Adenovirus 
vaccine vector 
259,260
 
F1-V Fusion protein 
of Fraction 
antigen 1 (F1) 
and V proteins 
Interest in 
commercialization 
from FDA 
N/A Polyanhydride 
nanovaccines 
131,218
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Table 2.2 (continued) 
Yersinia protein 
kinase A (YpkA) 
Bacterial virulence factor, 
induces apoptosis 
Potential for 
vaccine 
applications 
Yes  
261
 
Yersinia Outer 
Proteins (YopH-
YopK) 
Modulate host response Experimental Yes Oil-in-water 
emulsion 
262
 
Plasminogen 
activator protease 
(Pla) 
Role in spread of bacteria 
from subcutaneous to 
systemic infection 
Potential for 
vaccine 
applications 
Yes  
263
 
pH 6 antigen (pH 6 
Ag) 
Prevents bacterial 
phagocytosis 
Potential for 
vaccine 
applications 
No  
264
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Table 2.3. Summary of Influenza subunit protective antigens as vaccine candidates. 
Protective 
Antigen 
Biological 
Function 
Vaccine 
Status 
Cross-
Reactivity 
Adjuvant(s)  Selected 
References 
Hemagglutinin 
(HA) 
Fusion with 
cellular 
membrane for 
viral entry 
Liscenced 
by Novartis 
(Aggripal)  
Cross-
reactive 
across clades 
Diphtheria toxoid 
protein conjugate, 
polyanhydride 
nanovaccines, 
MF59® 
150,265–268
 
Neuraminidase 
(NA) 
Role in virion 
release from 
infected cells 
through sialic 
acid cleavage  
Liscenced 
by Novartis 
(Aggripal)  
Some cross-
reactivity 
across clades 
MF59® 
151,268
 
Nucleoprotein 
(NP) 
Role in RNA 
transcription  
Phase 1 
clinical 
trials 
Highly 
conserved 
 
269
 
Matrix protein 
2 (M2) 
Proton channel Phase 1 
clinical 
trials 
Nearly 
invariable 
across 
strains with 
potential for 
universal 
vaccine 
Expressed on 
Hepatitis B virus, 
and Neisseria 
meningitidis outer 
membrane 
protein 
270–272
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Table 2.4. Chemical structures of polymeric vaccine adjuvants. 
Polymeric Vaccine 
Adjuvant 
Chemical Structure Selected 
References 
Alginate     α-L-Guluronate            β-D-Mannuronate 
 
 
 
273,274
 
 
Chitosan 
 
275,276
 
 
Dextran 
 
277
 
Poly-ε-caprolactone 
 
278,279
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Table 2.4 (continued) 
Poly(glycolic-co-
lactides) 
    lactic acid LA              glycolic acid GA 
 
 
 
280,281
 
 
Polyanhydride sebacic acid SA 
 
1,3-bis(p-carboxyphenoxy)propane CPP 
 
1,6-bis(p-carboxyphenoxy)hexane CPH 
 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane CPTEG
 
 
282,283
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CHAPTER 3: RESEARCH GOALS AND THESIS ORGANIZATION 
The overall goal of this research is to design innovative strategies for the prevention and 
treatment of bacterial infections using polyanhydride nanoparticles. Through this work, we hope 
to design efficacious pneumonia and plague nanovaccines to prevent infections through a 
protective immune response to the pneumococcal surface protein, PspA, and the Yersinia fusion 
protein, F1-V, respectively. The specific goals (SGs) of this research are: 
SG1: Investigate the mechanism of action of polyanhydride nanoparticles as vaccine adjuvants 
through interactions with immune cells at early time points and through the evaluation of the 
immune response at extended time points; 
SG2: Study the sustained release of structurally stable, antigenic, and functional PspA from 
polyanhydride nanoparticles; 
SG3: Evaluate the in vivo immune response to vaccination with PspA nanovaccine formulations 
to design a protective vaccine against lethal challenge with S. pneumoniae; and 
SG4: Evaluate the in vivo immune response to vaccination with F1-V nanovaccine formulations 
to design a protective vaccine against lethal challenge with Y. pestis. 
The overall goal of this research is to design efficacious vaccines against the respiratory 
pathogens S. pneumoniae and Yersinia pestis based on polyanhydride nanoparticles. Polymers 
and copolymers based on CPTEG, CPH, and SA were investigated as nanovaccine formulations 
for antigen delivery. The mechanism of action of polyanhydride nanoparticles was investigated 
to better understand how these nanovaccines interact with the immune system both early and 
late. Fluorescently-labeled antigen was delivered in 50:50 CPTEG:CPH nanoparticles and 
compared to soluble protein and protein adjuvanted with MPLA initially (Chapter 4). To 
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investigate how prolonged antigen presence affects vaccine efficacy, several polyanhydride 
chemistries were tested and compared to MPLA at 14, 36, and 63 days after administration 
(Chapter 5). The bacterial surface protein PspA was found to retain stability and antigenicity 
upon release from 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticles (Chapter 6). Chapter 7 
describes the design of a protective polyanhydride nanovaccine against S. pneumoniae. Chapter 8 
details work done on including novel small molecule adjuvants in nanovaccine formulations with 
the goal of inducing protective immunity against Y. pestis challenge at early time points. Finally, 
Chapter 9 outlines ongoing and future work on the use of polyanhydride nanoparticles for the 
delivery of antimicrobial drugs and for a combination vaccine against both influenza and 
pneumonia. 
  
95 
 
 
 
CHAPTER 4: LUNG DEPOSITION AND CELLULAR UPTAKE BEHAVIOR OF 
PATHOGEN-MIMICKING NANOVACCINES IN THE FIRST 48 HOURS 
Reprinted from Advanced Healthcare Materials 3(7):1071–1077, 2014 
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4.1 Abstract 
Pulmonary immunization poses the unique challenge of balancing vaccine efficacy with 
minimizing inflammation in the respiratory tract. While previous studies have shown that mice 
immunized intranasally with F1-V-loaded polyanhydride nanoparticles were protected from a 
lethal challenge with Yersinia pestis, little is known about the initial interaction between the 
nanoparticles and immune cells following intranasal administration. Herein, the deposition 
within the lung and internalization by phagocytic cells of polyanhydride nanovaccines 
encapsulating F1-V are compared to that of soluble F1-V alone or F1-V adjuvanted with 
monophosphoryl lipid A (MPLA). Encapsulation of F1-V into polyanhydride nanoparticles 
prolonged its presence while F1-V administered with MPLA was undetectable within 48 hours. 
The inflammation induced by the polyanhydride nanovaccine was mild compared to the marked 
inflammation induced by the MPLA-adjuvanted F1-V. Even though F1-V delivered with saline 
was detected in the lung 48 hours after administration, it is known that this regimen does not 
elicit a protective immune response. The prolonged F1-V presence in the lung in concert with the 
mild inflammatory response provided by the nanovaccine provides new insights into the 
development of protective immune responses with a single intranasal dose.  
4.2 Introduction 
Many pathogens enter the body through mucosal surfaces, especially those of the 
gastrointestinal and respiratory tracts. When designing vaccines against respiratory pathogens, 
mucosal immunization (e.g., oral, intranasal, pulmonary, intrarectal, conjunctival) will likely 
provide both systemic and mucosal immunity
1,2
. Delivery to the lungs also increases the 
bioavailability of the antigen by avoiding first pass metabolism and by enabling high adsorption 
because of the large, permeable surface area
1-4
. The lungs encounter many airborne particles and 
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must differentiate between innocuous particles and pathogens, only initiating a response when 
true danger is present
5,6
. Therefore, an ideal delivery system for a subunit vaccine must enhance 
antibody and/or T cell responses to often weakly immunogenic proteins without disrupting 
homeostasis within the respiratory tract.  
Polyanhydride nanoparticles comprised of 1,6-bis(p-carboxyphenoxy)hexane (CPH), 1,8-
bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), and copolymers thereof are well suited for 
pulmonary administration because of their favorable safety profile, mild inflammatory response, 
and their ability to enhance the immune response
7,8
. However, compared to an approved adjuvant 
such as alum, polyanhydride nanoparticles are markedly less phlogistic
8
. Induction of a mild 
inflammatory response may be especially important when designing vaccine formulations to 
deliver antigens to the lungs, which are sensitive to inflammation. Additionally, polyanhydride 
nanoparticles provide pathogen-mimicking capabilities that enhance the activation of antigen 
presenting cells (APCs)
8-10
. These nanovaccines induce robust immune responses and provide 
protective immunity without the damaging effects of disease
7
. A recent study utilizing F1-V, a 
recombinant antigen derived from Yersinia pestis, showed that a single dose of intranasally 
administered polyanhydride nanovaccine induced full protection against a subsequent lethal 
challenge
7,10
. 
While it has been demonstrated that intranasally administered polyanhydride 
nanovaccines provide long-lasting protective immunity
7,10
, the role of deposition within the lung 
and internalization by phagocytic cells of nanoparticles on the induction of immune responses 
after delivery is largely unknown. The initial interactions between antigen and the immune 
system are often critical to the establishment of long-lasting protective immunity. For example, 
studies with nano-sized viral particles such as influenza virions have demonstrated pathogen 
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deposition and infection in the lower respiratory tract
11
. Likewise, vaccines that deposit within 
the same area of the respiratory tract would be ideal candidates for prevention of influenza. Such 
vaccines have demonstrated increased residence time and prolonged contact with APCs resulting 
in enhanced cell-mediated responses
12
. It is known that dendritic cells (DCs) that reside within 
lymph nodes and injection-site DCs play important roles during the first 50 hours post-
infection
13
. This study by Jenkins and co-workers demonstrated that while many resident DCs 
acquired antigen in the draining lymph nodes and presented peptide-MHC II complexes within 
30 minutes of injection of a soluble antigen, the interactions between these DCs and naïve CD4+ 
T cells were relatively short-lived. Injection-site DCs that migrated to the lymph node, however, 
interacted with CD4+ T cells for extended periods of time, inducing T cell proliferation despite 
arriving at the lymph nodes 18 hours post-injection
13
. It was also observed that sustained 
exposure of antigen enriched these interactions and enhanced T cell activation
13
. Based on these 
results, a reasonable hypothesis is that vaccine delivery vehicles that prolong the presence of 
antigen may enhance the immune response. 
This work focuses on the initial (i.e., the first 48 hours) deposition within the lung and 
internalization by phagocytic cells of intranasally administered polyanhydride nanovaccines. 
Using fluorescently labeled F1-V antigen, the kinetics of soluble and encapsulated F1-V 
distribution within the lungs and its uptake by APCs were investigated. This work demonstrates 
key differences in antigen presence and inflammation when administered as part of a 
polyanhydride nanovaccine formulation compared to that associated with monophosphoryl lipid 
A (MPLA), providing new insights into the protective capabilities of pathogen-mimicking 
nanovaccines. 
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4.3 Experimental Section  
4.3.1 Materials 
Compounds for polymer synthesis included 1,6-dibromohexane, 1-methyl-2-
pyrrolidinone, hydroxybenzoic acid, N,N-dimethylacetamide, sebacic acid, and tri-ethylene 
glycol (Sigma Aldrich, St. Louis, MO). Acetic acid, acetic anhydride, acetone, acetonitrile, 
chloroform, dimethyl formamide, ethyl ether, hexane, methylene chloride, pentane, petroleum 
ether, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were purchased from 
Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile was obtained from Apollo Scientific 
(Cheshire, UK). F1-V fusion protein was obtained from BEI Resources (Manassas, VA) and 
fluorescently labeled with Vivo Tag 680 according to manufacturer instructions (Vivo Tag 680, 
Perkin Elmer, Waltham, MA). The inflammatory probe ProSense
®
 750 FAST was also 
purchased from Perkin Elmer. Flow cytometric analysis utilized anti-mouse antibodies and their 
respective isotypes for PerCP-Cy5.5 labeled anti-CD11c, Biotinylated anti-CD324, Streptavidin-
conjugated eFluor 710 (eBioscience, San Diego, CA), PE-CF594 labeled anti-CD11b (BD 
Bioscience, San Jose, CA), and PE-Cy7 labeled anti-F4/80 (BioLegend, San Diego, CA). 
4.3.2 Polymer synthesis and characterization 
The anhydride monomers, CPH and CPTEG, and the 50:50 CPTEG:CPH copolymer 
were synthesized as previously described
18,19
. Copolymer composition, purity, and molecular 
weight (Mw~5100 Da, PDI = 1.5) were determined by 
1
H nuclear magnetic resonance 
spectroscopy (VXR 300 MHz, Varian, Palo Alto, CA) and found to be consistent with previously 
published results
19
. 
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4.3.3 Nanoparticle synthesis 
  F1-V was conjugated to Vivo Tag 680 per the manufacturer’s instructions (Perkin 
Elmer). 50:50 CPTEG:CPH nanoparticles loaded with 2% (w/w) Vivo Tag 680-conjugated F1-V 
were fabricated by nanoprecipitation as described previously
7
. Briefly, 20 mg/mL polymer with 
0.2 mg lyophilized F1-V was dissolved in methylene chloride and sonicated to ensure uniform 
protein distribution. The solution was then poured into chilled pentane (at a solvent:non-solvent 
ratio of 1:250) to precipitate the nanoparticles. Particles were collected using vacuum filtration 
and their morphology and size (mean diameter of 180 ± 57 nm) were characterized with 
scanning electron microscopy (FEI Quanta 250, FEI, Hillsboro, OR). 
4.3.4 Intranasal immunization 
  Female C57BL/6 mice were purchased from Harlan (Haslett, MI). Mice were housed 
under specific pathogen-free conditions where all bedding, caging, water, and feed were 
sterilized prior to use. All studies were conducted with the approval of the Iowa State University 
Institutional Animal Care and Use Committee. There were five separate treatment groups of 
mice that were intranasally administered following administration of 100 µL of 20 mg/mL 
ketamine with 1 mg/mL xylazine anesthesia with either i) 10 μg of F1-V encapsulated within 500 
μg of 50:50 CPTEG:CPH nanoparticles, ii) 50 μg of soluble F1-V and 10 μg encapsulated within 
500 μg of 50:50 CPTEG:CPH nanoparticles, iii) 50 μg of soluble F1-V adjuvanted with 10 μg 
MPLA, iv) 50 μg of soluble F1-V alone, or v) saline (Figure 1). These groups were chosen based 
upon previous studies by Ulery et al.
[7, 10]
 All formulations were administered in 50 μL sterile 
phosphate buffered saline (PBS). Six mice per group were used and two independent 
experiments were performed. 
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4.3.5 Ex vivo imaging of antigen distribution in lung tissue 
Animals were euthanized 2 and 48 hours post-immunization. After perfusing the lungs 
with 5 mL sterile PBS, the lungs were excised and imaged to detect the distribution of the Vivo 
Tag 680-conjugated antigen within the lung using an in vivo imaging system (Carestream 
Multispectral FX, Rochester, NY). Images were captured using a white light image with a 2 
second exposure followed by a fluorescent image with a 10 second exposure with an excitation 
wavelength of 670 nm and a 750 nm emission filter. All images were analyzed with ImageJ 
software (Version 1.46r, NIH, Bethesda, MD). To calculate MFI, regions of interest were 
selected around each fluorescent lung image to obtain a MFI value for each sample. To obtain ex 
vivo fluorescent lung images (Figure 1), the false-color look-up table “fire” was applied to the 
fluorescent image and an overlay was created with the white light and fluorescent images. It is 
important to recognize that the methods described herein detect the deposition of the 
fluorescently labeled F1-V antigen, either delivered solubly or in the context of adjuvants such as 
MPLA and polyanhydride nanoparticles. 
4.3.6 Inflammatory response of adjuvants 
The pulmonary inflammation was measured using ProSense® 750 FAST (Perkin Elmer, 
Waltham, MA), a fluorescent probe activated by cathepsins. ProSense® 750 FAST was prepared 
according to manufacturer instructions and administered via tail vein injection six hours prior to 
imaging. Mice (n = 3) received intranasal administrations with 500 µg of blank 50:50 
CPTEG:CPH nanoparticles or 10 µg MPLA in 50 µL, and euthanized at 6, 24, and 48 hours 
post-administration. No F1-V was used in these experiments. Perfused lung tissue was excised 
from each mouse and imaged for the presence of activated ProSense® 750 FAST. Images were 
captured as described above using a white light image with a 2 second exposure followed by a 
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fluorescent image with a 10 second exposure with an excitation wavelength of 750 nm and an 
830 nm emission filter. Regions of interest were selected around each fluorescent lung image and 
the background was subtracted using a rolling ball radius of 40 to obtain a MFI value for each 
sample. To obtain ex vivo fluorescent lung images (Figure 1), the false-color look-up table “fire” 
was applied to the fluorescent image and an overlay was created using the white light and 
fluorescent images.     
4.3.7 High-throughput multi-spectral imaging flow cytometry 
Excised lungs were incubated in Hank’s balanced salt solution with 1 mg/mL collagenase 
D and 60 U/mL DNase II for 20 minutes at 37°C. Single cell suspensions were prepared using a 
gentleMACS
TM
 dissociator (Miltenyi Biotec, Cambridge, MA). Debris was removed by passing 
the tissue homogenate through a 40 μm cell filter and red blood cells were lysed with ACK lysis 
buffer (150 mM ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM EDTA). The cells 
(2.5 x 10
6
 cells/mL) were washed with 2% heat inactivated fetal bovine serum and 0.1% sodium 
azide in PBS and re-suspended in 50 μL 1% paraformaldehyde in PBS. Cell samples were 
analyzed using multi-spectral imaging flow cytometry (ImageStreamX, Amnis, Seattle, WA) by 
exciting the samples with a 658 nm laser and collecting emission spectra using a 600-745 nm 
filter. Internalization of F1-V antigen was determined following the manufacturer’s instructions 
using IDEAS
®
 software (Amnis). 
4.3.8 Flow cytometry 
Single cell suspensions were prepared as described above. Cell suspensions (2.5 x 10
6
 
cells/mL) were subsequently blocked for non-specific antibody binding using 0.1 mg/mL rat IgG 
and 10μg/mL mouse anti-CD16/32. Cells were surface-stained for CD11c, CD11b, CD324, and 
F4/80. All samples were fixed with stabilizing fixative (BD Biosciences) and analyzed using a 
103 
 
 
 
FACS Canto flow cytometer (BD Biosciences, San Jose, CA) and data analysis was performed 
with FlowJo software (Treestar, Inc., Ashland, OR). 
4.3.9 Statistics 
The statistical tests were performed in MiniTab software (Minitab Inc, State College, PA). 
Significant differences between two indicated groups were evaluated by Student's t-test. The 
level of significance was set at p < 0.05, unless otherwise stated. 
4.4 Results and Discussion 
4.4.1 Encapsulation prolongs antigen presence 
Mice received an intranasal administration of the vaccine formulations shown in Figure 
1. After 2 and 48 hours post-administration, separate groups of animals were euthanized and 
their lungs were excised to visualize and quantify the distribution of fluorescently labeled F1-V 
antigen. The lungs of all mice showed a uniform spatial distribution of F1-V at 2 and 48 hours 
post-administration, regardless of the formulation (Figure 1). Ex vivo analysis of lung tissues 
showed that the mice administered the nanovaccine formulations (i.e., encapsulated or soluble + 
encapsulated) showed prolonged presence of antigen. Figure 1 shows the percentage loss in 
fluorescence in the lung between 2 and 48 hours for each formulation administered. Statistically 
significant decreases in fluorescence intensity, i.e., statistically significant differences in mean 
fluorescence intensity (MFI) values at 2 and 48 hours post-immunization, were observed in the 
lungs of mice that received soluble F1-V or F1-V adjuvanted with MPLA (Figure 1) while that 
of mice that received only nanoparticle-encapsulated F1-V (i.e., no soluble antigen) displayed 
stable fluorescence intensity (i.e., no statistical significance between MFI values at 2 and 48 
hours). The lungs of the mice that received the soluble F1-V + nanoparticle-encapsulated F1-V 
also showed a marked decrease in fluorescence between 2 and 48 hours. In this formulation, 80% 
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of the antigen was delivered solubly and thus cleared quickly, accounting for the decreased 
fluorescence. However, the nanoparticles prolonged the presence of F1-V in the lungs, as noted 
by the stable fluorescence intensity between 2 and 48 hours in the lungs of the mice that received 
only the F1-V encapsulated nanoparticles (i.e., without any soluble antigen). In order to make 
comparisons with the formulations tested in previous work
7, the “encapsulated only” formulation 
contained 10 µg of antigen, while the soluble protein formulation contained 50 µg, and the 
“soluble + encapsulated” group received 60 µg of F1-V. Therefore, it is important to note that 
only differences between 2 and 48 hours within each group are being compared, because the 
actual MFI may vary between groups.  
4.4.2 Reduced pulmonary inflammation after deposition of polyanhydride nanoparticles 
Because inflammation may affect the disappearance of antigen from the site of 
deposition, the inflammatory response induced by MPLA and the nanoparticles was evaluated. It 
is known that MPLA induces a marked inflammatory response
16
 and recruits inflammatory cells 
to the site of antigen administration, which aids in the clearance of antigen. While 
subcutaneously administered polyanhydride nanoparticles have previously been shown to induce 
less inflammation in comparison to alum
8
, the inflammation induced by intranasally delivered 
polyanhydride nanovaccines is unknown. Mice that were previously administered blank 
polyanhydride nanoparticles or MPLA alone (i.e., no antigen) intranasally were injected with 
ProSense® 750 FAST, a fluorescent imaging agent that is activated by cathepsins produced by 
inflammatory cells such as monocytes and macrophages
20
. While both polyanhydride 
nanoparticles and MPLA displayed similar magnitudes of inflammation at 6 hours post-
administration (Figure 2), by 48 hours the level of cathepsin-activated fluorescent probe detected 
in the lungs of mice treated with MPLA was double that of the mice that received nanoparticles. 
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We hypothesize that the increased inflammation induced by MPLA led to a greater recruitment 
of macrophages that enabled the more rapid clearance of F1-V depicted in Figure 1.  
Thus far, our data indicate that polyanhydride nanovaccines prolonged the presence of 
F1-V in the lungs (Figure 1) while inducing mild inflammation (Figure 2). The prolonged F1-V 
presence in the lung in concert with the mild inflammatory response provided by the 
nanovaccine suggests a novel paradigm related to the development of the long-lasting protective 
immune response following the administration of a single intranasal dose as previously 
observed
7
. It is instructive to note that F1-V delivered with MPLA induced a relatively higher 
level of inflammation, and was cleared from the lung by 48 hours. F1-V delivered alone does 
remain in the lung for up to 48 hours, but failed to elicit a measurable immune response in 
previous studies
7,10
. An important benefit of the F1-V nanovaccine formulation is to enhance the 
stimulation of the immune system through the induction of an inflammatory response (albeit 
mild in comparison to MPLA), while simultaneously prolonging the presence of antigen within 
the lung, potentially leading to increased interactions with T cells and enhanced immune 
activation
13
. 
4.4.3 Cellular internalization of antigen is sustained by polyanhydride nanovaccine 
It is known that continual exposure of antigen to APCs at the site of administration 
increases APC-T cell interactions and T cell proliferation in the draining lymph nodes
13
. These 
enhanced cellular interactions suggest that vaccine delivery regimens which provide a sustained 
presence of antigen in the lungs would better enable the induction of long-lasting immunity. In 
this work, high-throughput multi-spectral imaging flow cytometry was used to detect APCs that 
had internalized F1-V. At 48 hours post-administration, cells recovered from the lungs of mice 
that received soluble and/or nanovaccine formulations were positive for internalized F1-V. In 
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addition, there was a marked decrease (from 2 to 48 hours) in the percentage of cells containing 
F1-V from the mice that had been administered F1-V adjuvanted with MPLA (Figure 3). This 
observation is consistent with the results in Figure 1. While soluble F1-V is rapidly internalized 
by APCs, antigen delivered in the context of the nanovaccine formulations is continuously 
released and can be internalized by both resident as well as recruited APCs. In contrast, the mice 
treated with MPLA-adjuvanted F1-V demonstrated a significant decrease in both tissue 
fluorescence and cellular internalization within 48 hours after immunization.  
It is important to recognize that the cellular population at the administration site is 
dynamic and involves both resident and recruited APCs. While the inflammatory responses 
induced by MPLA (Figure 2) recruits APCs that can internalize foreign antigen, the antigen may 
be rapidly exported to the lymph node and/or degraded, resulting in little antigen remaining in 
the lungs to interact with newly recruited cells. In contrast, more F1-V positive cells were 
present at 48 hours in the lungs of mice that received the polyanhydride nanovaccines. This 
suggests that APCs recruited to the lung were able to internalize F1-V released from the 
nanovaccine.  
Although soluble antigen is still present within the lung at 48 hours, it was previously 
demonstrated that soluble F1-V antigen alone did not elicit a protective immune response
7,10
. It is 
hypothesized that soluble F1-V alone likely failed to induce an inflammatory response and it is 
conceivable that fewer APCs were recruited to the lungs that resulted in less clearance of the F1-
V by 48 hours. This poses an additional consideration to the above argument. While presence 
(i.e., dose and time) of antigen is necessary for the induction of an immune response, soluble F1-
V delivered alone was not sufficient to initiate an immune reponse
7
. Therefore, an appropriate 
adjuvant is necessary to prolong the presence of the antigen within the lung for internalization by 
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and activation of recruited APCs. As demonstrated in this work, polyanhydride nanovaccine 
formulations are able to bridge this shortfall by prolonging the presence of antigen at the site of 
administration coupled with a mild inflammatory immunological stimulation that may explain 
the ability of the nanovaccines to induce long-lasting protective immunity
7
.
 
4.4.4 Cellular uptake of antigen prolonged by polyanhydride nanovaccines 
To ascertain the specific cell types interacting with antigen, flow cytometry was used to 
characterize cellular populations of F1-V+ cells. In these analyses, all F1-V+ cells were gated 
first before using the following cell surface marker combinations to characterize the cellular 
populations: DCs: CD11c+ CD11b-; alveolar macrophages (aMΦs): CD11c- CD11b+ F4/80+; 
and epithelial cells: CD11c- CD11b- CD324+ (Figure 4A). While the percentage of different 
cellular populations associated with antigen was independent of formulation (Figure 4B), the 
MFI or amount of F1-V within the cell populations varied among the different treatment groups 
(Figure 4C). Consistent with the data presented in Figures 1 and 3, the amount of antigen in the 
F1-V+ DCs and aMØs was reduced significantly to background by 48 hours for cells recovered 
from mice administered MPLA-adjuvanted F1-V (Figure 4C). This is likely associated with the 
more rapid clearance of antigen (Figure 1) induced by inflammation (Figure 2). In contrast, mice 
administered nanovaccines or soluble antigen alone displayed stable or increased MFI of antigen 
associated with DCs or aMØs and was comparable to cells recovered from mice that received 
only the soluble antigen (Figure 4C). It is likely that the previously identified protective 
nanovaccine formulation
7
, consisting of both soluble and nanoparticle-encapsulated antigen, 
demonstrated superior performance because of the initial priming of the immune response by 
soluble protein and the maturation of the serum antibody response (e.g., titer and avidity) 
facilitated by the prolonged presence of F1-V provided by the nanovaccines. 
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4.5 Conclusions 
These studies provide confirmatory evidence relating to the ability of the pathogen 
mimicking 50:50 CPTEG:CPH nanovaccine to induce prolonged APC uptake of antigen in 
concert with a mild inflammatory response. Furthermore, the nanovaccine was able to overcome 
limitations associated with the MPLA and soluble dose formulations in its ability to bridge the 
gap between prolonged antigen presence and activation of APCs. These characteristics of 
polyanhydride nanovaccines suggest a novel paradigm related to the development of the long-
lasting protective immune response following the administration of a single intranasal dose as 
previously observed. Together with their low phlogistic potential and their capacity to prolong 
antigen presence at the site of administration, polyanhydride nanovaccines are excellent 
candidates for pulmonary vaccination. 
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Figure 4.1. Ex vivo detection of F1-V in the lungs of mice following intranasal administration. 
Images of excised lungs show presence of fluorescently labeled F1-V at 2 and 48 hours after 
administration. The table on the right depicts the different treatment groups with the respective 
dose of F1-V administered per mouse. The table also includes the percent decrease in mean 
fluorescence intensity (MFI) of the labeled-F1-V from the 2 to 48 hour time point for each group 
± standard error of mean. * indicates statistical significance between the MFI values at 2 and 48 
hours for that treatment at p < 0.05. Six mice per group were used from two independent 
experiments. 
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Figure 4.2. Comparison of the pulmonary inflammation induced following intranasal 
administration of 50:50 CPTEG:CPH nanoparticles compared to that induced by MPLA. 
ProSense® 750 FAST, a cathepsin activated fluorescent probe, was used to detect inflammation. 
Mean fluorescence intensity, represented on the y-axis, corresponds to the level of inflammation 
present at the indicated time points after administration. Error bars represent standard error of the 
mean (SEM) and n=3. * indicates statistical significance between 50:50 CPTEG:CPH and 
MPLA at the indicated time point (p < 0.05). Background levels of inflammation observed at 6 
hours in the mice administered saline, n=2, had an average MFI of 63.8. 
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Figure 4.3. Assessment of internalized F1-V by lung cells using multispectral imaging flow 
cytometry. All error bars represent SEM with n=6. One thousand events per sample were 
acquired and analyzed as described in Materials and Methods. * indicates statistical significance 
between 2 and 48 hours for that treatment at p < 0.05. “Encap“ is an abbreviation for 
“Encapsulated“. 
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Figure 4.4. Use of flow cytometry to assess the pulmonary cellular populations of F1-V
+
 cells. 
(A) Representative contour plots demonstrate the gating used to determine dendritic (CD11c+ 
CD11b-), macrophage (CD11c- CD11b+ F4/80+), and epithelial (CD11c- CD11b- CD324+) cell 
types. (B) Percent of each cell type within the F1-V+ population and (C) MFI of F1-V associated 
with dendritic cells (top), macrophages (middle), and epithelial cells (bottom). All error bars 
represent SEM and n=6. Ten thousand events per sample were collected. * indicates statistical 
significance between 2 and 48 hours for that treatment at p < 0.0001. 
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5.1 Abstract 
Acute respiratory infections represent a significant portion of global morbidity and 
mortality annually. There is a critical need for efficacious vaccines against respiratory pathogens. 
To vaccinate against respiratory disease, pulmonary delivery is an attractive route because it 
mimics the route of natural infection and can confer both mucosal and systemic immunity. We 
have previously demonstrated that a single dose, intranasal vaccine based on polyanhydride 
nanoparticles elicited a protective immune response against Yersinia pestis for at least 40 weeks 
after immunization with F1-V. Herein, we investigate the effect of nanoparticle chemistry and its 
attributes on the kinetics and maturation of the antigen-specific serum antibody response. We 
demonstrate that manipulation of polyanhydride nanoparticle chemistry facilitated differential 
kinetics of development of antibody titers, avidity, and epitope specificity. The results provide 
new insights into the underlying role(s) of nanoparticle chemistry in providing long-lived 
humoral immunity and aid in the rational design of nanovaccine formulations to induce long-
lasting and mature antibody responses. 
5.2 Introduction 
Acute respiratory infections represent a significant portion of global morbidity and 
mortality annually
1,2
. With the alarming increase in multi-drug resistant pathogens and the threat 
of aerosolized bioterrorism agents, there is an urgent need for the development of safe and 
efficacious vaccines against respiratory pathogens
3,4
. To vaccinate against respiratory disease, 
intranasal and pulmonary delivery are attractive routes because intranasal or inhaled vaccines can 
confer both mucosal and systemic immunity, and deliver antigen to immune inductive sites 
within the lung that can result in increased protection
5,6
. Recombinant protein technology has led 
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to the development of protective antigens against many respiratory pathogens, often based on 
surface proteins of viruses and bacteria
7,8
. It is often noted, however, that antigen delivered alone 
does not induce protective immunity, and therefore, requires the use of adjuvants
9,10
.  
Polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) have previously been 
demonstrated to be a safe11 and efficacious delivery platform for protein antigens
12,13
. These 
biodegradable polymers demonstrate pathogen-mimicking properties that adjuvant poorly 
immunogenic subunit proteins and enhance the immune response
12
. Additionally, particle 
chemistry may be tailored to stabilize labile proteins as well as to control the rate of protein 
release
14
. A single intranasal dose of a polyanhydride nanovaccine formulation based on F1-V, a 
recombinant fusion protein of Yersinia pestis that has been shown to be a protective antigen 
against pneumonic plague
15
, was demonstrated to provide protective immunity in mice up to 40 
weeks after vaccination
12
.  
Previously, we have described the deposition, distribution, and prolonged presence of 
antigen delivered in the context of polyanhydride nanoparticles at early time points (i.e., 2 to 48 
hours) after intranasal administration.16 These nanoparticles were based on 1,6-bis(p-
carboxyphenoxy) hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG). 
While the initial interactions between antigen and antigen presenting cells (APCs) are important 
in laying a foundation for vaccine efficacy, the chemistry of the nanovaccine formulation plays 
an important role in the continual recruitment of APCs and for the development of high antibody 
titers with high avidity. In this work, we systematically analyzed the effect of nanoparticle 
chemistry on antigen availability, sustained internalization of antigen by immune cells, and the 
kinetics and maturation of the humoral immune response. 
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5.3 Materials and Methods 
5.3.1 Materials 
The materials used for monomer synthesis include sodium hydroxide, hydrobenzoic acid, 
dibromohexane, 1-methyl-2-pyrrolidinone, triethylene glycol, and sebacic acid (SA) (Sigma 
Aldrich, St. Louis, MO). Acetone, sulfuric acid, potassium carbonate, dimethyl formamide, 
toluene, acetonitrile, N,N-dimethylacetamide, and acetic acid were purchased from Fisher 
Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile used in the synthesis of CPTEG monomer was 
purchased from Apollo Scientific (Cheshire, UK). Acetic anhydride, ethyl ether, petroleum ether, 
chloroform, methylene chloride, and hexane used in acetylation and polymerization were 
purchased from Fisher Scientific. Deuterated chloroform and dimethyl sulfoxide were used in 1H 
NMR analysis of the polymers and monomers (Cambridge Isotope Laboratories, Andover, MA). 
Pentane and methylene chloride used in nanoparticle synthesis were purchased from Fisher 
Scientific. 
F1-V fusion protein (BEI Resources, Manassas, VA) was conjugated to the fluorescent 
label Vivo Tag 680 (Perkin Elmer, Waltham, MA). Flow cytometry utilized anti-mouse 
antibodies and their respective isotypes for PerCP-Cy5.5-conjugated anit-CD11c, biotinylated 
anti-CD324, streptavidin eFluor 710 (eBioscience, San Diego, CA), PE-CF594-conjugated anti-
CD11b (BD Bioscience, San Jose, CA), and PE-Cy7-conjugated anti-F4/80 (BioLegend, San 
Diego, CA). 
5.3.2 Polymer synthesis 
The CPH and CPTEG monomers were synthesized as described previously
17–20
. Pre-
polymers of CPH and SA were synthesized from monomers as described previously
18,19
. 
Copolymers based on CPH, CPTEG, and SA were synthesized using melt condensation as 
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described by Kipper et al. and Torres et al
17,18
. Polymer purity and molecular weight were 
determined using 1H NMR (Varian VXR300). 
5.3.3 Nanoparticle fabrication 
The Vivo Tag 680 fluorescent label was conjugated to F1-V fusion protein according to 
manufacturer instructions (Perkin Elmer). Briefly, 10 µL of Vivo Tag 680 was added per mg of 
F1-V and incubated at room temperature for 1 h. Excess unconjugated Vivo Tag 680 was 
removed using a 5 kDa MWCO dialysis microcentrifuge tube. The protein was lyophilized 
overnight at -40˚C under vacuum. The F1-V loaded polyanhydride nanoparticles were 
formulated using an anti-solvent precipitation method as described previously
13
. Polymer and 2% 
(w/w) F1-V were dissolved in methylene chloride at a concentration of 20 mg/mL. The solution 
was sonicated (Vibra-CellTM, Sonics & Materials, Newton, CT) at an output of 40 Hz to ensure 
a homogenized mixture. The resulting solution was rapidly poured into pentane at a solvent:non-
solvent ratio of 1:250 at room temperature for CPH:SA formulations or at -40°C for 
CPTEG:CPH copolymers due to the lower glass transition temperature of the CPTEG-containing 
copolymers
17
. Nanoparticles were collected via vacuum filtration and characterized using 
scanning electron microscopy (FEI Quanta SEM, Hillsboro, OR). Particle size distribution was 
determined from resultant images using ImageJ (Version 1.46r, NIH, Bethesda, MD) software 
and found to be consistent with previous work
20,21
. 
5.3.4 Mice 
Five to six week old C57BL/6 mice were obtained from Harlan Laboratories (Haslett, 
MI). Mice were housed under specific pathogen-free conditions where all bedding, caging, 
water, and feed were sterilized prior to use. All studies were conducted with the approval of the 
Iowa State University Institutional Animal Care and Use Committee.   
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5.3.5 Immunization protocol 
Mice (between 7 and 9 weeks of age) were anesthetized with a 100 µL injection of a 
solution containing 20 mg/mL ketamine and 1 mg/mL xylazine and immunized intranasally. 
Experimental groups consisted of 10 µg of F1-V encapsulated into 500 µg of 50:50 
CPTEG:CPH, 20:80 CPTEG:CPH, or 20:80 CPH:SA nanoparticles with 40 µg of soluble F1-V 
delivered concurrently in 50 µL of PBS, 50 µg of F1-V delivered with 10 µg MPLA derived 
from Salmonella enterica serotype Minnesota Re 595 (Sigma Aldrich), or 50 µg of F1-V alone. 
While the animals were anesthetized, saline suspensions of the polyanhydride nanovaccines, 
protein alone, or protein with MPLA were delivered to the mice using a 100 µL pipettor fitted 
with a pipet tip to deliver a total of 50 µL of fluid to the animal. Approximately 25 µL was 
delivered through each nare of the nose. Sterile PBS was administered to all control animals. 
Mice were euthanized at 14, 36, or 63 days post-immunization. Samples were collected from 
four mice per group per time point and the experiment was repeated resulting in a total of eight 
mice per group per time point. The soluble protein alone and PBS control groups contained a 
total of four animals per treatment group. 
5.3.6 Ex vivo lung imaging 
 Mice were euthanized to measure the amount of protein remaining in the lung at 14, 
36, and 63 days after intranasal immunization. A lung perfusion with 5 mL of sterile PBS was 
performed to reduce background autofluorescence caused by red blood cells and the lungs were 
then excised. An in vivo live animal imaging system (Carestream Multispectral FX, Rochester, 
NY) was used to measure the fluorescence of antigen remaining in the lungs. A white light 
image (2 s exposure) followed by a fluorescent image (60 s exposure) with an excitation of 670 
nm and a 750 nm emission filter was used. 
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 Images were analyzed with ImageJ software. Mean fluorescence intensity (MFI) was 
calculated using the fluorescent lung images. A region of interest was drawn around the 
fluorescent image and the mean was recorded. Background was then subtracted from each 
sample and a MFI value was obtained. For the ex vivo lung images (Figure 1), background was 
subtracted from the fluorescent images with a rolling ball radius of 40, the images were 
smoothed, and the false-color look-up table “fire” was applied. White light images were adjusted 
to have the same minimum and maximum values and a z-projection of the two images was 
created. 
5.3.7 Multi-spectral imaging flow cytometry 
After imaging, lung samples were incubated in Hank’s balanced salt solution (HBSS) 
with 1 mg/mL of collagenase D and 60 U/mL of DNase II for 20 min at 37°C. Tissue was then 
homogenized to a single cell suspension using a gentleMACSTM dissociator (Miltenyi Biotec, 
Cambridge, MA). The cellular suspensions were centrifuged at 250 rcf for 30 s to remove large 
debris. The supernatants were then passed through a 40 µm filter and the filtrate was then 
centrifuged at 250 rcf for 10 min at 4˚C to pellet the cells. Remaining red blood cells in the lung 
homogenates were lysed with ACK lysis buffer (150 mM ammonium chloride, 10 mM 
potassium bicarbonate, 0.1 mM EDTA), and cells were centrifuged once more before 
enumeration using a Coulter counter (Beckman Coulter, Indianapolis, IN). Cells were washed 
once in buffer (2% heat inactivated fetal bovine serum and 0.1% sodium azide in PBS) and re-
suspended in 60 μL of 1% paraformaldehyde (PFA) in PBS. Samples were analyzed using an 
ImageStreamX (Amnis, Seattle, WA) with a 658 nm laser and 600-745 nm emission filter to 
measure the internalized F1-V using IDEAS® software (Amnis). 
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5.3.8 Flow cytometry 
Single cell suspensions were prepared as described above. Cell solutions were incubated 
with 0.1 mg/mL rat IgG and 10 μg/mL mouse anti-CD16/32 to prevent non-specific binding of 
fluorescent antibodies. Cells were surface-labeled with specific monoclonal antibodies against 
CD11c, CD11b, CD324, and F4/80 for 30 min. After washing, the labeled cell samples were re-
suspended in 100 μL stabilizing fixative (BD Biosciences) and analyzed using a FACS Canto 
flow cytometer (BD Biosciences, San Jose, CA). Analysis of the flow cytometric data was 
performed with FlowJo software (Treestar, Inc., Ashland, OR). 
5.3.9 Anti-F1-V serum antibody titers and avidity assays 
Antibody titers were determined using an enzyme-linked immunosorbent assay (ELISA) 
as described elsewhere
13
. Briefly, high-binding microtiter plates were coated with 100 μL of F1-
V (0.5 µg/mL) in PBS and incubated overnight at 4˚C. F1-V coated microtiter plates were 
incubated with blocking buffer (0.05 M PBS with 0.05% Tween 20 (PBS-T) supplemented with 
2.5% powdered skim milk) for 2 h at room temperature before washing three times with PBS-T. 
Serum from immunized mice was added to the first well at a 1:200 dilution in PBS containing 
1% goat serum and three-fold serial dilutions were performed. After incubating at 4˚C overnight, 
plates were washed three times with PBS-T. Alkaline phosphatase-conjugated goat anti-mouse 
IgG (heavy and light chain) (Jackson ImmunoResearch, West Grove, PA) was added at a 
concentration of 1 µg/mL and incubated for 2 h at room temperature. Plates were washed again 
and 1 mg/mL of alkaline phosphatase substrate (Fisher Scientific, Pittsburgh, PA) dissolved in 
50 mM sodium carbonate, 2 mM magnesium chloride buffer (pH 9.3) was added for colorimetric 
development. The optical density (OD) was recorded after 30 min at 405 nm. All the samples 
were tested in technical replicates of two. Herein, we define titer as the serum dilution value that 
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produced an OD greater than twice the background (i.e., saline) value. Avidity assays were 
performed as described above for ELISA. After overnight incubation with 100 µL per well 
serum at a 1:200 dilution, a 5 M solution of sodium thiocyanate in a 0.1 M sodium phosphate 
buffer was added to the first well and serially diluted two-fold five times (i.e., for a final dilution 
of 1:32). Six control wells were used per sample and received sodium phosphate buffer alone. 
The solution was incubated for 15 min before washing thoroughly. The remainder of the assay 
followed the steps described above for ELISA. A relative avidity index was calculated by using 
an exponential fit of sodium thiocyanate serial dilutions to determine the concentration at which 
the OD is 50% of that of the non-treated wells containing the 1:200 diluted serum sample. 
5.3.10 Peptide array assay 
In order to measure the immune response to specific F1-V epitopes, an overlapping 
peptide array (BEI Resources) assay was performed. High-binding microtiter plates were coated 
with individual F1-V peptides at a concentration of 5 µg/mL in PBS. The ELISA protocol 
described above was followed with a single serum dilution of 1:200 used for each sample. The 
optical density (OD) was recorded at 405 nm after incubating for 2 h at room temperature. 
5.3.11 Statistics 
Statistical significance in Figures 1 and 3 was determined by one-way analysis of 
variance (ANOVA) followed by Tukey's post-test using GraphPad Prism software (Version 6.01, 
GraphPad Software, Inc., La Jolla, CA). A logarithmic transformation was performed on the 
antibody titer data presented in Figure 2 before determining statistical significance by ANOVA 
with a Bonferroni correction. In cases where the antibody titer was undetectable, a value of one-
half the limit of detection was used. P-values less than or equal to 0.05 were considered 
significant. 
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5.4 Results  
5.4.1 Immunization with polyanhydride nanovaccines induced prolonged availability of antigen 
in the lung for up to 63 days after administration 
In order to compare the antigen availability and the kinetics of the humoral immune 
response induced by the different nanoparticle chemistries, a 50 µg dose of F1-V was used in all 
the vaccine formulations. A comparison of the nanoparticle sizes and polydispersity is shown in 
Table 1. The use of nanoscale particles is motivated by previous work from our laboratories on 
the deposition and clearance kinetics of micron-sized vs. nm-sized particles in the lung
22
. These 
studies suggest optimum pulmonary deposition and cellular uptake of particles in the 300-500 
nm size range, without inducing any adverse tissue responses. Vaccination of mice using a 
combination of 40 µg soluble F1-V along with 50:50 CPTEG:CPH nanoparticle-encapsulated 
F1-V (10 µg) in a single intranasal dose has previously been demonstrated to induce protection 
against lethal challenge with Y. pestis
12,13
. The rationale of using a soluble bolus (40 µg) of 
antigen along with a portion (10 µg) encapsulated within the nanoparticles is that the soluble 
bolus rapidly primes the B cell response, while the encapsulated portion is released slowly over 
several weeks to sustain that immune response. In the present studies, F1-V was fluorescently 
labeled with Vivo Tag 680 in order to track the persistence of the protein in the lung after 
intranasal administration. Anesthetized C57B/6 mice were administered a single, intranasal dose 
of a given vaccine formulation and separate groups of mice were euthanized at 14, 36, and 63 
days in order to quantify the remaining fluorescence in the excised lungs followed by flow 
cytometric assessment of F1-V associated with or internalized by dissociated lung cells.  
Figure 1 demonstrates the persistence of F1-V within the lung following its 
administration in soluble form or encapsulated into polyanhydride nanoparticles. The data also 
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demonstrate the differential effect of nanoparticle chemistry on antigen availability. Consistent 
with our previous work
16
, F1-V adjuvanted with MPLA was essentially cleared from the lung by 
day 14. In contrast, F1-V administered in the context of the polyanhydride nanovaccine 
formulations continued to persist in the lung as a function of nanoparticle chemistry. The decay 
of fluorescence associated with nanoparticle clearance kinetics from the lung is qualitatively 
consistent with previous work examining antigen release kinetics from polyanhydride 
nanoparticles in vitro
23
. The nanoparticles based on the CPH-rich chemistries (i.e., 20:80 
CPTEG:CPH and 50:50 CPTEG:CPH) maintained visible and measurable fluorescence for at 
least 63 days after immunization indicating the prolonged availability of antigen within the lung. 
In contrast, nanoparticles based on the SA-rich 20:80 CPH:SA showed a marked decrease in 
fluorescence within the lung 36 days after immunization and returned to baseline levels by 63 
days.  
Quantification of antigen internalization within the lung was used to investigate the 
combined effects of nanoparticle chemistry and antigen availability. Nanoparticles based on SA-
rich chemistries were demonstrated previously to be more readily internalized by APCs in 
comparison to particles based on CPH-rich chemistries
20,24,25
. However, SA-rich chemistries 
have faster erosion and release kinetics than CPH-rich chemistries
24
, and, therefore, result in 
reduced antigen availability at later time points. Consistent with these observations, mice 
immunized with the 20:80 CPH:SA nanovaccine formulation demonstrated a qualitatively 
higher, though not statistically significant, percentage of lung cells that internalized antigen on 
day 14 post-immunization (Figure S1). However, by 36 and 63 days post-immunization, the 
percentage of cells containing internalized F1-V delivered in the 20:80 CPH:SA nanovaccine 
formulation had further decreased. In contrast, lung cells from mice administered the 
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hydrophobic and CPH-rich 20:80 CPTEG:CPH nanovaccine continued to demonstrate the 
presence of internalized antigen for at least 63 days, albeit at low levels. This observation can be 
attributed to the slower erosion profile of CPH-rich chemistries
26
, which enables sustained 
antigen release and availability. 
5.4.2 Polyanhydride nanovaccines elicit sustained high titer antibody responses 
The data in Figure 1 provides evidence regarding the kinetics of F1-V availability within 
the lung after intranasal immunization with polyanhydride nanovaccines. These data also suggest 
that F1-V is continuously present within lung cells for at least 36 days regardless of the 
formulation administered. Next, new insights are presented on the combined effects of polymer 
chemistry and antigen availability on the serum antibody response to F1-V. The data in Figure 2 
demonstrates that the kinetics of the resultant anti-F1-V IgG antibody titer was affected by the 
choice of polymer chemistry, while antigen availability had less of an impact on the antibody 
titer over time. The antibody titer elicited by all the formulations studied was statistically 
significant in comparison to that induced by the soluble F1-V alone at each time point. Other 
than the IgG responses induced by 50:50 CPTEG:CPH, the serum antibody response for mice 
immunized with all other formulations demonstrated serum antibody titer ≥ 50,000 by day 36; 
however, the day 63 titer in these groups indicated that the F1-V-specific IgG response began to 
wane. However, the mice that received the 50:50 CPTEG:CPH nanovaccine showed 
progressively increasing serum antibody titer through the nine weeks of this study. While 
detectable in the lung for 63 days (Figure 1), the animals that received soluble F1-V alone did 
not develop a measurable antibody titer demonstrating that the presence of immunogen alone is 
not sufficient and that an appropriate adjuvant is necessary to induce the development of a F1-V-
specific antibody response. 
126 
 
 
 
5.4.3 Antigen availability and release kinetics affects antibody avidity 
The availability of antigen may not only facilitate sustained antibody titer, but drive the 
development of avid antibodies as well. Similar to antibody titer, the evolution of the avidity of 
F1-V-specific IgG was found to be a function of the nanovaccine polymer chemistry (Figure 3). 
Nanovaccines based on 20:80 CPTEG:CPH and 20:80 CPH:SA nanoparticles induced antibody 
avidities similar to MPLA. Although these formulations developed highly avid antibodies by 36 
days post-immunization, there were no further increases in avidity at later time points. In 
contrast, the serum of mice that received the amphiphilic 50:50 CPTEG:CPH nanovaccine 
showed a significant increase in avid F1-V-specific IgG antibody at each time point. Only the 
mice administered the 50:50 CPTEG:CPH nanovaccine formulation showed continued 
maturation of the IgG avidity, as evidenced by the fact that the avidity was statistically different 
at each subsequent time point. These differences in avidity may be attributed in part to the 
differences in the antigen release kinetics from these polymers
14,17,26 
and, therefore, antigen 
availability. It is likely that the 20:80 CPH:SA nanoparticles release antigen too rapidly to 
stimulate the continual affinity maturation (i.e., sequentially higher avidity) of the F1-V-specific 
antibody response. Despite a similar antibody response induced by 20:80 CPH:SA nanovaccine, 
the most hydrophobic 20:80 CPTEG:CPH nanoparticles may release antigen too slowly such that 
there may not be sufficient F1-V to elicit an ever maturing antibody response. In contrast, the 
50:50 CPTEG:CPH nanoparticles must exhibit a release rate of antigen that results in a 
sequential improvement of the avidity of the F1-V-specific IgG response. 
5.4.4 Polyanhydride nanovaccines result in broader epitope specificity 
The ability of vaccines to induce responses towards a broad spectrum of epitopes may 
enhance protection. Because the antibody avidity (Figure 3) is the summation of the antibody 
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response towards all epitopes, an overlapping peptide array of the F1-V antigen was used to 
determine the antibody response to specific epitopes induced by each immunization regimen as 
shown by the heat map in Figure 4. Consistent with the antibody titer and avidity responses 
depicted in Figures 2 and 3, the responses to specific epitopes were highly dependent upon the 
nanoparticle chemistry and the kinetics of antigen release. The number of peptides recognized by 
serum IgG (i.e., peptides which showed an optical density (OD) value above background, or OD 
value ≥ 0.5) at each time point is shown across the bottom of the heat map. Serum antibodies 
from mice receiving the 20:80 CPTEG:CPH nanovaccine showed increased recognition in terms 
of the number of epitopes recognized by serum antibody between days 14 and 36 post-
immunization; however, this response saturated by 36 days post-immunization. Likewise, the 
number of recognized epitopes, while initially broad, waned over time in the case of serum from 
the mice that received the 20:80 CPH:SA nanovaccine. Interestingly, the 50:50 CPTEG:CPH 
nanovaccine induced an IgG response that continued to expand the epitopes recognized over 
time, which corroborates the increases in antibody titer and avidity discussed previously. 
The ability to induce antibodies specific for a broad spectrum of epitopes is no doubt 
important for long-term protection; however, the V1 and V2 epitopes in particular have been 
shown to be important for protection against Y. pestis in C57BL/6 mice
27,28
. The data in Figure 5 
compares the immune response to these two dominant epitopes in response to each of the 
formulations, with an OD value with a greater than 1.5-fold change from saline controls defined 
as epitope recognition
29
. The immune response to these dominant epitopes induced by the 50:50 
CPTEG:CPH nanovaccine exhibited a time dependent evolution and the optical density 
increased over time as the immune response narrowed to these epitopes. This type of kinetics 
was not observed with any of the other nanovaccine formulations nor with MPLA. Similar 
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responses were observed for the F18 epitope (data not shown), noting that the addition of 
responses to the F1 antigen enhanced the protection provided by the V antigen
15
. 
5.5 Discussion 
In this work, different polyanhydride nanovaccine formulations were systematically 
examined for their ability to affect in vivo antigen availability and the resultant induction of a 
humoral immune response. While all the formulations examined produced similar antigen-
specific antibody titers, the kinetics of the F1-V-specific immune response varied when antigen 
was delivered in the context of the different polymer nanovaccine chemistries. Building upon our 
previous work
12,13,16
, the studies presented herein shed new light upon the complex 
relationship(s) between polyanhydride nanoparticle chemistry and the kinetics and maturation of 
the induced humoral immune response. 
Of the three nanoparticle formulations evaluated, the 20:80 CPH:SA chemistry is the 
least hydrophobic. As a result, the 20:80 CPH:SA nanoparticles have the fastest polymer 
degradation kinetics, leading to the release of a vast majority of the protein within one 
month
26,30,31
. In agreement with the above in vitro observations of release kinetics, the 
fluorescently-labeled F1-V was nearly undetectable in the lung by 36 days post-immunization 
indicating that the 20:80 CPH:SA nanoparticles had eroded and released its payload (Figure 1). 
In addition to faster antigen release, the clearance of F1-V encapsulated within the 20:80 
CPH:SA nanoparticles can also be attributed to the enhanced internalization of these particles 
(Figure S1). As it is the antigen that is labeled in this work (rather than the particle), it is 
important to state that relative to the disappearance of the soluble protein alone, it is clear that the 
persistent F1-V in this group is due its encapsulation into 20:80 CPH:SA nanoparticles, which is 
in turn was cleared most rapidly among the polyanhydride chemistries tested. These observations 
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support previous work in which nanoparticles composed of SA-rich chemistries were rapidly 
internalized in comparison to CPH-rich chemistries
20,24,25
.  
While the 20:80 CPH:SA nanovaccine formulation more rapidly induced the 
development of antibody titers compared to the other nanoparticle formulations,(Figure 2), both 
the titer as well as the avidity of the antibody reached their peak values at 36 days post-
immunization (Figures 2 and 3, respectively). The number of F1-V epitopes recognized by the 
antibody from mice administered the 20:80 CPH:SA nanovaccine decreased with time (Figure 
4). This observation can be linked to the kinetics of the antibody titer and avidity of the response 
to the 20:80 CPH:SA nanovaccine formulation, which remain unchanged between the two later 
time points. The rapid release and clearance of antigen, and therefore decrease in antigen 
availability, may affect the ability of the 20:80 CPH:SA nanovaccine formulation to sustain long-
term protective immune responses. In addition, the decreased hydrophobicity and rapid 
degradation of this polymer, leading to a similarly rapid waning of the pro-inflammatory 
cytokine response induced after implantation, may present fewer danger signals to the immune 
system in comparison with more hydrophobic chemistries
32
. We hypothesize that the reduced 
danger signal elicited by this formulation, coupled with its rapid clearance from the lung, may 
lead to the induction of short-lived plasma cells
33
, which is consistent with the waning antibody 
titers and avidity as observed in Figures 2 and 3. Thus, it is likely the 20:80 CPH:SA 
nanovaccine formulation may be suitable for rapid induction of immunity, but not for induction 
of long-lived antigen-specific IgG, as suggested by the data. 
In contrast, the CPH-rich nanovaccine formulations (i.e., 20:80 CPTEG:CPH and 50:50 
CPTEG:CPH) are more hydrophobic and degrade more slowly, providing slower protein release 
kinetics
17
 and prolonging the presence of antigen in the lung for at least 63 days as shown in 
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Figure 1. However, the CPH-rich chemistries were also less readily internalized by lung cells 
than the SA-rich chemistries as shown in Figure S1 and in previous work
12,20
. The combination 
of the reduced internalization and slower degradation kinetics due to increased hydrophobicity 
enabled the CPH-rich nanovaccine formulations to provide sustained antigen presence. Together, 
these observations raise an important question on the effect of nanoparticle degradation and 
antigen availability on the generation and maintenance of humoral immune responses over 
time
32
. 
The antibody titer and avidity responses in mice administered the 20:80 CPTEG:CPH 
nanovaccine formulation reached their maximum by 36 days post-immunization (Figures 2 and 
3). The kinetics of these responses were similar to those observed in mice administered the 20:80 
CPH:SA nanovaccine formulation, albeit with higher titers. We hypothesize that the 
hydrophobicity of the 20:80 CPTEG:CPH nanovaccine formulation may promote a more 
inflammatory environment, possibly leading to an increased response to the initial soluble bolus 
of antigen, which is consistent with previous observations
11
. We propose that the lower 
availability of antigen at later time points, after the depletion of the soluble portion of the 
vaccine, from this slowly degrading formulation is offset by the greater inflammatory milieu 
(i.e., enhanced adjuvanticity) provided by this more hydrophobic formulation. This combination 
of hydrophobicity-induced inflammation and slow yet continuous release of antigen may lead to 
the induction of longer lived plasma cells, which are important for long-term maintenance of the 
antibody titers
33-35
. In addition, mice receiving this formulation demonstrated a greater breadth in 
the epitope specificity of the humoral immune response in terms of the ability to recognize more 
antigen-specific epitopes over time (Figure 4), possibly due to the prolonged exposure to F1-V in 
the lung. Together, these data suggest that highly hydrophobic nano-carriers can be used to 
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formulate vaccines that promote the maturation of potent and long-lived humoral immune 
responses. 
The 50:50 CPTEG:CPH nanovaccine formulation has been demonstrated in our previous 
work to possess pathogen-mimicking abilities in terms of its internalization by APCs and its 
activation and induction of long-term protective immunity
12,24
. The antibody titers and the 
avidity of the antigen-specific IgG responses of mice that received the 50:50 CPTEG:CPH 
nanovaccine formulation continued to increase at each successive time point (Figures 2 and 3). 
In contrast to the other formulations, the mean levels of circulating antibody increased between 
36 and 63 days after immunization only for the mice that received the 50:50 CPTEG:CPH 
nanovaccine formulation. We propose that this observation suggests that the immune response 
induced by the 50:50 CPTEG:CPH nanovaccine and the persistent presence of antigen would 
facilitate continual differentiation of B cells into long-lived plasma cells
33-35
. It is also important 
to note that memory B cells induced in early germinal centers typically develop broader antibody 
repertoires (i.e., greater avidity and increased epitope spread)
33-35
 as suggested by the data in 
Figures 3 and 4. There are several other factors to consider when analyzing these observations. 
First, CPTEG-rich polymers have lower glass transition temperatures compared to the other 
polyanhydrides studied herein that likely contributes to particle agglomeration within the lung, 
leading to a reduced surface area to volume ratio and resulting in slower release of antigen and 
prolonged presence of F1-V1
7,18
. Second, the alternating pattern (i.e., -CPTEG-CPH-CPTEG-
CPH-CPTEG-) provided by the 50:50 CPTEG:CPH copolymer (because of its equal monomer 
reactivity ratios)
17
 may be recognized by immune cells as a microbe-associated molecular 
pattern. As the nanoparticles erode, an increased number of oligomeric chains are generated with 
molecular patterns that might mimic an increasing microbial burden as with a replicating 
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pathogen or a replication-competent, live, attenuated vaccine. This is supported by previous 
work demonstrating protective immunity 40 weeks after a single intranasal immunization
12,13
. In 
light of these observations, we suggest that the pathogen-mimicking 50:50 CPTEG:CPH 
nanovaccine formulation more effectively primes the immune response and induces long-lived 
immunity. 
5.6 Conclusions 
We have herein demonstrated the importance of polymer chemistry in the design of a 
nanovaccines. There are several important factors that influence the design of an efficacious 
intranasal vaccine, including nanoparticle interactions with immune cells and the kinetics of 
antigen release. The performance of the 50:50 CPTEG:CPH nanovaccine formulation clearly 
demonstrates the impact of sustained release of antigen on the immune response to the F1-V 
antigen over time. The formulation delivered with this nano-carrier chemistry showed an 
increase in antibody titer throughout the duration of the experiment, indicating a continual 
addition of long-lived plasma cells to the pool of antibody-generating cells. In contrast, the other 
nanovaccine formulations as well as MPLA demonstrated a stable or decreased antibody titer at 
longer time points, suggesting a higher percentage of short-lived plasma cells. Finally, the 
maturation of antibody avidity and focus towards protective epitopes demonstrates the 
importance of persistent antigen in developing an efficacious immune response.  
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5.9 List of Figures     
 
Figure 5.1. Polyanhydride nanovaccines persisted in the lung for up to 63 days. Images represent 
fluorescence of remaining Vivo Tag 680 labeled F1-V antigen in excised lung tissue at the 
indicated time points. Mean fluorescence intensity (MFI) is represented graphically as the 
average of eight mice per group from a total of two independent experiments (days 14 and 36) 
and four mice per group from one experiment (day 63). Error bars represent the standard error of 
the mean. Letters represent statistical differences among formulations at one time point (e.g., 
comparing the MFI of the 50:50 CPTEG:CPH nanovaccine at day 36 to the 20:80 CPTEG:CPH 
nanovaccine at day 36). Asterisks represent statistical differences between time points within a 
single formulation (p ≤ 0.05). 
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Figure 5.2. Polyanhydride nanovaccines induced high titer anti-F1-V antibody responses. Error 
bars represent the standard error of the mean (n = 8) from two independent experiments (days 14 
and 36) and n = 4 from one experiment (day 63). The antibody titers elicited by all the 
formulations studied were statistically significant in comparison to that induced by the soluble 
formulation at each time point. Asterisks represent statistical differences between time points 
within a single formulation (p ≤ 0.0077). 
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Figure 5.3. Polyanhydride nanovaccine formulations induced highly avid antibodies to F1-V. 
Error bars represent the standard error of the mean (n = 8) from two independent experiments 
(days 14 and 36) and n = 4 from one experiment (day 63). Asterisks represent statistical 
differences between time points within a single formulation (p ≤ 0.0084). 
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Figure 5.4. Nanovaccine formulations resulted in enhanced epitope recognition by antibodies. 
The responses to eighty F1 and V peptides were evaluated by ELISA and are shown as a heat 
map, beginning at the top with the amino-terminal peptide and then moving down sequentially 
through the F1-V protein. The optical density of each peptide is indicated by a range of color 
from blue (no response) to red (maximum response). The number of reactive peptides (i.e., 
optical density (OD) value above background, or OD value ≥ 0.5) induced by each vaccine 
formulation at each time point is indicated below the heat map. Data presented is the average of 
eight individual mice for days 14 and 36, and four individual mice for the day 63 time point. 
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Figure 5.5. Evolution of the immune response to the immunodominant V1 and V2 peptides is 
affected by nanoparticle chemistry. The data is shown as a fold-change over saline. Data was 
collected from groups of animals for days 14 and 36 in two individual experiments and from four 
animals for day 63 in one experiment. Epitope recognition is defined as 1.5-fold or higher over 
saline. The dashed line represents a 1.5-fold change from saline controls for each peptide. 
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Supplemental Figure 5.1. Persistence of particles leads to sustained internalization of antigen. 
Multispectral imaging flow cytometry was used to determine the internalization of F1-V by lung 
cells. Error bars represent the standard error of the mean with n = 8 from two independent 
experiments (day 36) and n = 4 from one experiment (days 14 and 63). One thousand events per 
sample were acquired and analyzed as described. Asterisks represent statistical differences 
between time points within a single formulation (p ≤ 0.0082). 
5.10 List of Tables 
Table 5.1. Size and polydispersity of polyanhydride nanoparticles 
Chemistry Size (nm) PDI 
20:80 CPTEG:CPH 120 +/- 55  0.17 
50:50 CPTEG:CPH 151 +/- 63  0.15 
20:80 CPH:SA 324 +/- 162 0.17 
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6.1 Abstract 
Pneumococcal surface protein A (PspA) is a choline-binding protein which is a virulence 
factor found on the surface of all Streptococcus pneumoniae strains. Vaccination with PspA has 
been shown to be protective against a lethal challenge with S. pneumoniae, making it a 
promising immunogen for use in vaccines. Herein, the design of a PspA-based subunit vaccine 
using polyanhydride nanoparticles as a delivery platform is described. Nanoparticles based on 
sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG), specifically 50:50 CPTEG:CPH and 20:80 CPH:SA, were used to 
encapsulate and release PspA.  The protein released from the nanoparticle formulations retained 
its primary and secondary structure as well as its antigenicity. The released PspA was also 
biologically functional based on its ability to bind to apolactoferrin and prevent its bactericidal 
activity towards Escherichia coli. When the PspA nanoparticle formulations were administered 
subcutaneously to mice, the animals elicited a high titer and high avidity anti-PspA antibody 
response. Together, these studies provide a framework for the rational design of a vaccine 
against S. pneumoniae based on polyanhydride nanoparticles. 
6.2 Introduction 
The World Health Organization estimates that pneumonia causes 1.6 million deaths every 
year, with the majority occurring in children in developing countries1,2. Streptococcus 
pneumoniae is the leading cause of bacterial pneumonia worldwide, especially in children3. 
Current prophylactic options against S. pneumoniae include a 23-valent soluble polysaccharide 
vaccine (pneumovax) and 7 and 13-valent pneumococcal conjugate vaccine (PCV)
4
. The 
polysaccharide-based vaccine has been shown to induce humoral immunity in immune-
competent patients, but fails to stimulate a cellular immune response, making the vaccine 
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ineffective in high-risk groups such as infants, the elderly, and immune-compromised 
individuals
5
. Following the introduction of the multivalent, polysaccharide-protein conjugate 
pneumococcal vaccine into childhood immunization regimens, incidence of community-acquired 
pneumonia in children was reduced by 18%
6
. Although the PCV has been shown to be effective 
in reducing cases of pneumonia, it has several limitations. The vaccine is expensive and 
complicated to manufacture, leading to limited availability in developing countries; it does not 
provide cross-protection across pneumococcal serotypes; and while it reduces capsular type-
specific carriage it has not been shown to reduce nasopharyngeal carriage of pneumococci in 
general. Additionally, the PCV requires a three-dose vaccination regimen and the 7-valent 
vaccine leads to increased prevalence within the community of strains not included in the 
vaccine (i.e., serotype substitution) within several years of introduction
6, 7
.  
Subunit vaccines against pneumonia using non-capsular antigens, specifically protein-
based vaccines, have been extensively studied in recent years
5,8
. Of particular interest in this 
regard is pneumococcal surface protein A (PspA), which is a choline-binding protein found on 
the surface of all pneumococcal strains and a critical S. pneumoniae virulence factor
9
. PspA 
plays two different roles in invasive infection and nasopharyngeal carriage. During invasive, 
systemic infections with S. pneumoniae, PspA prevents the deposition of complement on the 
surface of the bacterium, thus inhibiting the opsonization and killing of S. pneumoniae
9, 10
. PspA 
also inhibits bactericidal activity medicated by apolactoferrin (ALF) found on mucosal surfaces 
and in sites of inflammation
9, 11-13
. Vaccination with PspA protects mice against a lethal 
challenge with S. pneumoniae via the generation of anti-PspA serum antibodies that are highly 
cross reactive to other strains
14-18
. However, PspA is poorly immunogenic and not capable of 
inducing a productive immune response without the addition of an adjuvant
19-21
. In fact, a 
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vaccine regimen based on the inclusion of aluminum hydroxide, a commonly used adjuvant, 
required three doses to provide protective immunity in a murine model
19-21
. Therefore, there is a 
need to design novel adjuvants and/or delivery vehicles for the formulation of efficacious 
vaccines that can protect against multiple strains of S. pneumonia and enhance patient 
compliance by utilizing an acceptable dose regimen.  
Because of the promise of PspA as a protective antigen against S. pneumoniae, it has 
been the subject of numerous studies to evaluate novel vaccine delivery systems. Several 
research groups have shown the induction of immune responses through delivery of PspA with 
live attenuated bacteria such as salmonella
22,23
 and through co-delivery with a whole-cell 
pertussis vaccine
4
.  Additionally, other novel, nanoscale delivery systems containing PspA have 
been evaluated, including gold nanoparticles
24
 and nanogel-based vaccine formulations
25
. In this 
work, we demonstrate that biodegradable polyanhydride nanoparticles can successfully 
encapsulate and release stable, antigenic PspA.  
Polyanhydrides have a number of benefits compared to other vaccine delivery systems. 
Their tunable polymer chemistry can allow for the modulation of the immune response and 
enable tailoring antigen release kinetics
26, 27
. Additionally, encapsulation into polyanhydride 
particles has been shown to protect fragile protein antigens from degradation
28, 29
. 
Polyanhydrides can be fabricated into nanoparticles for administration via inhalation or injection 
and have shown much promise as vaccine adjuvants and delivery vehicles
26, 30-33
. These 
polymers exhibit excellent biocompatibility and have been shown to degrade into non-toxic, non-
mutagenic products
34
. Polyanhydride particles have also been shown to stabilize fragile proteins 
throughout the manufacture, storage, and release steps and elicit immune responses in vitro and 
in vivo
28-30, 32, 35, 36. 
In particular, amphiphilic polyanhydrides, which degrade through a 
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combination of bulk and surface erosion, provide a sustained release of protein, while 
maintaining protein structure and function upon release
28, 37
. For example, encapsulation of the 
recombinant F1-V protein into nanoparticles made from a copolymer of 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
stabilized the protein
28
 and provided protective immunity against a lethal challenge with Yersinia 
pestis that persisted at least 23 weeks post-immunization using a single dose vaccine regimen
32
.  
In this work, we describe the encapsulation and release of stable PspA from 
polyanhydride nanoparticles. The released PspA retained its primary and secondary structure and 
preserved both its antigenicity and biological functionality. When the nanoparticle-based vaccine 
formulations consisting of soluble and encapsulated PspA were administered subcutaneously to 
mice, the animals developed and sustained high anti-PspA IgG titers that were also characterized 
by high avidity. These studies provide a framework for the rational design of an anti-S. 
pneumoniae vaccine based on PspA-containing polyanhydride nanoparticles. 
6.3 Materials and Methods 
6.3.1 Materials 
The materials used for monomer synthesis including sodium hydroxide, hydrobenzoic 
acid, dibromohexane, 1-methyl-2-pyrrolidinone, and triethylene glycol were purchased from 
Sigma Aldrich (St. Louis, MO); acetone, sulfuric acid, potassium carbonate, dimethyl 
formamide, toluene, acetonitrile, N,N-dimethylacetamide, and acetic acid were purchased from 
Fisher Scientific (Fairlawn, NJ); and 4-p-fluorobenzonitrile was purchased from Apollo 
Scientific (Cheshire, UK). Sebacic acid monomer was purchased from Sigma Aldrich. The 
following chemicals used for acetylation and polymerization were purchased from Fisher 
Scientific: acetic anhydride, ethyl ether, petroleum ether, chloroform, methylene chloride, and 
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hexane. Deuterated chloroform and dimethyl sulfoxide for 
1
H NMR analysis of the polymers and 
monomers, respectively, were purchased Cambridge Isotope Laboratories (Andover, MA). 
The K-12 MG1655 and the LPS-deficient K-12 NR688 Escherichia coli strains were 
provided by Dr. Gregory Phillips (Iowa State University).  
The following chemicals used in the development of the PspA functional assay were 
purchased from Sigma Aldrich: ALF, lactoferricin, erythromycin, deferoxamine, and 2,2-
bipyridine. The following materials for bacterial culture were purchased from Becton Dickinson 
(Franklin Lakes, NJ): Luria-Bertani (LB) agar, trypticase soy broth, yeast extract, and tryptone. 
Agar and sodium chloride were purchased from Fisher Scientific. Sterile phosphate-buffered 
saline was purchased from Mediatech Inc. (Manassas, VA).  
6.3.2 Polymer synthesis 
The CPH and CPTEG monomers and their corresponding prepolymers were synthesized 
as previously described
37-39
. Polymers and copolymers of CPH, CPTEG and SA were 
synthesized using melt condensation as described elsewhere
34, 37
. Polymer purity and molecular 
weight were determined using 
1
H NMR (Varian VXR300) and gel permeation chromatography 
(Waters GPC, Milford, MA) was used to confirm molecular weight. The purity and molecular 
weight of the 50:50 CPTEG:CPH and 20:80 CPH:SA copolymers used herein were consistent 
with previously published data
37, 40
. The copolymer compositions were determined by 1H NMR 
and were consistent with the co-monomer compositions (i.e., 18:82 for 20:80 CPH:SA and 47:53 
for 50:50 CPTEG:CPH). The number-average molecular weights of the 50:50 CPTEG:CPH and 
20:80 CPH:SA copolymers were 5,800 Da with a polydispersity index (PDI) of 1.5 and 21,000 
Da with a PDI of 1.4, respectively.  
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6.3.3 Nanoparticle fabrication 
PspA-loaded polyanhydride nanoparticles were formulated using an anti-solvent, 
solid/oil/oil nanoprecipitation method as previously described
41-43
. Briefly, lyophilized PspA (1% 
w/w) and polymer (20 mg/mL) were co-dissolved in methylene chloride. The solution was 
sonicated at an output of 40 Hz with a VibraCell ultrasonic probe (Sonics & Materials, Inc., 
Newton, CT) to ensure a homogenized mixture. The resulting solution was rapidly added to 
pentane at a 1 to 250 (v/v) ratio of methylene chloride to pentane at room temperature for the 
CPH:SA formulation or at -40°C for the CPTEG:CPH copolymer due to the lower glass 
transition temperature of this polymer
37
. Nanoparticles were collected using vacuum filtration. 
The nanoparticles were characterized using scanning electron microscopy (FEI Quanta SEM, 
Hillsboro, OR) and their size distribution was determined using ImageJ software (Version 1.44p, 
National Institutes of Health, Bethesda, MD). The resulting size distributions were 677 ± 254 nm 
for the 20:80 CPH:SA nanoparticles and 243 ± 84 nm for the 50:50 CPTEG:CPH nanoparticles.   
6.3.4 Preparation of recombinant protein 
The N-terminal region of a recombinant PspA (UAB055, PspA/Rx1 AA1 to 303, clade 2 
PspA of the PspA family 1) was produced by Dr. David McPherson (University of Alabama at 
Birmingham) as described previously
12
. Protein was dialyzed using a 10,000 MW cut-off dialysis 
cassette (Thermo Fisher Scientific, Rockford, IL) against sterile, nanopure water and frozen at -
80°C. Protein was then lyophilized at -40˚C under vacuum overnight and stored at -80°C until 
further use. For the in vivo vaccination and biological functionality assays, endotoxin was 
removed from the protein using endotoxin removal beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions prior to dialysis and lyophilization. The 
final endotoxin content of the protein prior to use was determined to be less than 1.9 EU/mg as 
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determined by a limulus amebocyte lysate (LAL) chromogenic endotoxin quantification kit 
(Thermo Fisher Scientific). 
6.3.5 Culture and storage of bacterial strains 
Two E. coli strains were used in this work, wild type MG1655 and LPS-deficient NR688. 
Prior to the start of experiments, LB broth was inoculated with approximately one colony of E. 
coli and allowed to grow overnight. Fresh LB broth was inoculated and incubated until an OD600 
of approximately 0.7 was obtained. Sterile glycerol (15% v/v) was added to aliquots of the 
bacterial culture and 1 mL aliquots were frozen and stored at -80˚C. 
6.3.6 Protein release and quantification 
The In vitro release of PspA protein from polyanhydride nanoparticles was carried out as 
previously described
28, 30, 35, 37, 44
. Briefly, 25 mg of nanoparticles loaded with 1% (w/w) PspA 
were weighed into 1.5 mL microcentrifuge tubes and suspended in 600 µL of 0.05 M phosphate 
buffered saline (PBS, pH 7.2). Microcentrifuge tubes containing the suspensions were incubated 
at 37°C under constant agitation. At each time point, suspensions were removed and centrifuged 
at 14,000 rcf for 20 min. The supernatant was removed and replaced with 450 µL of fresh PBS 
and the microcentrifuge tubes returned to incubation. Supernatant samples were stored at 4°C 
until analyzed. Supernatant samples were centrifuged at 10,000 rcf for 10 min before protein 
quantification to ensure removal of any remaining polymer particles. Protein released from 
polyanhydride nanoparticles was quantified using a micro bicinchoninic acid assay (Thermo 
Fisher Scientific) and was compared to the total protein used. The colorimetric changes were 
measured using a SpectraMax M3 microplate reader (Molecular Devices, Sunnyvale, CA) at an 
absorbance of 570 nm. All the samples were tested in triplicate. Encapsulation efficiency was 
determined by degrading PspA-loaded particles in a solution of 17 mM NaOH.  In order to 
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determine the pH of the particle microenvironment over time 25 µg of 20:80 CPH:SA and 50:50 
CPTEG:CPH nanoparticles were incubated in 600 µL of 0.05 M phosphate buffered saline (PBS, 
pH 7.2). At each time point samples were centrifuged and the supernatant was removed for 
analysis. Solution pH was measured using an Orion Ross pH electrode (Thermo Fisher 
Scientific).  
6.3.7 Analysis of released PspA by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
The primary structure of the released PspA was studied using SDS-PAGE under reducing 
conditions. After centrifugation, the protein concentration was adjusted to 100 µg/mL with PBS. 
Once concentrations of all the samples were standardized, 15 µL of solution was combined with 
15 µL of Laemmli sample buffer (Bio-Rad, Hercules, CA) with 5% (v/v) β-mercaptoethanol 
(Bio-Rad). The resultant mixture was heated at 96°C for 10 min and allowed to return to room 
temperature. Samples were loaded into the wells of a 12% acrylamide gel and subjected to 150 V 
constant voltage for 60 min. Approximate molecular size of protein bands were estimated using 
pre-stained protein standards (Bio-Rad, Hercules, CA). Gels were incubated in fixative solution 
(50% water, 40% ethanol, 10% acetic acid) for 3 h at 4°C and stained with Flamingo Gel Stain 
(Bio-Rad) at 4°C overnight before scanning. Gels were scanned with a Typhoon 9400 (GE 
Healthcare Piscataway, NJ) and analyzed using ImageQuant TL 8.1 software (GE Healthcare). 
6.3.8 Secondary structure of released PspA 
Circular dichroism was used to analyze the secondary structure of PspA released from 
polyanhydride nanoparticles. Aliquots of released PspA (100 µg/mL), collected after incubating 
for two hours in PBS at 37˚C, were analyzed on a Jasco J-710 spectropolarimeter (Jasco, Inc., 
Easton, MD) using a 1 mm cuvette at far-UV wavelengths from 190-260 nm. Values shown are 
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the average of two readings of at least two experimental replicates. In order to obtain a spectra of 
degraded protein, PspA at a concentration of 100 µg/mL was incubated in nanopure water 
adjusted to a pH of 2 with 12.1 N HCl (Thermo Fisher Scientific) overnight.  Protein was then 
collected and secondary structure was analyzed as described above. 
6.3.9 Antigenicity of released protein 
The ability of anti-PspA antibody to bind to PspA released from polyanhydride 
nanoparticles (i.e., antigenicity) was determined using an enzyme-linked immunosorbent assay 
(ELISA) as previously described28, 29. PspA released from polyanhydride nanoparticles was 
collected, adjusted to a concentration of 0.5 µg/mL, used to coat a high-binding chemistry 96-
well plate (Cole-Parmer, Vernon Hills, IL), and incubated overnight at 4˚C. The PspA solution 
was removed and PBS with 1% fish gelatin was added and incubated for 2 h at room 
temperature. Next, the blocking buffer was removed and the plates were washed three times with 
PBS containing 0.5% Tween 20 (PBS-T). Anti-PspA monoclonal antibody clone number 22003 
(QED Biosciences, San Diego, CA) was added at a concentration of 1 µg/mL and the plates were 
covered and incubated overnight at 4˚C. Plates were washed thrice with PBS-T before the 
addition of alkaline phosphatase-conjugated goat anti-mouse IgG (heavy and light chain) 
(Jackson ImmunoResearch, West Grove, PA) at a 0.1 µg/mL, which was incubated for 2 h at 
room temperature before developing. For the development of the ELISA, alkaline phosphatase 
substrate was added at 1 mg/mL substrate buffer (50 mM sodium carbonate 2 mM magnesium 
chloride buffer (pH 9.3)). After a 15 min incubation at room temperature, the colorimetric 
changes were measured at an absorbance of 405 nm using a SpectraMax M3 microplate reader. 
The data is presented as relative antigenicity, which is herein defined as the optical density (OD) 
ratio between the experimental replicate and the native protein. 
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6.3.10 Functional assay for released PspA 
E. coli strains NR688 (LPS-deficient) and wild type MG1655 (used as an experimental 
control), were cultured on Luria-Bertani (L-B) agar plates at 37˚C overnight. Approximately one 
colony was removed from the overnight plate and used to inoculate broth. It was necessary to 
remove iron from the experimental system in order to prevent binding to ALF, which forms iron-
rich hemolactoferrin. To accomplish this, both iron-free media and the iron-chelating agent, 
deferoxamine, were tested, and it was found that the addition of 1 mg/mL of deferoxamine 
successfully removed iron. The inoculated culture was grown at 37˚C to an OD600 of 
approximately 0.5. Cultures were diluted 1:20 into fresh broth and incubated until an OD600 of 
approximately 0.1 was obtained. Bacteria were plated into the wells of a 96-well microtiter plate 
at a final concentration of 1 million cells per well, as estimated by a SmartSpec 3000 (Bio-Rad). 
ALF was dissolved in the appropriate medium at 3 mg/mL and added to the plated bacteria. 
After incubation for 3 h at 37°C, 10 µL of the solution was removed and added to 90 µL of the 
appropriate broth. Six 1:10 dilutions were prepared before plating in triplicate on L-B agar 
plates. The plates were incubated at 37˚C overnight and colony forming units (CFUs) were 
counted. 
The same procedure was followed to test the abrogation of killing by ALF through the 
addition of recombinant PspA. Briefly, E. coli was grown on LB agar overnight, a colony was 
inoculated into 5 mL LB broth and incubated at 37˚C until the culture reached its exponential 
growth phase. The culture was diluted 1:20 into fresh broth and grown to its early log growth 
phase before inoculating at 10
6
 cells/well of a microtiter plate. ALF was dissolved in medium at 
a concentration of 3 mg/mL followed by the addition of native PspA or PspA collected after 
release from nanoparticles, which was mixed and allowed to incubate for approximately 5 min 
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before addition to the bacteria. The microtiter plate was incubated at 37˚C for 3 h before 
enumerating viable bacteria as described above. Although the nanoparticles were removed prior 
to the addition of released PspA, it was verified that the presence of nanoparticles did not 
interfere with the experimental system. Additionally, it was confirmed that the acidic 
microenvironment produced by the nanoparticle degradation products did not interfere with the 
growth of E. coli. 
CFUs were determined by counting colonies grown on LB agar plates after overnight 
incubation. The log CFU killed was calculated by subtracting the experimental values from 
control E. coli cultures grown under identical conditions. Data is presented as log CFU of killed 
E. coli. 
6.3.11 Immunization studies 
CBA/CaHN-Btk
xid
/J (CBA/N) mice purchased from Jackson Laboratory (Bar Harbor, 
ME) were used for the immunization studies.  Mice were immunized subcutaneously with 20 to 
25 µg reconstituted PspA and 0 to 5 µg PspA encapsulated into 500 µg of polyanhydride 
nanoparticles and/or formulated with MPLA (10 µg, derived from Salmonella enterica serotype 
Minnesota Re 595 (Sigma Aldrich)), a traditional adjuvant approved for human use
45
.  The 
treatment groups were: 20 µg PspA delivered solubly with 5 µg PspA encapsulated into 500 µg 
of 50:50 CPTEG:CPH nanoparticles,  20 µg PspA delivered solubly with 5 µg PspA 
encapsulated into 500 µg of 20:80 CPH:SA nanoparticles, 25 µg PspA delivered solubly with 10 
µg MPLA, and a saline control.  The volume of the inoculum was 100 µL in each case. At least 
six animals were used in each experimental group.  Blood was collected from animals via the 
saphenous vein before immunization and at 2, 4, and 7 weeks post-immunization.  Serum was 
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collected after centrifugation (10,000 rcf for 10 min) of the blood samples and stored at 4°C until 
use. 
6.3.12 Anti-PspA serum antibody titers 
Antibody titers were determined using an ELISA as described above. Plates were coated 
with PspA at a concentration of 0.5 µg/mL and incubated overnight at 4˚C. The blocking buffer 
used for these studies was 0.05 M PBS-T supplemented with 2% gelatin (Becton Dickinson, 
Franklin Lakes, NJ). PspA coated microtiter plates were incubated for 2 h at room temperature 
before washing thrice with PBS-T. Serum from immunized mice was added to the first well at a 
1:200 dilution in PBS with 1% (v/v) heat-inactivated goat serum and serially diluted two-fold. 
After an overnight incubation at 4˚C, plates were washed three times with PBS-T, and then 
alkaline phosphatase-conjugated goat anti-mouse IgG (heavy and light chain) (Jackson 
ImmunoResearch) was added at a concentration of 1 µg/mL followed by incubation for 2 h at 
room temperature. Plates were washed four times with PBS-T and 1 mg/mL alkaline phosphatase 
substrate (Fisher Scientific, Pittsburgh, PA) dissolved in 50 mM sodium carbonate 2 mM 
magnesium chloride buffer (pH 9.3) was added for colormetric development. The plates were 
read after 30 minutes at 405 nm. All the samples were tested in technical replicates of 2. Titer is 
herein defined as the serum dilution that produced an optical density value twice that of the 
saline group. 
6.3.13 Antibody avidity 
MagPlex-C microspheres (magbeads) were activated and coupled to PspA (20 µg/mL in 
PBS) as described by the manufacturer. Following the conjugation step, the PspA-magbeads 
were washed with PBS-T and stored in PBS with 1% bovine serum albumin and 0.05% sodium 
azide and covered to block overnight at 4°C. Serum samples were diluted in PBS-T and 50 µL 
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was added to each well of a 96 well black, clear bottom microtiter plate along with 50 µL of 
vigorously vortexed magbeads (120,000/mL) conjugated with PspA suspended in blocking 
buffer. Plates were immediately covered and placed on a plate shaker for 1 h at room 
temperature. Plates were washed three times with the blocking buffer using a BioPlex Pro II 
plate washer and 100 µL of either PBS-T or 6 M urea in PBS (chaotriopic agent) were added to 
the appropriate wells. Plates were covered and put on a shaker for 15 min, and then washed three 
more times. Biotin-conjugated goat anti-mouse IgG (eBioscience, San Diego, CA) was diluted 
1:200 and 50 µL was added to each well, and plates were covered and shaken at room 
temperature for 1 h. Plates were washed three times with wash buffer, 50 µL of streptavidin-
phycoerythrin (PE) diluted 1:20 in PBS-T was added to each well, and incubated for 30 min. 
Plates were washed three times and filled with 100 µL of blocking buffer per well, and the mean 
fluorescent intensity (MFI) was measured using a BioPlex 200. To calculate the relative avidity 
of a serum sample having a demonstrable antibody response to the target antigen, the MFI 
obtained for the sample well treated with 6 M urea was divided by the MFI obtained for the 
corresponding sample well incubated with only PBS-T. This value was multiplied by 100 to 
obtain a relative percent avidity for each serum sample.  
6.3.14 Calculations and statistics 
Log CFU killed were calculated by subtracting the log of the experimental group 
CFU/mL concentration from the log CFU/mL of bacteria alone after incubation. All error bars 
represent standard error of the mean (S.E.M). MiniTab statistical package (MiniTab, Inc., State 
College, PA) was used to perform statistical analysis. A two sample t-test was used and 
statistical significance was characterized by p < 0.05. 
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6.4 Results and Discussion 
Several proteins, including F1-V, Bacillus anthracis protective antigen (PA), bovine 
serum albumin (BSA), and ovalbumin have been shown to be stably released from 
polyanhydride particles
28, 29, 30, 36
. Each of these proteins has different mechanisms of instability 
and/or degradation. Herein, the lessons learned from these previous studies were applied to 
determine the optimal polyanhydride nanoparticle formulations for stabilization and sustained 
delivery of functional PspA for the development of a vaccine against S. pneumoniae.   
6.4.1 Polyanhydride nanoparticles provide for the release of stable and functional PspA 
PspA was encapsulated into and released from 50:50 CPTEG:CPH and 20:80 CPH:SA 
nanoparticles to study the release kinetics of the protein from different polyanhydride 
chemistries. These chemistries were chosen based on the previous success of 50:50 
CPTEG:CPH-based nanovaccine formulations in inducing protective immunity
32
 and the ability 
of 20:80 CPH:SA to stabilize proteins for extended periods at elevated temperatures, obviating 
the need for cold storage
29
. Additionally, 20:80 CPH:SA nanoparticles are readily internalized by 
antigen presenting cells, which could lead to enhanced internalization of PspA by these immune 
cells
41
. The particles were fabricated using a solid/oil/oil double emulsion method with 
encapsulation efficiencies of 62 and 68% for 50:50 CPTEG:CPH and 20:80 CPH:SA, 
respectively. PspA-loaded nanoparticles were characterized using SEM and the 
photomicrographs are shown in Figure 1. The size and shape  of the nanoparticles were 
consistent with previous work using polyanhydride nanoparticles, with smooth, roughly spherical 
surface morphology and  an average diameter of 677 ± 254 nm for the 20:80 CPH:SA 
nanoparticles and 243 ± 84 nm for the 50:50 CPTEG:CPH particles
41, 42
. Particles were stored at 
-20˚C until use and thoroughly sonicated before administration. Figure 2 shows the release of 
156 
 
 
 
PspA from polyanhydride nanoparticles over 30 days. Protein release from the 20:80 CPH:SA 
and 50:50 CPTEG:CPH chemistries showed an initial burst of 36% and 45%, respectively, 
followed by a sustained release, with smaller amounts of protein released from the particles over 
a period of time. The near-zero order release profile (after the initial burst) can be attributed to 
the surface erosion characteristics of polyanhydrides, in contrast to the bulk erosion exhibited by 
PLGA and other biodegradable polymers
46, 47
. The burst release observed is due to the relatively 
higher amount of surface area of the particle at initial time points and because of the propensity 
of the payload to migrate towards the surface of the particle during solvent evaporation. This 
burst release provides sufficient antigen initially to prime the immune response. These data are 
consistent with previous work on protein release kinetics from polyanhydride particles
28, 29, 35-37
.  
 
6.4.2 Preservation of PspA primary and secondary structure upon release from polyanhydride 
nanoparticles 
Following the release of PspA from the nanoparticles, the supernatants were collected 
and the primary and secondary structures were analyzed using SDS-PAGE and circular 
dichroism (CD), respectively. Figure 3 shows that the primary structure of PspA remained intact 
after encapsulation and release based on the presence of a single band just under 50 kDa and the 
absence of smaller bands in all the lanes of the gel. Additionally, the lack of any larger bands 
indicated that the polyanhydride nanoparticle formulations did not cause any PspA aggregation.  
It is known that the N-terminal portion of the recombinant PspA used in this work adopts 
a coiled coil, α-helical secondary structure48. Figure 4 shows CD spectra for PspA released from 
the different polyanhydride nanoparticle formulations. The data showed that the α-helical 
secondary structure of the protein was maintained after release from the nanoparticles, as 
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evidence by the presence of characteristic minima at 208 nm and 222 nm, which are known to be 
associated with an α-helical structure49. Additionally, the observed secondary structure is 
consistent with previously published work on PspA
48
. Additionally, we present a spectrum of 
PspA that has been degraded with acid (Figure 4). It is clear from this experiment that acidity 
compromises the secondary structure of PspA, thereby denaturing it. 
It is significant that both polyanhydride chemistries tested preserved the structure of 
PspA upon release. The option to choose from multiple chemistries provides the ability to tailor 
both the protein release profile and the host immune response. Differences in adjuvant chemistry, 
especially with respect to hydrophobicity and degradation kinetics, have been shown to 
significantly influence the character of the resulting immune response. For example, the 50:50 
CPTEG:CPH and 20:80 CPH:SA nanoparticle formulations differentially affect cytokine 
secretion
27
. These two polymer chemistries also have different in vivo distribution and 
inflammation profiles, which can be exploited to further modulate the desired immune 
response
50
. Moreover, 20:80 CPH:SA nanoparticles have excellent thermal properties and can 
preserve protein antigenicity for up to one year at room temperature
29
. This feature could be 
exploited to eliminate the requirement for maintaining a cold chain during vaccine storage and 
delivery
51
. 
6.4.3 Antigenicity of released PspA is retained upon release from polyanhydride nanoparticles  
The results depicted in Figure 5 show that the antigenicity of PspA is maintained after 
release from the polyanhydride nanoparticles. The antigenicity was determined using an ELISA 
with a PspA-specific monoclonal antibody; this assay measured the ability of PspA released 
from polyanhydride nanoparticles be recognized by an anti-PspA-specific antibody. The relative 
antigenicity of the PspA released from nanoparticles was preserved for both polyanhydride 
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chemistries tested. These results indicated that PspA may not be as susceptible to 
hydrophobicity-induced conformational changes that have been observed with other proteins
28
. 
However, it was observed that incubating PspA in acidic solutions, pH 5 and below, led to 
protein degradation (data not shown). Many biodegradable polymers, including polyanhydrides 
and polyesters such as PLGA, have acidic degradation products and, as demonstrated for PspA, 
incubation in acidic solution can lead to protein degradation. The amphiphilic 50:50 
CPTEG:CPH has been shown to have local microenvironments of approximately pH 6, as 
compared to more acidic chemistries such as 20:80 CPH:SA and PLGA, which have been shown 
have local microenvironments of pH < 4
37
. Supplemental Figure 1 shows the change in the pH of 
the release buffer in which the polyanhydride nanoparticles are eroding over time. These data 
show that degradation of 50:50 CPTEG:CPH nanoparticles results in a small decrease in pH, 
with a stable pH of 6.9 maintained for the duration of the study. In contrast, the degradation of 
the 20:80 CPH:SA nanoparticles resulted in a more pronounced pH decline to pH~5.2. Given 
this information, it is expected that PspA released from 50:50 CPTEG:CPH nanoparticles would 
maintain antigenicity, while PspA released from 20:80 CPH:SA nanoparticles would degrade 
from acidic effects. However, in the current experiments, PspA released from both 50:50 
CPTEG:CPH and 20:80 CPH:SA nanoparticles maintained 90% relative antigenicity.  Unlike 
bulk-eroding polymers such as PLGA, polyanhydrides degrade through surface erosion, which 
may explain why the PspA was well preserved. This erosion characteristic protects the 
encapsulated protein from the acidic microenvironment by preventing water penetration into the 
bulk
46
. It is also important to note that during these in vitro release studies, released protein 
remained under these acidic conditions for 24 h before the supernatant was removed for testing 
and replaced with fresh PBS. However, when administered in vivo, polyanhydride nanoparticle 
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vaccine formulations disseminate quickly, which would prevent the local build-up of acidic 
degradation products
50
. The preservation of 90% relative antigenicity of PspA upon release from 
both the 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticles under these harsh in vitro 
conditions indicates that these formulations may be promising delivery vehicles for in vivo 
administration.  
6.4.4 Polyanhydride nanoparticles preserve the biological functionality of released PspA 
In order to test the biological functionality of PspA released from polyanhydride 
nanoparticles, an E. coli killing assay was developed. This assay takes advantage of the 
bactericidal nature of ALF, which is found in the human mucosa in two forms, the iron-deficient 
ALF and the iron-rich hemolactoferrin
12
. The role of PspA in pneumococcal infection is to bind 
to ALF and prevent its bactericidal and bacteriostatic effects
12
. In the current studies, two E. coli 
strains were tested, the wild type MG1655 and the LPS-deficient NR688. Due to the absence of 
LPS, the NR688 strain proved to be more susceptible to killing by ALF.  
Figure 6 shows that PspA released from both polyanhydride nanoparticle formulations 
retained its biological functionality using native PspA as a control. The log CFU of E. coli killed 
by ALF in the nanoparticle groups was statistically different from that of the untreated ALF 
group but not statistically different from the native PspA control. This indicates that the PspA 
protein released from polyanhydride nanoparticles is able to perform its biological function as 
well as the PspA control. 
6.4.5 Vaccination with a single dose of PspA-containing polyanhydride nanoparticles provides a 
sustained immune response 
 CBA/N mice were vaccinated subcutaneously with polyanhydride nanoparticle-
based and MPLA-based single dose vaccination regimens. Each animal was given a total of 25 
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µg of PspA.  For the MPLA group, 10 µg of MPLA was used as an adjuvant.  For the 
nanoparticle groups, 20 µg of PspA was delivered as soluble protein along with 5 µg of PspA 
encapsulated into 500 µg of polyanhydride nanoparticles of the specified chemistry.  Based on 
the results from the in vitro studies described above, both nanoparticle formulations were tested. 
All vaccinated mice, regardless of chemistry (except for the saline formulation), developed anti-
PspA antibody titers between 8,000 and 20,000 by seven weeks post-immunization (Figure 7a). 
These titers are consistent with those reported to be protective against lethal challenge with S. 
pneumoniae
15
. The mice receiving the 50:50 CPTEG:CPH nanoparticle vaccine formulation 
maintained their titer for at least seven weeks at titers above 10,000. The mice administered the 
20:80 CPH:SA nanoparticle formulation and the MPLA formulation tended to have a decline in 
titer between weeks four and seven, although not statistically significant. In other work, the 
controlled release provided by nanoparticle-based vaccine formulations, specifically the 50:50 
CPTEG:CPH chemistry, has sustained titer 23 weeks post-immunization and provided long-
lasting immunity in a single dose
32
. The prolonged presence of protein as a consequence of the 
persistence of the nanoparticles may explain the effectiveness of the soluble plus encapsulated 
protein combination in the nanoparticle-based vaccine formulations.   
The sustained release of protein is important as the continuous release of small quantities 
of antigen may be significant for the induction of a long-lasting immunity characterized by a 
high titer, high avidity antibody response. This effect may also have important implications in 
the development of a single dose PspA vaccine, limiting the need for repeat administrations. 
Many vaccine regimens typically require more than one immunization, including the current S. 
pneumoniae 7 and 23-valent conjugate vaccines, which require three primary doses in infants 
and a booster dose at age two
52
. The single dose administration of particles based on 
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biodegradable polymers such as polyanhydrides has demonstrated the ability to provide antibody 
titers consistent with those induced by multiple doses of traditional adjuvants
52
. Continuous 
release of antigen would mimic a replicating pathogenic infectious agent and generates a robust, 
long-lasting immune response as the continual exposure of B cells to antigen induces a strong 
memory response
53
. Additionally, the initial burst of released antigen observed with both the 
20:80 CPH:SA and 50:50 CPTEG:CPH nanoparticle formulations may provide sufficient antigen 
to successfully prime the immune response and generate T cell help. This step is critical because 
T cell interactions with B cells lead to development of germinal centers and generation of high 
affinity antibodies
54
.  
To assess the quality of the antibody response, avidity was measured. High avidity is 
indicative of high strength of binding antibody, which is important for a sustained and effective 
humoral immune response
55
. The data in Figure 7b shows the relative avidity of the serum anti-
PspA IgG antibody response at seven weeks post-immunization. Both of the polyanhydride 
chemistries tested demonstrated similar relative avidities, with the 50:50 CPTEG:CPH 
nanoparticle formulation resulting in a slightly higher relative avidity, though not significantly 
so, over the 20:80 CPH:SA. Additionally, the variability of the avidity of the anti-PspA antibody 
between mice was smaller with the nanoparticle formulations compared to that of the MPLA-
immunized animals. The induction of highly avid antibodies by polyanhydride nanoparticle 
formulations is consistent with the sustained release demonstrated by these particles in vitro. The 
avidity indices observed in this work were similar to those generated against capsular 
polysaccharide 6B through a triple-immunization of an 11-valent pneumococcal conjugate 
vaccine adjuvanted with alum
56
. In that study, it was demonstrated that the addition of alum to 
the vaccine did not provide a benefit with respect to avidity. Those observations, paired with our 
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present findings, highlight an important contrast between the use of alum and polyanhydride 
nanoparticle-based vaccine platforms in terms of the ability to increase antibody avidity
57
.  
This current work demonstrates the importance of rationally designing adjuvants and/or 
delivery vehicles for vaccine optimization. The encapsulation of PspA into polyanhydride 
nanoparticles provided a number of benefits over using off-the-shelf adjuvants such as MPLA, 
including sustained release, long-lasting immune responses, and higher avidity antibodies, as 
demonstrated previously with other protein antigens
32, 53
. Because PspA was found to be 
structurally stable, antigenic, and biologically functional upon release from two separate 
polyanhydride nanoparticle chemistries, there exists the ability to rationally select nanoparticle 
formulations to protect vaccine antigens while tailoring the immune response to a phenotype that 
is most effective against S. pneumoniae. The current studies lay the groundwork for the design of 
more robust and versatile vaccines against pneumonia that have the potential to provide 
significant benefits over current vaccination regimens.   
6.5 Conclusions 
The primary and secondary structure, antigenicity, and biological functionality of PspA 
protein were preserved during encapsulation and release from polyanhydride nanoparticles. This 
result is significant because the release of intact, functional protein increases the probability of 
preserving important, neutralizing epitopes and facilitates the development of an effective 
immune response. Herein, we demonstrate not only the release of functionally intact protein, but 
also demonstrate how a PspA vaccine based on polyanhydride nanoparticles can be used to 
generate a robust humoral immune response. PspA-containing polyanhydride nanoparticle 
vaccine formulations induced stable, high titers and avid antigen-specific antibody. These studies 
provide a critical foundation for the future design of robust and versatile vaccines against 
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streptococcal pneumonia that address both colonization and infection in a more patient-friendly 
manner.  
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6.8 List of Figures 
 
Figure 6.1. Representative scanning electron photomicrographs of sonicated 1% PspA 
encapsulated (a) 20:80 CPH:SA and (b) 50:50 CPTEG:CPH nanoparticles. Scale bar: 5 µm.  
 
 
Figure 6.2. Kinetic profile of PspA released from two polyanhydride nanoparticle formulations. 
Cumulative fraction of PspA released from 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticles 
is presented as a function of time. Data are presented as the mean ± SEM of at least two 
independent experiments with three technical replicates each.  
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Figure 6.3. The primary structure of PspA was preserved upon release from polyanhydride 
nanoparticles. Lanes: a) Molecular weight ladder, b) PspA, c) PspA plus MPLA, d) PspA 
released from 50:50 CPTEG:CPH nanoparticles, and e) PspA released from 20:80 CPH:SA 
nanoparticles.  
 
Figure 6.4. The secondary structure of PspA was preserved during encapsulation and release 
from polyanhydride nanoparticles. The presence of characteristic minima at 208 and 222 nm 
indicates preservation of α-helical secondary structure. Each measurement represents the average 
of at least two independent experiments, with two technical replicates each. 
170 
 
 
 
 
Figure 6.5. Antigenicity of PspA is preserved upon release from polyanhydride nanoparticles. 
Relative antigenicity is defined as the optical density ratio between the experimental replicate 
and the native protein. Day 0 represents the antigenicity of released protein samples after two 
hours of incubation. Data are presented as the mean ± SEM of at least two independent 
experiments with three technical replicates each.  
 
Figure 6.6. PspA released from nanoparticles retained biological functionality as indicated by the 
ability to reduce the bactericidal activity of ALF. Separate cultures of E. coli K-12 NR688 were 
incubated with bacteria culture medium containing ALF alone, ALF plus control PspA, or ALF 
plus PspA released from either 50:50 CPTEG:CPH or 20:80 CPH:SA as described in Materials 
and Methods. Data are presented as the mean ± SEM of two independent experiments with at 
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least six technical replicates each. Treatments identified with asterisks are statistically different 
from the cultures treated with ALF alone (p < 0.005).   
 
Figure 6.7. CBA/N mice immunized with polyanhydride nanoparticle formulations produced 
high titer, high avidity anti-PspA antibodies. a. Anti-PspA IgG(H+L) antibody titer measured by 
ELISA at two, four, and seven weeks after vaccination. b. Antibody avidity indices measured 
seven weeks after vaccination. Error bars represent the mean ± the SEM. 
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Supplemental Figure 6.1. pH of supernatant from release samples evaluated as a function of 
time. In this experiment, 25 µg of 20:80 CPH:SA and 50:50 CPTEG:CPH nanoparticles were 
incubated in 600 µL of 0.05 M phosphate buffered saline (PBS, pH 7.2). At each time point 
samples were centrifuged and the supernatant was removed for analysis. Solution pH was 
measured using an Orion Ross pH electrode (Thermo Fisher Scientific). It was observed that 
degradation of 50:50 CPTEG:CPH nanoparticles resulted in a small decrease in pH to 6.9 
whereas 20:80 CPH:SA nanoparticle degradation resulted in a more pronounced pH decrease to 
5.2.  
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7.1 Abstract 
Since its first isolation in the 1880s, Streptococcus pneumoniae has been found to be 
endemic globally in all areas that have been tested. Given the number of serotypes of the 
polysaccharide capsule of S. pneumoniae, a universal vaccine based on the capsule 
polysaccharides has not yet been developed. In the search for a universal vaccine many bacterial 
virulence factors have been investigated for use as protective antigens in vaccine formulations. 
The most well-known and well-studied S. pneumoniae subunit for potential vaccines is 
pneumococcal surface protein A (PspA). Polyanhydride nanoparticles have previously been 
reported to stabilize PspA and provide sustained release of the antigen. Herein we report the 
design of a novel combination nanovaccine that brings together innate immunity inducing cyclic 
dinucleotides (CDNs) and polyanhydride nanoparticles to elicit a protective immune response 
within two weeks of a single-dose vaccination.   
7.2 Introduction 
Since its first isolation in the 1880s, Streptococcus pneumoniae has been found to be 
endemic globally in all areas that have been tested
1
.  Considered to be part of the commensal 
bacteria flora of the human nasopharynx, with rates of colonization peaking in those of 1-2 years 
of age and declining thereafter
2
, the bacteria may colonize the upper respiratory tract, 
specifically the nasopharynx, asymptomatically for anywhere from several to upwards of 30 
weeks depending on the immunogenicity of the serotype
2,3
. The use of antibiotics has greatly 
improved the morbidity and mortality associated with S. pneumoniae, but with the increase in 
prevalence of antibiotic-resistant strains of S. pneumoniae, vaccination against this pathogen 
remains one of the most important strategies in combating pneumococcal disease.
4
 However, 
pneumonia vaccination programs have not been prioritized in the same way as influenza vaccine 
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programs
5
.  The increasing prevalence of antibiotic resistant S. pneumoniae strains and the lack 
of widespread pneumococcal vaccinations has led to renewed public health awareness about this 
pathogen.   
Given the number of serotypes of the polysaccharide capsule of S. pneumoniae, a 
universal vaccine based on the capsule polysaccharides has not yet been developed. 
Polysaccharide-based vaccines have been utilized including Pneumovax 23 (Merck) and Pnu-
Immune 23 (Lederle Laboratories). The 23-valent polysaccharide vaccine against S. pneumoniae 
has been shown to protect against the serotypes included in the vaccine, which are 1, 2, 3, 4, 5, 
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
4
. These 
vaccines tend to induce antibody-based immunity against the serotypes included in the vaccines, 
with a limitation being the T cell-independent nature of the immune response generated. 
Polysaccharide-conjugate vaccines use a carrier protein for the delivery of the purified 
polysaccharide capsule, eliciting a T cell-dependent immune response
6
. However the limited 
number of serotypes (7-13) in this vaccine can lead to an increase in the prevalence of strains not 
included in the vaccine, from 5% to 49% of invasive pneumococcal disease (IPD) cases
7
, known 
as serotype substitution.  
In the search for a universal vaccine many bacterial virulence factors have been 
investigated for use as protective antigens in vaccine formulations, including pneumococcal 
surface protein A (PspA), PsaA, pilus components, and pneumolysin. The most well-known and 
well-studied S. pneumoniae subunit for potential vaccines is PspA. This choline-binding surface 
protein is an important virulence factor in S. pnuemoniae infections and is therefore present on 
all medically relevant strains of the bacterium
8
. PspA plays two different roles in invasive 
infection and nasopharyngeal carriage. In invasive systemic infections with S. pneumoniae, PspA 
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prevents the deposition of complement, an immune protein that assists antibodies and phagocytic 
cells
9,10
. PspA also plays a role in carriage by binding the bactericidal glycoprotein, 
apolactoferrin
11
. Vaccination with PspA has been shown to be protective against a lethal 
challenge with S. pneumoniae making it a promising candidate for use in an improved vaccine
12–
14
. In addition, PspA can be economically synthesized as a recombinant protein and the protein-
based vaccine avoids the loss of antigenicity in at-risk populations observed with the 
polysaccharide-based vaccine
15
.  
We have previously demonstrated the encapsulation and sustained release of stable, 
antigenic PspA from two polyanhydride chemistries based on sebacic acid (SA), 1,6-bis-(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG)
16
. 
Herein we demonstrate the development of a protective subunit vaccine based on PspA using 
polyanhydride nanoparticles as a vaccine adjuvant/delivery vehicle. With the need to induce 
protective immunity at early time points, we combined the polyanhydride nanovaccines with 
cyclic dinucleotides (CDNs), a bacterial second messenger based on DNA nucleotides, that have 
been shown to stimulate the innate immune system through interactions with the STimulator of 
INterferon Gene (STING) pathway
17,18
. Additionally we demonstrate the potential to formulate 
an effective PspA nanovaccine in which all the antigen is encapsulated with the nanoparticles. 
This eliminates the need for a soluble bolus of protein as previously included in polyanhydride 
nanovaccine formulations
16,19
. When all of the antigen is encapsulated within the polyanhydride 
nanoparticles without a soluble component, there are potential implications for increased shelf-
life and stability of the vaccine outside of the cold chain
20
. 
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7.3 Materials and Methods 
7.3.1 Materials 
The following chemicals were used in the synthesis of polyanhydride copolymers and 
nanoparticles. Acetic acid, acetic anhydride, acetone, acetonitrile, chloroform, dimethyl 
formamide, ethyl ether, hexane, methylene chloride, pentane, petroleum ether, potassium 
carbonate, sodium hydroxide, sulfuric acid, and toluene were purchased from Fisher Scientific 
(Fairlawn, NJ). 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hydroxybenzoic acid, N,N-
dimethylacetamide, sebacic acid, and tri-ethylene glycol were purchased from Sigma Aldrich (St. 
Louis, MO). 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK). 
Deuterated chloroform and dimethyl sulfoxide for 
1
H NMR analysis were purchased from 
Cambridge Isotope Laboratories (Andover, MA).  
7.3.2 Polymer synthesis 
Copolymer synthesis based on the monomers, 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was performed as described 
previously
21,22
. A 50:50 molar composition of CPTEG and CPH was synthesized using melt 
condensation polymerization
22
. The copolymer molecular weight was confirmed using 
1
H NMR 
analysis. The molecular weight of the 50:50 CPTEG:CPH copolymer used in these studies 
ranged from 4,790 g/mol – 6,160 g/mol. 
7.3.3 Nanoparticle synthesis 
50:50 CPTEG:CPH nanoparticles were synthesized using solid/oil/oil nanoprecipitation, 
as previously described
21
.  PspA protein was dialyzed against water to remove salts before 
undergoing lyophilization overnight at -40˚C. The resultant, dry PspA protein was encapsulated 
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into 50:50 CPTEG:CPH nanoparticles. The protein-loaded particles were characterized for size 
and morphology by scanning electron microscopy (SEM, FEI Quanta SEM, Hillsboro, OR). 
7.3.4 Cyclic dinucleotides 
Cyclic dinucleotides were synthesized by Aduro BioTech.  Canonical rr-diGMP CDNs 
were synthesized from commercially available DMT-rA(Bz)-βCE-TBDMS-phosphoramidite12 
using a phosphoramidite dimerization method followed by a H-phosphonate cyclization 
method
13
.  
7.3.5 Streptococcus pneumoniae 
Infectious doses of S. pneumoniae were prepared. 50 mL of Todd Hewitt + Yeast broth 
was inoculated with A66.1 S. pneumoniae. Cultures were grown to log growth phase, which was 
indicated by an optical density of ~0.45. Cultures were then cooled on ice followed by the 
addition of 5 mL of 80% glycerol. Frozen aliquots of the suspension were made and kept at -
80°C until use.  
7.3.6 Recombinant PspA protein 
The N-terminal region of a recombinant PspA (UAB055, PspA/Rx1 AA1 to 303, clade 2 
PspA of the PspA family 1) was produced by Dr. David McPherson (University of Alabama at 
Birmingham). Protein was dialyzed using a 10,000 MW cut-off dialysis cassette (Thermo Fisher 
Scientific, Rockford, IL) against sterile, nanopure water and frozen at -80°C. Protein was then 
lyophilized at -40˚C under vacuum overnight and stored at -80°C until further use. Endotoxin 
was removed from the protein using endotoxin removal beads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s instructions prior to dialysis and 
lyophilization. The final endotoxin content of the protein prior to use was determined to be less 
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than 3.7 EU/mg as determined by a limulus amebocyte lysate (LAL) chromogenic endotoxin 
quantification kit (Thermo Fisher Scientific). 
7.3.7 Mice 
Four to five week old male CBA/CaHN-Btk
xid
/J (CBA/N) mice were purchased from 
Jackson Laboratory (Bar Harbor, ME). All studies were conducted upon receiving approval from 
the Iowa State University Institutional Animal Care and Use Committee. 
7.3.8 Vaccination and challenge 
CBA/N mice were used for the vaccination studies. Animals were vaccinated 
subcutaneously at the nape of the neck. All formulations were prepared in 100 µL sterile 
phosphate buffered saline (PBS).  The vaccine formulations used are shown in Table 1. All 
animals received a total of 5-25 µg of PspA. Sterile PBS was used for the control group.  Five to 
eight animals were used per group. Animals were challenged at 14 or 24 days after challenge 
with 2500 CFU of A66.1 S. pneumoniae in a total volume of 100 µL through injection with a 26 
gauge needle into the mouse tail vein. 
7.3.8 Anti-PspA enzyme-linked immunosorbent assay 
In order to determine anti-PspA antibody titers, enzyme-linked immunosorbent assays 
were performed, as previously described
16
.  Briefly, high-binding surface chemistry 96-well 
plates were coated with 100 µL of 0.5 µg/mL PspA suspended in PBS.  Plates were incubated 
overnight at 4˚C. The protein solution was removed and 300 µL of blocking buffer (2.5% skim 
milk dissolved on PBS with 0.05% Tween (PBS-T)). Plates were incubated with blocking buffer 
for 2 hours at room temperature.  After incubation, plates were washed three times with PBS-T 
and serum was added to PBS-T containing 1% goat serum beginning at a 1:200 dilution, and 
serially diluted 3-fold 12 times.  After the addition of serum, plates were incubated overnight at 
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4˚C. Samples were washed three times with PBS-T, and alkaline phosphatase-conjugated goat 
anti-mouse IgG (heavy and light chain) (Jackson ImmunoResearch) was added at a concentration 
of 1 µg/mL followed by incubation for 2 hours at room temperature.  Another three washes were 
performed with PBS-T, followed by the addition of 1 mg/mL alkaline phosphatase substrate 
(Fisher Scientific, Pittsburgh, PA) in 50 mM sodium carbonate 2 mM magnesium chloride buffer 
at pH 9.3.  Plates were developed for 30 minutes before reading the optical density at 405 nm.  
7.4 Results and Discussion  
7.4.1 Soluble plus encapsulated nanovaccine formulation provides protection against lethal 
challenge with S. pneumoniae 
We have previously demonstrated the encapsulation and sustained release of stable, 
antigenic pneumococcal surface protein A (PspA), a surface protein of S. pneumoniae, from two 
polyanhydride chemistries based on sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane 
(CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG)
16
. PspA is a choline-binding 
protein found on the surface of all pneumococcal strains and has been shown to be able to elicit 
protective immunity against S. pneumoniae
13,15,23
. 
In the current studies, mice were vaccinated with 25 µg PspA delivered alone or with 20 
µg PspA and 5 µg PspA encapsulated into either 50:50 CPTEG:CPH nanoparticles or 20:80 
CPH:SA nanoparticles (Figure 7.1). The immunization regimens are summarized in Table 7.1. 
Serum antibody titers were measured at 7 and 17 days after immunization and animals were 
challenged with 2500 CFU of S. pneumoniae 24 days post-vaccination (Figure 7.2). The data 
showed that adding CDNs to the nanovaccine formulations boosted the antibody response. 
Animals immunized with the 50:50 CPTEG:CPH nanovaccine formulation and two types of 
CDN formulations demonstrated 100% protection against challenge, while those receiving the 
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20:80 CPH:SA nanovaccine formulation alone (i.e., no CDNs) demonstrated 75% protection 
against challenge, and mice that received 25 µg PspA alone elicited only 25% protection against 
challenge (Figure 7.3).  
7.4.2 100% antigen-encapsulated nanovaccine formulations provide protection against lethal 
challenge with S. pneumoniae  
Next, animals mice were vaccinated with 5 µg PspA encapsulated at 10% (w/w) into 
50:50 CPTEG:CPH nanoparticles (with no soluble antigen). The immunization regimens are 
summarized in Table 7.2. Animals were challenged with 2500 CFU of S. pneumoniae 14 days 
post-vaccination with the survival results summarized in Table 7.3. All the animals immunized 
with adjuvanted vaccine formulations demonstrated 100% survival against challenge, while the 
animals vaccinated with PspA alone had a survival rate of 87.5%. These results show a marked 
increase in the response to vaccination with the soluble PspA at a 5X reduced dose when 
compared to the previous study. Theis leads to the opportunity to further reduce the amount of 
protein needed, which has important implications for dose sparing with the combination 
nanovaccine formulations. 
7.4.3 Dose sparing effects on 100% antigen-encapsulated nanovaccine formulation for enhanced 
protection against S. pneumoniae with reduced antigen requirements 
With successful proof of concept studies, summarized above, indicating that mice 
vaccinated with 5 µg PspA encapsulated into 50:50 CPTEG:CPH nanoparticles (with no soluble 
antigen) were 100% protected against lethal challenge with S. pneumoniae, we next investigated 
whether the dose of PspA could be further reduced while maintaining high levels of vaccine 
efficacy. The total amount of PspA used in experimental vaccine formulations was reduced to a 
total dose of 1 µg. A formulation in which 100% of the antigen was encapsulated (i.e., no soluble 
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antigen) was investigated with 1 µg of PspA encapsulated at 5% loading into 20 µg of 50:50 
CPTEG:CPH nanoparticles, with 30 µg of blank (i.e., no antigen) 50:50 CPTEG:CPH 
nanoparticles added to be consistent across groups, all of which contained 50 µg of 
nanoparticles.  Additionally, a soluble + encapsulated formulation was included with 0.5 µg 
PspA encapsulated at 1% loading into 50 µg of 50:50 CPTEG:CPH nanoparticles, with 0.5 µg of 
PspA delivered as soluble protein. Finally, 1 µg PspA was delivered alone and 1 µg PspA with 
Alum was used as a positive control group. The experimental groups are summarized in Table 
7.4.  
Upon experimental challenge with 2500 CFU of S. pneumoniae it was found that the 
polyanhydride nanoparticles were able to provide greater than 80% protection in all of the nano-
formulations studied with the reduced dose of PspA as shown in Figure 7.4. In contrast, the 
protection induced by the soluble 1 µg protein alone drops significantly, with only one animal 
out of eight surviving challenge. This clearly shows the adjuvant effect of the polyanhydride 
nanovaccine formulations. Antibody titer data, as shown in Figure 7.5, reflects these results. All 
of the nanovaccine formulations exhibit enhanced antibody titer over PspA alone and PspA 
adjuvanted with alum. Future studies will focus on the effect of shelf-life to demonstrate the 
benefit of the all-encapsulated nanovaccine formulation in comparison to the soluble + 
encapsulated formulation, which appear to be demonstrating an adjuvant effect on the protein. 
7.5 Conclusions 
Herein we demonstrate the development of a protective subunit vaccine based on PspA 
using a combination nanovaccine formulation based on polyanhydride nanoparticles and CDNs 
as vaccine adjuvants. The use of the CDNs obviated the need for soluble protein, resulting in a 
formulation that was protective upon lethal challenge only 14 days post vaccination. The use of 
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this formulation may have implications for increased shelf-life and stability outside of the cold-
chain. We have also demonstrated the dose-sparing capabilities of the polyanhydride 
nanovaccine formulations, eliciting enhanced protection with just 1 µg of PspA. Additionally, in 
this work, we demonstrated protection both at early and late time points post-vaccination, 
providing foundational data for the development of a robust pneumonia nanovaccine. 
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7.7 List of Figures 
 
Figure 7.1 Scanning electron microscopy images of 1% PspA-loaded 20:80 CPH:SA (left) and 
50:50 CPTEG:CPH (right) nanoparticles. Scale bars: 4 µm (left) and 1 µm (right). 
 
Figure 7.2 Anti-PspA antibody titers after subcutaneous vaccination of CBA/N mice with 25 µg 
PspA-based formulations (PspA alone, PspA adjuvanted with Alum, and PspA encapsulated 
within two different types of polyanhydride nanoparticles) measured at 7 and 17 days after 
immunization.   
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Figure 7.3. Survival data for CBA/N mice immunized with the PspA-based formulations in 
Table 7.2. The animals were challenged with 2500 CFU of A66.1 S. pneumoniae 24 days post 
immunization. 
 
Figure 7.4. Survival data for CBA/N mice immunized with the PspA-based formulations in 
Table 7.4. The animals were challenged with 2500 CFU of A66.1 S. pneumoniae 30 days post 
immunization. 
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Figure 7.5. Anti-PspA antibody titers after subcutaneous vaccination of CBA/N mice with 1 µg 
PspA-based formulations (PspA alone, PspA adjuvanted with Alum, and PspA with three 
different polyanhydride nanoparticle formulations). 
7.8 List of Tables 
Table 7.1. Experimental groups of CBA/N mice immunized with 25 µg PspA in polyanhydride 
nanovaccine formulations or with Alum. 
Formulation Soluble PspA (µg) Encapsulated PspA 
(µg) 
50:50 CPTEG:CPH 20 5 
20:80 CPH:SA 20 5 
PspA + Alum 25 0 
PspA Alone 25 0 
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Table 7.2. Experimental groups of CBA/N mice immunized with 5 µg PspA in polyanhydride 
nanoparticles with and without CDNs or with Alum. 
Formulation Soluble PspA 
(µg) 
Encapsulated 
PspA (µg) 
CDN (µg) 
50:50 CPTEG:CPH 0 5 0 
50:50 CPTEG:CPH + CDN 0 5 25 
PspA + Alum 5 0 0 
PspA Alone 5 0 0 
PspA + CDN 5 0 25 
 
Table 7.3. Survival data for CBA/N mice immunized with the formulations showed in Table 7.2. 
The animals were challenged with 2500 CFU of A66.1 S. pneumoniae 14 days post 
immunization. 
Group Survival @ D14 
5 µg PspA 7/8 (87.5%) 
5 µg PspA + Alum 8/8 (100%) 
5 µg PspA + 25 µg CDN 8/8 (100%) 
5 µg PspA in 50 µg 50:50 CPTEG:CPH 8/8 (100%) 
5 µg PspA in 50 µg 50:50 CPTEG:CPH + 25 µg CDN 8/8 (100%) 
Saline 1/8 (12.5%) 
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Table 7.4. Experimental groups of CBA/N mice immunized with 1 µg PspA in polyanhydride 
nanoparticles or with Alum. 
Formulation Soluble PspA 
(µg) 
Encapsulated 
PspA (µg) 
Blank 50:50 
CPTEG:CPH 
Nanoparticles 
(µg) 
Encapsulated PspA 0 1 30 
Soluble + Encapsulated 0.5 0.5 0 
Soluble PspA 1 0 0 
PspA + Alum 1 0 0 
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8.1 Abstract 
Infectious diseases pose a significant threat to the world population. In the case of re-
emerging pathogens, and those that have been classified as potential bioterrorism agents, the 
need exists for a vaccine platform which can confer protective immunity in a short amount of 
time and also maintain a highly protective immune response for longer periods.  Polyanhydride 
nanoparticles have previously been reported to generate a long-lasting protective immune 
response against pneumonic plague. Herein we report that combining novel innate immunity 
inducing cyclic dinucleotides (CDNs) with the polyanhydride nanovaccine platform elicited a 
protective immune response within days of a single-dose vaccination.  We also confirmed the 
longevity of the immune response by demonstrating protection with this combination 
nanovaccine formulation up to six weeks after immunization.  
8.2 Introduction 
The use of biological agents as bioterrorism weapons remains a considerable threat due to 
their relative ease of manufacture and the high mortality rates induced by many select 
pathogens
1
.  One pathogen that is considered to have the potential to be used as a biological 
weapon is Yersinia pestis, the causative agent of plague-related diseases, due to its ability to 
spread through aerosolized droplets and the ability to easily introduce antibiotic resistance
2
. 
Despite this, and the fact that plague is still endemic in many regions globally, no commercial 
vaccine against Y. pestis is available
2,3
. There are many experimental vaccines in development 
including live attenuated vaccines and a number of vaccines based on Y. pestis subunits, 
especially F1, LcrV, and F1-LcrV (F1-V) fusion proteins
2
. 
A F1-V subunit vaccine based on polyanhydride nanoparticles has recently been 
demonstrated to provide protective immunity against lethal challenge with pneumonic plague. 
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The polyanhydride nanovaccine formulation provided 100% protection against challenge with 
CO92 Y. pestis, with both soluble protein alone and protein adjuvanted with MPLA failing to 
elicit a protective immune response
4
. These results suggest the potential for an effective, easily 
synthesized vaccine against Y. pestis. 
When designing a vaccine against a potential bioterrorism agent, post-exposure 
prophylaxis (PEP) is an important consideration, which has received much attention for potential 
bioterrorism agents such as Bacillus anthracis, the causative agent of anthrax, and Flioviridae 
viruses such as Ebola
5,6
.  
While polyanhydride nanovaccines have demonstrated protective immunity against lethal 
challenge with Y. pestis, the earliest time point after administration that has been tested is six 
weeks.  In order to elicit protective immunity at early time points after administration, a vaccine 
formulation must effectively engage innate immune mechanisms as well as develop a potent 
adaptive immune response.  Cyclic dinucleotides (CDNs), a bacterial second messenger based on 
DNA nucleotides have been shown to stimulate the innate immune system through interactions 
with STING
7,8
. Herein, it is hypothesized that using these molecules in combination with 
polyanhydride nanoparticles will rapidly elicit an immune response after immunization.  
While the short-term induction of protective immunity is important in the event of a 
bioterrorism attack, long-term immunity may be just as crucial for those who may be vaccinated 
against select agents as a preventative measure. In this work, we describe the design and 
performance of a protective combination nanovaccine formulation based on polyanhydride 
nanoparticles and novel CDNs that can fully protect upon challenge 10 days after administration, 
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without compromising the generation of long-term immunity, as evidenced by protective 
immune responses when challenged up to six weeks after immunization.   
8.3 Materials and Methods 
8.3.1 Materials 
The following chemicals were used in the synthesis of polyanhydride polymers and the 
fabrication of nanoparticles. Acetic acid, acetic anhydride, acetone, acetonitrile, chloroform, 
dimethyl formamide, ethyl ether, hexane, methylene chloride, pentane, petroleum ether, 
potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were purchased from Fisher 
Scientific (Fairlawn, NJ). 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hydroxybenzoic acid, 
N,N-dimethylacetamide, sebacic acid, and tri-ethylene glycol were purchased from Sigma 
Aldrich (St. Louis, MO). 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, 
UK). Deuterated chloroform and dimethyl sulfoxide for 
1
H NMR analysis were purchased 
Cambridge Isotope Laboratories (Andover, MA). F1-V fusion protein was obtained from BEI 
Resources (Manassas, VA). 
8.3.2 Polymer synthesis 
Synthesis of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG) was performed as described
9,10
. A 50:50 molar copolymer of CPTEG 
and CPH was synthesized through melt condensation polymerization, as described elsewhere
10,11
.  
Molecular weight was confirmed using 
1
H NMR. 
8.3.3 Nanoparticle synthesis 
50:50 CPTEG:CPH nanoparticles were synthesized using solid/oil/oil nanoprecipitation, 
as previously described
4,9
.  F1-V protein was dialyzed against water to remove salts before 
194 
 
 
 
undergoing lyophilization overnight at -40˚C. The resultant dry F1-V protein (2.5 µg) was 
encapsulated into 50:50 CPTEG:CPH nanoparticles (500 µg). The protein-loaded particles were 
characterized for size and morphology by scanning electron microscopy (SEM, FEI Quanta 
SEM, Hillsboro, OR). 
8.3.4 Cyclic dinucleotides 
Cyclic dinucleotides were synthesized by Aduro BioTech.  Canonical rr-diGMP CDNs 
were synthesized from commercially available DMT-rA(Bz)-βCE-TBDMS-Phosphoramidite12 
using a phosphoramidite dimerization method followed by a H-phosphonate cyclization 
method
13
.  
8.3.5 Yersinia pestis 
Infectious doses of Y. pestis CO92 were prepared by scraping bacteria cultured overnight 
on Brain Heart Infusion (BHI) agar at 37°C. A bacterial suspension was made in PBS (pH 7.4) 
and cell density was adjusted to ~ 1 x 10
9
 CFU/mL according to OD600 spectrophotometric 
readings. Frozen aliquots of the suspension were prepared and kept at -80°C.  
8.3.6 Mice 
Five to eight-week old female C57BL/6 were purchased from Harlan Laboratories 
(Haslett, MI). All studies were conducted in accordance with the Iowa State University 
Institutional Animal Care and Use Committee. 
8.3.7 Vaccination and challenge 
Animals were vaccinated subcutaneously at the nape of the neck. All formulations were 
prepared in 100 µL sterile phosphate buffered saline (PBS).  Sterile PBS was used as the control 
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group.  Five to eight animals were used per group with data representing between one and two 
independent experiments, as noted. 
Enumeration of viable CFU was performed by thawing aliquots and plating serial 
dilutions of Y. pestis on BHI medium and incubating at 37°C. Viability of bacteria within the 
intranasal inoculum was confirmed in this manner to contain ~880 CFU within 20 µL PBS 
placed on the nares of anesthetized mice. Health of the infected mice was monitored several 
times daily for signs and symptoms of distress. Moribund mice were euthanized by CO2 
overdose. Animals found deceased and euthanized mice were recorded as having died on that 
day. Animals were challenged at either 14 or 42 days post-immunization. Mice were monitored 
for 14 days for clinical signs of infection and surviving mice were euthanized by CO2 overdose. 
8.3.8 Anti-F1-V enzyme-linked immunosorbent assay 
In order to determine anti-F1-V antibody titers, enzyme-linked immunosorbent assays 
were performed, as previously described
4,14,15
.  Briefly, high-binding surface chemistry 96-well 
plates were coated with 100 µL of 0.5 µg/mL F1-V suspended in PBS.  Plates were incubated 
overnight at 4˚C. The protein solution was removed and 300 µL of blocking buffer (2.5% skim 
milk dissolved on PBS with 0.05% Tween (PBS-T)). Plates were incubated with blocking buffer 
for 2 hours at room temperature.  After incubation, plates were washed three times with PBS-T 
and serum was added to PBS-T containing 1% goat serum beginning at a 1:200 dilution, and 
serially diluted 3-fold 12 times.  After the addition of serum, plates were incubated overnight at 
4˚C. Samples were washed three times with PBS-T, and alkaline phosphatase-conjugated goat 
anti-mouse IgG (Jackson ImmunoResearch) was added at a concentration of 1 µg/mL followed 
by incubation for 2 hours at room temperature.  Another three washes were performed with PBS-
T, followed by the addition of 1 mg/mL alkaline phosphatase substrate (Fisher Scientific, 
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Pittsburgh, PA) in 50 mM sodium carbonate 2 mM magnesium chloride buffer at pH 9.3.  Plates 
were developed for 30 minutes before reading the optical density at 405 nm.  
8.4 Results  
8.4.1 Immunization nanovaccine formulations elicits higher antibody titers and provides 
enhanced protection over F1-V alone when challenged at 42 days post-administration 
Protective immunity of vaccine formulations at extended time points was investigated 
through challenge with a lethal dose of Y. pestis at six weeks post-immunization. Animals were 
immunized with a total of 5 µg F1-V administered as soluble protein, encapsulated into 100 µg 
of 50:50 CPTEG:CPH polyanhydride nanoparticles, or 2.5 µg delivered as soluble protein along 
with 2.5 µg encapsulated into 500 µg of 50:50 CPTEG:CPH nanoparticles.  Antibody titers were 
measured at 14 and 35 days after vaccine administration, as shown in Figure 8.1a.  A statistically 
significant increase in the antibody response was observed at day 14 for the soluble plus 
encapsulated nanovaccine formulation as compared to the soluble protein alone and the 
nanovaccine formulation in which 100% of the antigen was encapsulated within the 
nanoparticles (i.e., no soluble antigen). By day 35 after administration, the statistical difference 
between the soluble protein and the soluble plus encapsulated vaccine formulation had waned, 
though the soluble plus encapsulated nanovaccine formulation remained significantly higher than 
the 100% antigen-encapsulated formulation. This may be explained by the lack of enough 
protein present initially to stimulate a robust B cell response to the vaccine administration for the 
100% antigen-encapsulated formulation. This hypothesis is supported by the induction of weak 
antibody titers compared to the soluble plus encapsulated nanovaccine formulation and even the 
un-adjuvanted protein delivered solubly.  
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These observations are reflected in the survival data when the vaccinated animals were 
challenged 42 days after immunization, as shown in Figure 8.1b. The soluble plus encapsulated 
vaccine formulation provided 100% protection against lethal challenge with 880 CFU of CO92 
Y. pestis. In contrast, both soluble protein and the 100% antigen-encapsulated nanovaccine 
demonstrated poor protection, with all animals succumbing to challenge, though it may be 
interesting to note that the 100% antigen-encapsulated formulation resulted in a delayed onset of 
clinical signs of infection and death, hinting at a possibly weak immune response to challenge.  
8.4.2 The addition of CDNs to nanovaccine formulations stimulates the innate immune responses 
eliciting high titers at early time points and shifts the response from IgG1-dominated to balanced 
(i.e., IgG1/IgG2) immune response 
The addition of CDNs to the each of the vaccine formulations tested above stimulated 
innate immune responses and elicited high titers at early time points when compared to the 
formulations without the CDNs, as shown in Figure 8.2a. The addition of the CDN adjuvant to 
the soluble plus encapsulated vaccine formulation and the addition of CDNs to the soluble F1-V 
provided a marked increase because CDNs are known to stimulate innate immunity through the 
STING pathway, the observed results align with the expected response upon the inclusion of the 
CDNs in the nanovaccine regimens. It is interesting to note that, while higher, the antibody titers 
elicited by the 100% antigen-encapsulated formulation with CDNs, do not appear to indicate the 
same innate immune stimulation observed with the other groups. Again, this may be due to the 
lack of sufficient antigen present initially to stimulate a robust B cell response to immunization. 
Due to this lack of antigen, the adaptive immune response does not benefit from the recruitment 
of innate immune cells by the CDNs, as is suggested by the soluble plus encapsulated 
nanovaccine and the soluble F1-V group. It is also interesting to note that in addition to 
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improving the antibody response and survival of vaccinated animals, the addition of CDNs 
shifted response from an IgG1-dominated to a balanced (i.e., IgG1/IgG2) immune response, as 
shown in Figure 8.3. 
Consistent with these observations the survival data when the vaccinated animals were 
challenged 42 days after immunization indicate the benefit of the addition of the CDNs to the 
vaccine regimens, as shown in Figure 8.2b. As shown in the previous figures, the soluble plus 
encapsulated vaccine formulation provided 100% protection against lethal challenge with 880 
CFU of CO92 Y. pestis. Similarly the addition of CDNs did not hinder the efficacy of the 
formulation, with the soluble plus encapsulated vaccine with CDN formulation also providing 
100% protection. In contrast, both soluble protein and the 100% antigen-encapsulated 
nanovaccine demonstrated little response, with all animals succumbing to challenge, without 
CDNs.  The addition of CDNs to the soluble F1-V vaccine improved the response, with 80% of 
animals surviving challenge. Not surprisingly, based on the antibody titer results, the addition of 
CDNs did not improve survival of animals vaccinated with the all-encapsulated F1-V, with all of 
the animals succumbing to challenge. 
8.4.3 An increase in the dose of F1-V along with the use of a hydrophobic polyanhydride 
nanoparticle chemistry increases efficacy of 100% antigen-encapsulated nanovaccine 
formulations at late time points 
 Based on our previous work, the chemistry of the nanoparticle adjuvant plays a critical 
role in the evolution of the immune response
14
. The more hydrophobic the chemistry, the more 
danger signals are elicited by the presence of the polymer, leading to a more rapid response to 
immunization.  Based on these observations, a more hydrophobic adjuvant (i.e., 20:80 
CPTEG:CPH) was utilized in order to induce a protective response at earlier time points after 
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vaccination.  Additionally, though the soluble plus encapsulated vaccine formulation provided 
protection against challenge, the use of soluble protein in a vaccine formulation may reduce 
shelf-life and need cold storage conditions in comparison to a 100% antigen-encapsulated 
nanovaccine formulation, which may be stored at room temperature for longer periods of time.  
Encapsulation into polyanhydride nanoparticles has been shown to prolong the shelf-life of 
fragile proteins and eliminate the need for cold storage
16
. With this goal in mind, the dose of F1-
V was increased to 10 µg in 100 µg of 20:80 CPTEG:CPH nanoparticles, which also increases 
the loading percentage from 5% to 10%. Increased loading has been shown to lead to a greater 
initial burst of antigen from the particles, resulting in higher a higher antibody titer response, 
possibly due to the protein needed initially to stimulate a robust B cell response
17
.  
 Similar to the previous experiment, the inclusion of CDNs in the nanovaccine 
formulations increased the antibody response.  In contrast to the data obtained from the 5 µg 
dose of F1-V delivered in the all-encapsulated formulation, the 10 µg dose elicited measurable 
antibody titers, which were increased by the addition of CDNs to the vaccine formulation, as 
shown in Figure 8.4. Additionally, these titers were maintained, and even increased, until at least 
63 days post administration. By 63 days post vaccination, the mice that received 100% antigen-
encapsulated formulation with CDNs also showed increased antibody titers, similar to the titers 
in animals that received the soluble plus encapsulated formulation. This observation indicates 
that, though less antigen may be available initially due to encapsulation, the continuous release 
of protein from the polyanhydride nanoparticles may lead to a sustained immune response and 
the accumulation of antibody in vaccinated animals. It has previously been shown that the 
persistent presence of antigen may lead to enhanced differentiation of B cells into long-lived 
plasma cells
18–20
.  
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8.4.4 Immunization with CDN + nanoparticle formulations enhances protection as compared to 
soluble F1-V when challenged at 14 days after immunization 
 Finally, based on the promising results from the 10 µg dose and the use of 20:80 
CPTEG:CPH nanoparticle adjuvants, challenge studies at early time points were investigated. 
Additionally, an increased dose of F1-V of 20 µg in 200 µg of 20:80 CPTEG:CPH nanoparticles 
was tested, keeping the loading percentage the same (i.e., 10%). The results from this study are 
summarized in Table 1. While no vaccine formulation tested offered 100% protection, the 20 µg 
in 200 µg of 20:80 CPTEG:CPH nanoparticles with and without CDNs offered enhanced 
protection over 20 µg F1-V delivered alone.  
8.5 Discussion 
  The plague causing pathogen, Yersinia pestis, remains a concern from the standpoints of 
antibiotic resistance and potential use as a biological weapon. Despite this, there is currently no 
commercially available vaccine in the United States and Western Europe. This work builds on 
previous work from our laboratories on the use of polyanhydride nanoparticles as a vaccine 
platform for Y. pestis, in which the use of a nanovaccine formulation with soluble antigen plus 
nanoparticle-encapsulated antigen was shown to be protective. In this work the titers induced by 
the soluble plus encapsulated nanovaccine formulation were significantly higher than the titers 
induced by the 100% antigen-encapsulated formulation. This may be due to the lack of sufficient 
protein present initially to stimulate a robust B cell response to the vaccine administration. This 
is supported by the reduced antibody titers compared to the soluble plus encapsulated 
nanovaccine formulation and even the un-adjuvanted protein delivered solubly (Figure 8.1a).  
The use of cyclic dinucleotides (CDNs), which are viral and bacterial nucleic acids that 
regulate gene expression, is combination with the nanovaccine, was also investigated in this 
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work.  These molecules are secreted by intracellular bacteria into the cytosol and are recognized 
by the innate immune system as PAMPs.  This stimulates innate immunity and induces the 
release Th1-skewing pro-inflammatory cytokines and chemokines. This innate immune 
stimulating capability of the CDNs was utilized by combining them with the nanovaccine 
formulation to induce immune responses at earlier time points.  In each case, the benefit of the 
combination nanovaccine is clear, as evidenced by the increased antibody titers, particularly 
within 14 days after immunization (Figure 8.2a.).   
Additionally, the effect of increasing the antigenic dose was investigated in the attempt to 
design a protective, 100% antigen-encapsulated vaccine formulation, which is likely to exhibit 
enhanced shelf-life for extended periods of time.  The elimination of the soluble portion of the 
nanovaccine formulation will have implications in the shelf-life, storage, and, possibly, 
administration of the final vaccine formulation, as a dry powder vaccine may allow for inhaled or 
intranasal delivery, thereby enhancing patient compliance
16,21,22
.  At later time points, the 
elimination of the soluble portion of the nanovaccine appears to not hinder the immune response 
in the presence of the CDNs. This provides promising evidence that a 100% antigen-
encapsulated nanovaccine with extended shelf life at elevated temperatures will be protective 
when challenged at sufficiently long times (i.e., 6 weeks or later) post-vaccination.   
Another consideration for a successful Y. pestis vaccine however, is the induction of early 
immunity, with implications for use as a PEP therapy for those exposed to Y. pestis, as well as 
for rapid vaccination in the event of a mass exposure event.  In order to test the efficacy of the 
100% antigen-encapsulated nanovaccine formulations, animals were challenged 14 days after 
vaccine administration, particularly with the use of a nanoparticle formulation that in our 
previous work showed rapid induction of antibody responses. An increased dose of F1-V of 20 
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µg in 200 µg of 20:80 CPTEG:CPH nanoparticles was tested in these experiments. While no 
vaccine formulation tested offered 100% protection, the 20 µg in 200 µg of 20:80 CPTEG:CPH 
nanoparticles, both with and without CDNs, offered enhanced protection over 20 µg of F1-V 
delivered alone (Table 1). These experiments are promising first steps in the design of a safe and 
versatile single dose combination nanovaccine with extended storage shelf fife at elevated 
temperature that can provide protective immunity upon both pre- and post-exposure to Y. pestis. 
8.6 Conclusions 
 Herein we demonstrate the development of a single dose combination nanovaccine 
formulation against Y. pestis with the goal of eliciting protective immunity in the first 14 days 
after administration and also generating long-lasting immunity at up to 6 weeks after vaccination. 
These studies have promising implications for use as a PEP therapy for those exposed to Y. 
pestis, as well as for rapid vaccination in the event of a mass exposure event.   
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8.8 List of Figures 
 
Figure 8.1. Anti-F1-V titers induced by 5 µg F1-V encapsulated into 100 µg of 50:50 
CPTEG:CPH nanoparticles, 2.5 µg F1-V encapsulated into 500 µg of 50:50 CPTEG:CPH 
nanoparticles, and 5 µg soluble F1-V 14 and 35 days post a single intranasal immunization. The 
50:50 CPTEG:CPH nanovaccine formulation provided 100% protection against lethal challenge 
with Y. pestis CO92 (880 CFU), while both the 100% antigen-encapsulated and soluble F1-V 
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formulations failed to provide any protection. Error bars represent standard error of the mean. 
Letters represent statistical significance between treatment groups at a given time point.  
 
Figure 8.2. The addition of CDNs to nanovaccine formulations stimulates innate immune 
responses by eliciting high titers at early time points. Error bars represent standard error of the 
mean. Protection data indicates that both the soluble plus encapsulated nanovaccine formulation 
with and without CDN provided 100% protection against lethal challenge.  Additionally, the 
inclusion of CDNs in the vaccine formulation enhanced the protection by soluble protein to 80% 
survival. Responses to the all-encapsulated formulations with and without CDN remained low, 
with no survivors. 
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Figure 8.3. The addition of CDNs shifts the immune response from an IgG1-dominated to a 
balanced (i.e., IgG1/IgG2) response. Optical density of serum samples of vaccinated mice was 
measured seven days post-vaccination and plated at a 1:1000 serum dilution. Error bars represent 
standard error of the mean. 
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Figure 8.4. The use of hydrophobic 20:80 CPTEG:CPH nanoparticles with an increased dose (20 
µg) and loading percentage (10%) rapidly induced robust antibody titers. The total antibody titer 
of vaccinated animals was measured at days 14, 35 and 63 post-administration. Error bars 
represent standard error of the mean. 
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8.9 List of Tables 
Table 8.1. Survival results for animals challenged with 1200 CFU of CO92 Y. pestis 14 days 
after a single intranasal immunization. 
  
Group Survival @ D7 
10 µg F1-V 2/8  25% 
20 µg F1-V 1/8  12.5% 
10 µg F1-V + 25 µg CDN 3/8  37.5% 
20 µg F1-V + 25 µg CDN 5/8  62.5% 
10 µg F1-V in 100 µg 20:80 CPTEG:CPH 3/8  37.5% 
20 µg F1-V in 200 µg 20:80 CPTEG:CPH 5/8  62.5% 
10 µg F1-V in 100 µg 20:80 CPTEG:CPH + 25 µg CDN 3/8  37.5% 
20 µg F1-V in 200 µg 20:80 CPTEG:CPH + 25 µg CDN 4/7  57% 
Saline 3/8  37.5% 
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CHAPTER 9: CONCLUSIONS AND FUTURE WORK  
 
9.1 Conclusions 
 With increasing threats of biological pathogens such as Yersinia pestis being used as 
weapons in bioterror attacks and widespread overuse of antibiotics leading to multi-drug-
resistant strains of bacteria, vaccination remains an important tool in the global fight against 
infectious diseases. Acute lower respiratory infections such as pneumonia are the leading cause 
of death among infectious diseases, and many microbes can be responsible for these deadly 
lower respiratory tract infections. In addition to bacterial pneumonia strains such as 
Staphylococcus aureus, Psuedomonysis aeruginosa, and Streptococcus pneumoniae, viral 
infections such as influenza and respiratory syncytial virus as well as some fungi also contribute 
to the disease burden. However, community-acquired pneumonia remains the leading cause of 
lower respiratory infections, with S. pneumoniae being the most common causative agent. With 
this backdrop, the overall goal of this thesis is to design efficacious vaccine platforms against 
bacterial pathogens such as S. pneumoniae and Y. pestis, which offer improvements over 
commercially available vaccine regimens. 
We first investigated the mechanism of protection associated with polyanhydride 
nanovaccines (Chapters 4 and 5). The F1-V fusion protein has been demonstrated previously to 
provide protection against Y. pestis challenge when delivered in the context of 50:50 
CPTEG:CPH polyanhydride nanoparticles
1,2
. Herein, we investigated how F1-V encapsulated in 
50:50 CPTEG:CPH nanoparticles interacted with immune cells at early time points after 
administration, and how these interactions compared with soluble protein alone and soluble 
protein delivered with MPLA. We demonstrated that polyanhydride nanoparticles bridged the 
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gap between the inert persistence of soluble protein alone and the rapid, inflammation-induced 
clearance observed with F1-V-MPLA formulations. The particles prolonged the presence of 
antigen in the lungs and induced a relatively mild inflammatory response compared to MPLA, 
while still inducing a long-lasting protective immune response. Finally, we assessed the long-
term immune response induced by polyanhydride nanovaccines of different chemistries to 
determine the effect of particle persistence and polymer chemistry on the immune response. We 
determined that while long-term persistence seemed to have little effect on the immune response 
to F1-V, polymer chemistry affected the antigen release kinetics and the development and 
phenotype of the immune response to the nanovaccine. This work has important implications for 
vaccine design against different pathogens, which may require different phenotypes of immune 
responses.  
Next, we demonstrated the value of polyanhydride nanoparticles in delivering and 
adjuvanting pneumococcal surface protein A (PspA), a protective antigen against S. pneumoniae 
(Chapter 6). PspA was encapsulated into polyanhydride nanoparticles of two different 
chemistries and released for one month. The released protein was found to retain its structure, 
antigenicity, and biological functionality upon release. Additionally we demonstrated the 
development of a protective subunit vaccine based on PspA using polyanhydride nanoparticles as 
a vaccine adjuvant (Chapter 7). Through the incorporation of cyclic dinucleotides in the 
nanovaccine formulation, we demonstrated the potential to formulate an effective PspA 
nanovaccine with 100% of the antigen encapsulated within the nanoparticles, which may have 
implications for increased shelf-life and stability outside of the cold-chain. Additionally, we 
designed combination nanovaccine formulations that demonstrated protection against lethal 
challenge at early time points after vaccination. 
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Finally, we investigated the development of a single dose combination nanovaccine 
formulation against Y. pestis with the goal of eliciting protective immunity in the first 14 days 
after administration and also generating long-lasting immunity at up to 6 weeks after vaccination 
(Chapter 8). These studies have promising implications for use as a post-exposure prophylaxis 
therapy for those exposed to Y. pestis, as well as for rapid vaccination in the event of a mass 
exposure event.   
9.2 Future work 
 In addition to optimizing the nanovaccine formulations for bacterial infections that have 
been developed in this thesis, the nanoparticle platform can also be exploited to deliver 
antibiotics in a potentially simultaneous format with the vaccines. The particles offer advantages 
in terms of dose sparing (thus addressing antibiotic resistance), safety, and enhanced patient 
compliance. Some ongoing and future work in this area is described below. 
9.2.1 Polyanhydride nanoparticle platform for the delivery of antibiotics against Streptococcus 
pneumoniae 
In addition to designing polyanhydride nanovaccines for post-exposure prophylaxis 
against emerging diseases and potential bioterrorism threats, polyanhydride nanoparticles can be 
used for post-exposure treatment through the delivery of antibiotics against S. pneumoniae 
infection. Polyanhydride nanoparticles have previously been shown to be an effective delivery 
platform for antibiotics
3
. Encapsulation of antibiotics into particles resulted in an increase in the 
local concentration of drug and prevented rapid clearance of the antibiotic after administration.  
Additionally, particle persistence and sustained release of antibiotic (or antimicrobial agent) may 
obviate the need for a multiple-dose course of treatment. Together, these studies lay the 
groundwork for a polyanhydride nanoparticle-based combination treatment against S. 
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pneumoniae that addresses both pre-exposure (i.e., prophylaxis) as well as post-exposure (i.e., 
therapeutics). 
9.2.2 Polyanhydride nanoparticle platform for the delivery of antibiotics against Brucella abortus 
and Brucella melitensis 
Brucellocis, caused by the etiologic agents Brucella abortus and Brucella melitensis, 
which are gram-negative intracellular pathogens of humans and animals, is a chronic infection 
that infects both humans and animals
4
. In humans brucellosis is known as Maltese fever and 
Mediterranean fever and persists within resident monocytes in the spleen, liver and lymphatic 
system
4,5
.  Brucella infections require dual antibiotic therapy of doxycycline twice daily and 
rifampicin once daily for 3-6 weeks due to difficulty of targeting antimicrobials into host cells at 
high enough concentrations to be therapeutic without inducing toxicity in host cells and tissues
6
. 
There are a number of obstacles in reaching intracellular Brucella including limited cellular 
uptake by the host cell’s eukaryotic membrane and the presence of intracellular membranes that 
sequester the pathogen’s intracellular compartments, further protecting the bacteria from 
antibiotic exposure, even after cellular internalization
7
. Additionally, antibiotics can become 
inactivated through exposure to the acidic lysosomal environment after uptake. For example 
gentamycin requires a 64-fold higher dose to reach the minimum inhibitory concentration (MIC) 
when exposed to a pH 5 solution
7
.  
Polyanhydride nanoparticles have been demonstrated to be readily internalized by antigen 
presenting cells, primarily through actin-mediated uptake
3
. In our initial studies, we 
demonstrated in vitro that nanoparticles were effectively internalized by monocytes, were able to 
enhance delivery of antibiotic to the cells, and were able to kill virulent Brucella persisting 
within monocytes as shown in Figure 9.1.  Brucella abortus infection was established in a THP-1 
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cell human monocyte cell line for 24 hours followed by the delivery of equivalent amounts of 
doxycycline either soluble or encapsulated into four different chemistries of polyanhydride 
nanoparticles: 50:50 CPH:SA, 20:80 CPH:SA, 50:50 CPTEG:CPH, and 20:80 CPTEG:CPH. 
This was followed by bacterial enumeration as shown in Figure 9.1. The most readily 
internalized chemistries, 20:80 CPH:SA and 20:80 CPTEG:CPH, demonstrated up to a four log 
reduction in intracellular bacterial concentration. 
The animals receiving nanoparticle-encapsulated antibiotic treatment also exhibited an 
improved safety profile in comparison with antibiotic alone with reduced liver toxicity based on 
alanine and aspartate transaminase concentrations. The liver enzymes alanine (ALT) and 
aspartate (AST) transaminases were elevated upon delivery of one mg of soluble doxycycline. In 
contrast, encapsulation of one mg of doxycycline into 20:80 CPH:SA nanoparticles reduced liver 
toxicity and the liver enzymes ALT and AST remained in the normal range, as shown in Figure 
9.2.  
The nanoparticle-based treatment regimens also provided dose sparing effects, which in 
addition to the lack of adverse side effects, will reduce antibiotic resistance and lead to enhanced 
patient compliance. Weekly does of 0.5 mg doxycycline encapsulated into 20:80 CPH:SA and 
20:80 CPTEG:CPH nanoparticles were shown to be as effective as 0.5 mg of soluble 
doxycycline given daily for a period of three weeks, with the animals treated with the 
polyanhydride nanoparticle group receiving a seven-fold reduction in the amount of doxycycline 
over the length of study, as shown in Figure 9.3. Both the 10.5 mg total regimen of soluble 
doxycycline and the 1.5 mg regimen of doxycycline encapsulated into polyanhydride 
nanoparticles demonstrated significantly lower colonization compared to the untreated control in 
the spleen (Figure 9.3A) and liver (Figure 9.3B). No significance was observed between the two 
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chemistries of polyanhydride nanoparticles used, indicating that both performed equally in 
reducing Brucella colonization. This work sets the stage for optimizing polyanhydride-based 
nanoparticle systems for antibiotic delivery. 
9.2.3 Polyanhydride nanoparticle platform for the delivery of antiparasitic agents to filarial 
worms, Brugia malayi 
Lymphatic filarial diseases, transmitted by mosquitos in endemic regions, represent a 
significant global burden. The parasites are endemic in over 80 countries worldwide, particularly 
India and sub-Saharan Africa
8,9
, and infecting up to 120 million individuals.  This parasitic 
infection can cause diseases such as lymphedema, hydrocele, and elephantiasis.
9
  Traditional 
therapies utilize antifilarial drugs such as ivermectin, diethylcarbamazine, and albendazole. 
Many of these drugs have unwanted side effects and the use of up to four drugs over several 
months of continuous treatment can affect patient compliance.  The use of amphiphilic 
polyanhydride nanoparticles for drug delivery may significantly improve the standard of 
treatment of filarial diseases by lowering the drug dose, shortening the killing time, and 
enhancing patient compliance. Antimicrobial treatments such as doxycycline have been added to 
antifilarial regimens to target Wolbachia, which are intracellular bacteria that exist in a symbiotic 
relationship with adult worms
10
. Anti-Wolbachia drugs have been shown to reduce pathogenicity 
and reproductive capacity of adult filarial worms
11
. Herein we demonstrate enhanced antifilarial 
activity upon co-delivery of doxycycline and the antiparasitic, ivermectin, using polyanhydride 
nanoparticles. 
The unique chemistry of polyanhydride nanoparticles may be applied to address many of 
the challenges associated with mass drug administration against lymphatic filariasis. Drug-
loaded nanoparticles were synthesized as described previously
12
 and their surface morphology 
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was found to be consistent with previous work as shown by the scanning electron 
photomicrographs in Figure 9.4
13–15
.  Additionally, particle size was also found to be consistent 
with previous publications
16,17
. The average size for the 20:80 CPH:SA nanoparticles was found 
to be 494 ± 195 nm, and the average size for the 20:80 CPTEG:CPH nanoparticles was slightly 
smaller at 218 ± 56 nm. The surface erosion profile of the polyanhydride nanoparticles provided 
sustained release of drug over an extended time.
13,18,19
 The sustained release of doxycycline and 
ivermectin from the two polyanhydride chemistries is shown in Figure 9.5.  A larger initial burst 
of the doxycycline was observed from the 20:80 CPH:SA nanoparticles, consistent with previous 
work
12,13,17
 . Additionally, a distinct profile was observed for the release of ivermectin from both 
polyanhydride chemistries, characterized by a very low burst, followed by a zero-order release 
over the course of the experiment. This may indicate a preferential partitioning of the ivermectin 
to the slower-degrading CPH-rich regions of both polymer chemistries.
20
 Effectiveness of the 
polyanhydride nanoparticles when directly compared to the standard soluble treatment was 
demonstrated by the overall percent survival of B. malayi worms over the duration of the study 
period with a single treatment of the previously described groups (Table 9.1). The results clearly 
show the effectiveness of the nanoparticle-administered groups compared to the soluble group. 
This work sets the stage for testing the efficacy of polyanhydride nanoparticle-based delivery 
systems in animal models. 
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9.4 List of Figures 
 
Figure 9.1. Intracellular concentration of Brucella abortus is reduced when an equivalent amount 
of doxycycline (10 µg/mL) is delivered together with 20:80 CPH:SA and 20:80 CPTEG:CPH 
nanoparticles as compared to soluble doxycycline.  
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Figure 9.2. Liver enzymes alanine (ALT) (A) and aspartate (AST) (B) transaminases are elevated 
upon delivery of one mg of soluble doxycycline while encapsulation of equivalent amount of 
doxycycline into 20:80 CPH:SA nanoparticles reduced liver toxicity. 
 
Figure 9.3. Weekly doses of 0.5 mg doxycycline encapsulated into polyanhydride nanoparticles 
are as effective as 0.5 mg of soluble doxycycline given daily to mice for a period of three weeks, 
with the mice treated with the polyanhydride nanoparticle group receiving a seven-fold reduction 
in the amount of doxycycline over the length of study. * represents statistical significance (p < 
0.05) in CFU colonization compared to the untreated control in the spleen (A) and liver (B). No 
significance was observed between the nanoparticle and soluble treatment groups. 
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Figure 9.4 Polyanhydride nanoparticles of 20:80 CPH:SA (A) and 20:80 CPTEG:CPH (B) were 
synthesized with 5% (w/w) of doxycycline and ivermectin. Particle size was analyzed using 
ImageJ software.  
 
Figure 9.5. Cumulative release profile of doxycycline and ivermectin from 20:80 CPH:SA and 
20:80 CPTEG:CPH nanoparticles. Cumulative mass of drug released was determined using high 
performance liquid chromatography (HPLC).  
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9.5 List of Tables 
Table 9.1 Effects of soluble and 20:80 CPH:SA nanoparticle-encapsulated drugs on the survival 
of adult B. malayi worms in vitro. 
Formulation # Treated % Death 
195 µM Soluble IVM/Dox 11 64% 
195 µM Nano-IVM/Dox 13 100% 
  
49 µM Soluble IVM/Dox 5 40% 
49 µM Nano-IVM/Dox 5 100% 
  
10 µM Soluble IVM/Dox 7 43% 
10 µM Nano-IVM/Dox 4 100% 
  
5 µM Soluble IVM/Dox 7 14% 
5 µM Nano-IVM/Dox 7 100% 
 
 
 
 
